

# Antiretroviral Prophylaxis for HIV Prevention in Hetero

New England Journal of Medicine

367, 399-410

DOI: [10.1056/nejmoa1108524](https://doi.org/10.1056/nejmoa1108524)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. , 2009, , CD007189.		61
3	Sexually Transmitted Diseases Treatment Guidelines, 2010. Annals of Emergency Medicine, 2011, 58, 67-68.	0.3	925
4	Preparing for PrEP. European Journal of Contraception and Reproductive Health Care, 2012, 17, 482-486.	0.6	1
5	The Potential Impact of Pre-Exposure Prophylaxis for HIV Prevention among Men Who Have Sex with Men and Transwomen in Lima, Peru: A Mathematical Modelling Study. PLoS Medicine, 2012, 9, e1001323.	3.9	76
6	Clinical round-up. Sexually Transmitted Infections, 2012, 88, 475-476.	0.8	0
7	Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy. Public Health Ethics, 2012, 5, 263-282.	0.4	17
8	Antiretroviral-Based HIV-1 Prevention: Antiretroviral Treatment and Pre-Exposure Prophylaxis. Antiviral Therapy, 2012, 17, 1483-1493.	0.6	34
9	Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings. Current Opinion in HIV and AIDS, 2012, 7, 557-562.	1.5	5
10	The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Current Opinion in HIV and AIDS, 2012, 7, 563-568.	1.5	18
11	Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Current Opinion in HIV and AIDS, 2012, 7, 593-599.	1.5	76
12	Antiretrovirals and safer conception for HIV-serodiscordant couples. Current Opinion in HIV and AIDS, 2012, 7, 569-578.	1.5	122
14	Clinical round-up. Sexually Transmitted Infections, 2012, 88, 394-394.	0.8	0
15	Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine, 2012, 367, 411-422.	13.9	1,377
16	Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. New England Journal of Medicine, 2012, 367, 423-434.	13.9	1,692
17	Antiretroviral treatment in low-resource settings: what has changed in the last 10 years and what needs to change in the coming years?. Expert Review of Anti-Infective Therapy, 2012, 10, 1287-1296.	2.0	5
18	Preexposure Prophylaxis for HIV " Where Do We Go from Here?. New England Journal of Medicine, 2012, 367, 459-461.	13.9	55
19	RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses, 2012, 28, 1412-1421.	0.5	129
20	A Perspective on Progress and Gaps in HIV Prevention Science. AIDS Research and Human Retroviruses, 2012, 28, 1373-1378.	0.5	7

#	ARTICLE	IF	CITATIONS
21	Oral antiretroviral chemoprophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 514-519.	1.5	23
22	Next-generation oral preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 600-606.	1.5	29
23	A feasibility analysis of implementing interventions for discordant couples in 14 African countries. <i>Aids</i> , 2012, 26, 1969-1971.	1.0	5
24	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. <i>Antiviral Therapy</i> , 2013, 18, 301-310.	0.6	21
25	Human papillomavirus vaccination. <i>Aids</i> , 2012, 26, 2251-2252.	1.0	6
26	Truvada for HIV prophylaxis in heterosexual patients. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 14-15.	0.1	0
27	What Primary Care Providers Need to Know About Preexposure Prophylaxis for HIV Prevention. <i>Annals of Internal Medicine</i> , 2012, 157, 490.	2.0	32
28	Why I Voted "No" to Truvada PrEP. <i>Annals of Internal Medicine</i> , 2012, 157, 519.	2.0	10
29	Truvada PrEP: Why I Voted "Yes". <i>Annals of Internal Medicine</i> , 2012, 157, 521.	2.0	5
30	Pharmacists as providers of HIV pre-exposure prophylaxis. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 803-806.	1.0	29
31	As Good As It Gets? The Problem of HIV Persistence despite Antiretroviral Drugs. <i>Cell Host and Microbe</i> , 2012, 12, 132-138.	5.1	35
33	Intimacy and Sexual Decision Making: Exploring the Perspective of HIV Positive Women Over 50. <i>AIDS Patient Care and STDs</i> , 2012, 26, 755-760.	1.1	32
34	"We Weren't Using Condoms Because We Were Trying to Conceive": The Need for Reproductive Counseling for HIV-Positive Women in Clinical Care. <i>AIDS Patient Care and STDs</i> , 2012, 26, 700-707.	1.1	39
35	NRTI Backbone in HIV Treatment. <i>Drugs</i> , 2012, 72, 2051-2062.	4.9	19
36	A conceptual framework for understanding HIV risk behavior in the context of supporting fertility goals among HIV-serodiscordant couples. <i>Reproductive Health Matters</i> , 2012, 20, 50-60.	1.3	59
37	Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. <i>The Cochrane Library</i> , 2012, , CD007189.	1.5	73
38	Understanding Factors That Modulate HIV Infection at the Female Genital Tract Mucosae for the Rationale Design of Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1485-1497.	0.5	7
39	Prevention of Vaginal SHIV Transmission in Macaques by a Coitally-Dependent Truvada Regimen. <i>PLoS ONE</i> , 2012, 7, e50632.	1.1	64

#	ARTICLE	IF	CITATIONS
40	Wary approval for drug to prevent HIV. <i>Nature</i> , 2012, 487, 283-283.	13.7	2
41	Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda. <i>Trials</i> , 2013, 14, 33.	0.7	12
42	Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1777-1785.	0.9	14
43	Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. <i>BMC Infectious Diseases</i> , 2013, 13, 217.	1.3	63
44	Portfolios of Biomedical HIV Interventions in South Africa: A Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2013, 28, 1294-1301.	1.3	35
45	Combination HIV Prevention: The Value and Interpretation of Mathematical Models. <i>Current HIV/AIDS Reports</i> , 2013, 10, 195-198.	1.1	7
46	HIV Testing: Current Practice and Future Directions. <i>Current HIV/AIDS Reports</i> , 2013, 10, 134-141.	1.1	34
47	Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don't We Know?. <i>Current HIV/AIDS Reports</i> , 2013, 10, 142-151.	1.1	60
48	State of Condom Use in HIV Prevention Science and Practice. <i>Current HIV/AIDS Reports</i> , 2013, 10, 59-64.	1.1	36
49	Methodological Lessons from Clinical Trials and the Future of Microbicide Research. <i>Current HIV/AIDS Reports</i> , 2013, 10, 89-102.	1.1	29
50	Synthesizing Gender Based HIV Interventions in Sub-Sahara Africa: A Systematic Review of the Evidence. <i>AIDS and Behavior</i> , 2013, 17, 2831-2844.	1.4	25
51	Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis. <i>Drugs</i> , 2013, 73, 279-291.	4.9	31
52	Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2083-2090.	6.3	1,197
53	Sexual behaviour among users of antiretroviral pre-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 996-997.	4.6	3
54	Mobilizing women at the grassroots to shape health policy: a case study of the Global Campaign for Microbicides. <i>Reproductive Health Matters</i> , 2013, 21, 174-183.	1.3	6
56	HIV treatment as prevention: The key to an AIDS-free generation. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S95-S101.	0.9	40
57	Study designs for identifying risk compensation behavior among users of biomedical HIV prevention technologies: Balancing methodological rigor and research ethics. <i>Social Science and Medicine</i> , 2013, 94, 115-123.	1.8	41
58	Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1 neutralizing activity. <i>Nature Biotechnology</i> , 2013, 31, 1047-1052.	9.4	46

#	ARTICLE	IF	CITATIONS
59	Exploring Concentration Response in HIV Pre-Exposure Prophylaxis to Optimize Clinical Care and Trial Design. <i>Cell</i> , 2013, 155, 515-518.	13.5	60
60	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
61	HIV prevention strategies. <i>Medicine</i> , 2013, 41, 466-469.	0.2	4
62	Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting. <i>AIDS and Behavior</i> , 2013, 17, 3108-3119.	1.4	9
63	Daily Short Message Service Surveys to Measure Sexual Behavior and Pre-exposure Prophylaxis Use Among Kenyan Men and Women. <i>AIDS and Behavior</i> , 2013, 17, 2977-2985.	1.4	36
64	Dual HIV Risk: Receptive Syringe Sharing and Unprotected Sex Among HIV-Negative Injection Drug Users in New York City. <i>AIDS and Behavior</i> , 2013, 17, 2501-2509.	1.4	36
65	Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. <i>Retrovirology</i> , 2013, 10, 82.	0.9	6
66	Knowledge and Use of Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in New York City. <i>AIDS and Behavior</i> , 2013, 17, 2180-2184.	1.4	60
67	Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials. <i>AIDS and Behavior</i> , 2013, 17, 2143-2155.	1.4	123
68	Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. <i>Retrovirology</i> , 2013, 10, 161.	0.9	69
69	Women and HIV in Sub-Saharan Africa. <i>AIDS Research and Therapy</i> , 2013, 10, 30.	0.7	206
70	Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US. <i>Pharmacoeconomics</i> , 2013, 31, 1091-1104.	1.7	10
71	Antiretroviral Preexposure Prophylaxis for HIV Prevention. <i>New England Journal of Medicine</i> , 2013, 368, 82-84.	13.9	31
72	Pharmacokinetics and Pharmacodynamics in HIV Prevention; Current Status and Future Directions: A Summary of the DAIDS and BMGF Sponsored Think Tank on Pharmacokinetics (PK)/Pharmacodynamics (PD) in HIV Prevention. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1418-1427.	0.5	24
73	Integrating Behavioral HIV Interventions Into Biomedical Prevention Trials With Youth: Lessons From Chicago's Project PrEPare. <i>Journal of HIV/AIDS and Social Services</i> , 2013, 12, 333-348.	0.7	18
74	In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Nonvaccine Prevention Modalities. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1513-1523.	0.5	19
75	Microbicides for the prevention of sexually transmitted HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 12-23.	2.0	11
76	Knowledge of and Opinions on HIV Preexposure Prophylaxis Among Front-Line Service Providers at Canadian AIDS Service Organizations. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1183-1189.	0.5	22

#	ARTICLE	IF	CITATIONS
77	Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection. <i>SIAM Journal on Applied Mathematics</i> , 2013, 73, 904-928.	0.8	45
78	Participant Experiences and Facilitators and Barriers to Pill Use Among Men Who Have Sex with Men in the iPrEx Pre-Exposure Prophylaxis Trial in San Francisco. <i>AIDS Patient Care and STDs</i> , 2013, 27, 560-566.	1.1	76
79	HIV and AIDS in Women. , 2013, , 505-522.		0
80	Advances in catheter-ablation treatment of AF. <i>Nature Reviews Cardiology</i> , 2013, 10, 63-64.	6.1	7
81	Adherence and Acceptability in MTN 001: A Randomized Cross-Over Trial of Daily Oral and Topical Tenofovir for HIV Prevention in Women. <i>AIDS and Behavior</i> , 2013, 17, 737-747.	1.4	65
82	Thinking about an AIDS end game. <i>Lancet, The</i> , 2013, 382, 1462-1464.	6.3	0
83	Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 1021-1028.	4.6	95
84	Challenges in clinical trial design for HIV-1 cure research. <i>Lancet, The</i> , 2013, 382, 1464-1465.	6.3	37
85	HIV antiretroviral prophylaxis for injecting drug users “ Authors' reply. <i>Lancet, The</i> , 2013, 382, 855.	6.3	1
86	HIV antiretroviral prophylaxis for injecting drug users. <i>Lancet, The</i> , 2013, 382, 853-854.	6.3	0
87	Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. <i>Lancet, The</i> , 2013, 381, 1561-1569.	6.3	56
88	Management of Human Immunodeficiency Virus in Primary Care. <i>Primary Care - Clinics in Office Practice</i> , 2013, 40, 589-617.	0.7	3
89	Delivering on MPTs: addressing the needs, rising to the challenges and making the opportunities. <i>Contraception</i> , 2013, 88, 321-325.	0.8	14
90	A Pill for HIV Prevention: DÃ©jÃ Vu All Over Again?. <i>Clinical Infectious Diseases</i> , 2013, 56, 1604-1612.	2.9	51
91	The development and validation of an UHPLCâ€MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma. <i>Bioanalysis</i> , 2013, 5, 2771-2783.	0.6	24
92	Serodiscordancy and HIV prevention in sub-Saharan Africa. <i>Lancet, The</i> , 2013, 381, 1519-1521.	6.3	5
93	Prioritizing multipurpose prevention technology development and investments using a target product profile. <i>Antiviral Research</i> , 2013, 100, S32-S38.	1.9	25
94	Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. <i>Lancet Infectious Diseases, The</i> , 2013, 13, 65-76.	4.6	115

#	ARTICLE	IF	CITATIONS
95	A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns. BMC Systems Biology, 2013, 7, 11.	3.0	20
96	Systemic and Topical Drugs for the Prevention of HIV Infection: Antiretroviral Pre-exposure Prophylaxis. Annual Review of Medicine, 2013, 64, 219-232.	5.0	59
97	Poliomyelitis in Pakistan: time for the Muslim world to step in. Lancet, The, 2013, 381, 1521-1523.	6.3	16
98	<i>In Vitro</i> and <i>Ex Vivo</i> Evaluation of Polymeric Nanoparticles for Vaginal and Rectal Delivery of the Anti-HIV Drug Dapivirine. Molecular Pharmaceutics, 2013, 10, 2793-2807.	2.3	74
99	Human Immunodeficiency Virus Infection. , 2013, , 217-247.		0
100	Response to the AIDS Pandemic – A Global Health Model. New England Journal of Medicine, 2013, 368, 2210-2218.	13.9	141
101	Social Justice, Public Health Ethics, and the Use of HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine, 2013, 44, S137-S140.	1.6	27
102	Provider-Initiated HIV Risk Behavior Counseling in the Context of HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine, 2013, 44, S108-S111.	1.6	3
103	Moving HIV Pre-Exposure Prophylaxis Into Clinical Settings. American Journal of Preventive Medicine, 2013, 44, S86-S90.	1.6	7
104	Preparing for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine, 2013, 44, S80-S85.	1.6	36
105	A Proposed Framework to Monitor Daily Oral Antiretroviral Pre-Exposure Prophylaxis in the U.S. American Journal of Preventive Medicine, 2013, 44, S141-S146.	1.6	8
106	Using Registries to Monitor HIV Pre-Exposure Prophylaxis Safety in Clinical Settings. American Journal of Preventive Medicine, 2013, 44, S151-S155.	1.6	3
107	Antiretroviral Prophylaxis for Sexual and Injection Drug Use Acquisition of HIV. American Journal of Preventive Medicine, 2013, 44, S63-S69.	1.6	24
108	Adherence to Antiretroviral Medications for HIV Pre-Exposure Prophylaxis. American Journal of Preventive Medicine, 2013, 44, S91-S98.	1.6	78
109	Pre-Exposure Prophylaxis for HIV. American Journal of Preventive Medicine, 2013, 44, S161-S162.	1.6	8
110	Pre-Exposure Prophylaxis for HIV. American Journal of Preventive Medicine, 2013, 44, S163-S166.	1.6	24
111	From Efficacy to Impact. American Journal of Preventive Medicine, 2013, 44, S167-S170.	1.6	6
112	Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. Journal of Infectious Diseases, 2013, 207, S101-S106.	1.9	21

#	ARTICLE	IF	CITATIONS
113	Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?. BMC Medicine, 2013, 11, 186.	2.3	17
114	Preventing HIV Among Young People. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, S155-S160.	0.9	85
115	Intentions to Use Preexposure Prophylaxis Among Current Phase 2B Preventive HIV-1 Vaccine Efficacy Trial Participants. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 259-262.	0.9	17
116	HIV Testing and Counseling Leads to Immediate Consistent Condom Use Among South African Stable HIV-Discordant Couples. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 226-233.	0.9	65
118	Innovation and Biomedicine. , 2013, , .		21
119	Integrated Strategies for Combination HIV Prevention. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, S213-S220.	0.9	20
120	Hormonal contraceptive use and risk of HIV-1 disease progression. Aids, 2013, 27, 261-267.	1.0	33
121	The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 447-456.	0.9	159
122	Translational Research Insights From Completed HIV Vaccine Efficacy Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, S150-S154.	0.9	6
123	Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals. Aids, 2013, 27, 2155-2160.	1.0	124
124	Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 79-86.	0.9	158
125	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. Aids, 2013, 27, 2943-2951.	1.0	61
126	Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 239-244.	0.9	15
127	Preparing for the Unexpected. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, S183-S186.	0.9	24
128	HIV Prevention. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, S115-S116.	0.9	11
129	Fertility Intentions and Interest in Early Antiretroviral Therapy Among East African HIV-1-Infected Individuals in Serodiscordant Partnerships. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e33-e35.	0.9	18
130	Rectal Microbicide Development. Current Topics in Microbiology and Immunology, 2013, 383, 117-136.	0.7	15
131	Microbicides for Prevention of HIV Infection: Clinical Efficacy Trials. Current Topics in Microbiology and Immunology, 2013, 383, 97-115.	0.7	10



#	ARTICLE	IF	CITATIONS
132	Mixed results of pre-exposure prophylaxis for HIV prevention. <i>Nature Reviews Urology</i> , 2013, 10, 74-75.	1.9	1
133	From IEDs to AIDS? Detection of HIV in human corpses by rapid screening tests after suspected intentional transmission in terrorist attacks. <i>Journal of the Royal Army Medical Corps</i> , 2013, 159, 278-282.	0.8	6
134	HIV pre-exposure prophylaxis trials: the road to success. <i>Clinical Investigation</i> , 2013, 3, 295-308.	0.0	16
135	HIV-1 Prevention With ART and PrEP: Mathematical Modeling Insights Into Resistance, Effectiveness, and Public Health Impact. <i>Journal of Infectious Diseases</i> , 2013, 208, 189-191.	1.9	33
136	Significant publications on infectious diseases pharmacotherapy in 2012. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1930-1940.	0.5	11
137	Starting Treatment According to Guidelines Evaluation: a multicentre audit of HIV patients in the UK. <i>International Journal of STD and AIDS</i> , 2013, 24, 243-245.	0.5	0
138	Antiretroviral Therapy and Pre-exposure Prophylaxis: Combined Impact on HIV Transmission and Drug Resistance in South Africa. <i>Journal of Infectious Diseases</i> , 2013, 208, 224-234.	1.9	75
139	Incident HSV-2 Infections Are Common Among HIV-1-discordant Couples. <i>Journal of Infectious Diseases</i> , 2013, 208, 1093-1101.	1.9	9
140	The Cost and Impact of Scaling Up Pre-exposure Prophylaxis for HIV Prevention: A Systematic Review of Cost-Effectiveness Modelling Studies. <i>PLoS Medicine</i> , 2013, 10, e1001401.	3.9	188
141	Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. <i>PLoS Medicine</i> , 2013, 10, e1001511.	3.9	192
142	Identifying the Correlates of Membership in HIV-Serodiscordant Partnerships in New York City. <i>Sexually Transmitted Diseases</i> , 2013, 40, 784-791.	0.8	2
143	HIV Partner Notification. <i>Sexually Transmitted Diseases</i> , 2013, 40, 915-916.	0.8	12
144	Animal models for microbicide safety and efficacy testing. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	1.5	33
145	The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 50-58.	1.5	54
146	Long-acting injectable antiretrovirals for HIV treatment and prevention. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 565-571.	1.5	216
147	Antibody and Antiretroviral Preexposure Prophylaxis Prevent Cervicovaginal HIV-1 Infection in a Transgenic Mouse Model. <i>Journal of Virology</i> , 2013, 87, 8535-8544.	1.5	24
148	Age-dependent partnering and the HIV transmission chain: a microsimulation analysis. <i>Journal of the Royal Society Interface</i> , 2013, 10, 20130613.	1.5	44
149	New clinical trial designs for HIV vaccine evaluation. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 437-442.	1.5	6

#	ARTICLE	IF	CITATIONS
150	Stay current with options for HIV prevention. JAAPA: Official Journal of the American Academy of Physician Assistants, 2013, 26, 14-20.	0.1	3
151	Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. Current Opinion in HIV and AIDS, 2013, 8, 19-26.	1.5	70
152	Lack of Prophylactic Efficacy of Oral Maraviroc in Macaques despite High Drug Concentrations in Rectal Tissues. Journal of Virology, 2013, 87, 8952-8961.	1.5	52
153	Ethics of medical care and clinical research: a qualitative study of principal investigators in biomedical HIV prevention research. Journal of Medical Ethics, 2013, 39, 231-235.	1.0	5
154	How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2013, 25, 573-578.	0.6	7
155	Editorial Commentary: To B or Not to B? That Is the Question, for Global Mother-to-Child HIV-1 Transmission Prevention Programs. Clinical Infectious Diseases, 2013, 56, 447-449.	2.9	2
156	Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women. Evidence-Based Medicine, 2013, 18, 184-185.	0.6	3
157	Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?. Sexually Transmitted Infections, 2013, 89, 628-634.	0.8	30
158	Preexposure prophylaxis for the prevention of HIV transmission to women. Aids, 2013, 27, F1-F5.	1.0	22
159	Prophylactic Efficacy of Oral Emtricitabine and Tenofovir Disoproxil Fumarate Combination Therapy Against a Tenofovir-Resistant Simian/Human Immunodeficiency Virus Containing the K65R Mutation in Macaques. Journal of Infectious Diseases, 2013, 208, 463-467.	1.9	20
160	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1231-1239.	1.9	73
161	Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network) Tj ETQq1 1 0.784314 rgBT /Overlook	1.9	68
162	Safety of Tenofovir During Pregnancy for the Mother and Fetus: A Systematic Review. Clinical Infectious Diseases, 2013, 57, 1773-1781.	2.9	81
163	From the Laboratory to Clinical Trials and Back Again: Lessons Learned from <sc>HIV</sc> Prevention Trials. American Journal of Reproductive Immunology, 2013, 69, 106-115.	1.2	4
164	HIV drug resistance: problems and perspectives. Gastroenterology Insights, 2013, 5, e5.	0.7	117
165	Controlling the HIV Epidemic with Antiretrovirals. Journal of the International Association of Providers of AIDS Care, 2013, 12, 208-216.	0.6	36
166	Ethical Considerations in Determining Standard of Prevention Packages for <sc>HIV</sc> Prevention Trials: Examining <sc>P</sc><sc>r</sc><sc>EP</sc>. Developing World Bioethics, 2013, 13, 87-94.	0.6	28
167	Ethical Use of Antiretroviral Resources for <sc>HIV</sc> Prevention in Resource Poor Settings. Developing World Bioethics, 2013, 13, 79-86.	0.6	9

#	ARTICLE	IF	CITATIONS
168	Highly Active Antiretroviral Therapy is Associated with Decreased Incidence of Sexually Transmitted Diseases in a Taiwanese HIV-Positive Population. <i>AIDS Patient Care and STDs</i> , 2013, 27, 155-162.	1.1	6
169	The Female Condom in the Age of Antiretroviral-Based HIV Prevention. <i>Journal of Women's Health</i> , 2013, 22, 7-8.	1.5	4
170	Anti-retrovirals for treatment and prevention – time for new paradigms in our response to the HIV/AIDS epidemic?. <i>Developing World Bioethics</i> , 2013, 13, ii-iii.	0.6	6
171	Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1443-1450.	0.5	134
172	Attitudes Toward HIV Pre-Exposure Prophylaxis Among Men Who Have Sex with Men in Western China. <i>AIDS Patient Care and STDs</i> , 2013, 27, 137-141.	1.1	60
173	Acceptability of vaginal microbicides among female sex workers and their intimate male partners in two Mexico-US border cities: A mixed methods analysis. <i>Global Public Health</i> , 2013, 8, 619-633.	1.0	18
174	Ethics of ARV Based Prevention: Treatment as Prevention and PrEP. <i>Developing World Bioethics</i> , 2013, 13, 63-69.	0.6	22
175	From Efficacy to Effectiveness: Facilitators and Barriers to PrEP Acceptability and Motivations for Adherence Among MSM and Transgender Women in New York City. <i>AIDS Patient Care and STDs</i> , 2013, 27, 248-254.	1.1	297
176	Pre-Exposure Prophylaxis (PrEP) for HIV Infection: Results of a Survey of HIV Healthcare Providers Evaluating Their Knowledge, Attitudes, and Prescribing Practices. <i>AIDS Patient Care and STDs</i> , 2013, 27, 553-559.	1.1	119
177	Inefficient Vaginal Transmission of Tenofovir-Resistant HIV-1. <i>Journal of Virology</i> , 2013, 87, 1274-1277.	1.5	19
178	Substance Use Disorders and HIV/AIDS Prevention and Treatment Intervention: Research and Practice Considerations. <i>Social Work in Public Health</i> , 2013, 28, 333-348.	0.7	24
179	Isoosmolar Enemas Demonstrate Preferential Gastrointestinal Distribution, Safety, and Acceptability Compared with Hyperosmolar and Hypoosmolar Enemas as a Potential Delivery Vehicle for Rectal Microbicides. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1487-1495.	0.5	39
180	Editorial Commentary: HIV Chemoprophylaxis for Adolescents: Educable Moment, Not Magic Bullet. <i>Clinical Infectious Diseases</i> , 2013, 56, 1156-1158.	2.9	2
181	Griffithsin Protects Mice from Genital Herpes by Preventing Cell-to-Cell Spread. <i>Journal of Virology</i> , 2013, 87, 6257-6269.	1.5	97
182	Standard of Prevention in the Real World: A Qualitative Study of Principal Investigators in HIV Biomedical Prevention Trials. <i>American Journal of Bioethics Primary Research</i> , 2013, 4, 14-25.	1.5	2
183	Tenofovir-based HIV pre-exposure prophylaxis. <i>Future Virology</i> , 2013, 8, 1207-1218.	0.9	1
184	Fertility treatment options for HIV-infected individuals. <i>Future Virology</i> , 2013, 8, 1219-1231.	0.9	1
185	How Does HIV Affect the Reproductive Choices of Women of Childbearing Age?. <i>Antiviral Therapy</i> , 2013, 18, 35-44.	0.6	11

#	ARTICLE	IF	CITATIONS
186	Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. <i>Retrovirology</i> , 2013, 10, 113.	0.9	19
187	AIDS prevention: Africa's circumcision challenge. <i>Nature</i> , 2013, 503, 182-185.	13.7	7
188	Engaging HIV Care Providers in Conversations With Their Reproductive-Age Patients About Fertility Desires and Intentions: A Historical Review of the HIV Epidemic in the United States. <i>American Journal of Public Health</i> , 2013, 103, 1357-1366.	1.5	39
189	Tenofovir Diphosphate and Emtricitabine Triphosphate Concentrations in Blood Cells Compared With Isolated Peripheral Blood Mononuclear Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 260-266.	0.9	37
190	Phylogenetic inferences on HIV-1 transmission. <i>Aids</i> , 2013, 27, 1045-1057.	1.0	83
191	Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 87-94.	0.9	118
192	Antiretroviral Therapy for Prevention of HIV and Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S200-S207.	0.9	10
193	Ethics and Pre-exposure Prophylaxis for HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S135-S139.	0.9	18
194	Preexposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S122-S129.	0.9	139
195	Assessing the effect of HIV counselling and testing on HIV acquisition among South African youth. <i>Aids</i> , 2013, 27, 2765-2773.	1.0	38
196	Integrating Behavioral and Biomedical Research in HIV Interventions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S6-S11.	0.9	16
197	Resource allocation for HIV prevention. <i>Aids</i> , 2013, 27, 1997-1998.	1.0	1
198	Why vulnerable young women at risk of HIV should be prioritized for access to preexposure prophylaxis. <i>Aids</i> , 2013, 27, 1998-1999.	1.0	1
199	Can Combination Prevention Strategies Reduce HIV Transmission in Generalized Epidemic Settings in Africa? The HPTN 071 (PopART) Study Plan in South Africa and Zambia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S221-S227.	0.9	39
200	The new role of antiretrovirals in combination HIV prevention. <i>Aids</i> , 2013, 27, 447-458.	1.0	122
201	Microbicides from a regulatory perspective. <i>Aids</i> , 2013, 27, 2261-2269.	1.0	4
202	Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and Persistent Viremia in Patients Initiating ARVs in Rural Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 317-321.	0.9	43
203	Preventing HIV Infection in Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, S168-S173.	0.9	38

#	ARTICLE	IF	CITATIONS
204	HIV Medical Providers' Perceptions of the Use of Antiretroviral Therapy as Nonoccupational Postexposure Prophylaxis in 2 Major Metropolitan Areas. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 64, S68-S79.	0.9	36
205	Study Design Considerations for Evaluating Efficacy of Systemic Preexposure Prophylaxis Interventions. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, S130-S134.	0.9	17
206	Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women. <i>Antiviral Therapy</i> , 2013, 18, 1005-1013.	0.6	32
207	Pre-exposure prophylaxis for HIV prevention: Ready for prime time in South Africa?. <i>South African Medical Journal</i> , 2013, 103, 515.	0.2	13
208	Antiretroviral therapy, pregnancy, and birth defects: a discussion on the updated data. <i>HIV/AIDS - Research and Palliative Care</i> , 2013, 5, 181.	0.4	7
209	Neurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenya. <i>International Medical Case Reports Journal</i> , 2013, 6, 91.	0.3	5
211	Personalized Biobehavioral HIV Prevention for Women and Adolescent Girls. <i>Global Advances in Health and Medicine</i> , 2013, 2, 100-108.	0.7	6
212	Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial. <i>PLoS ONE</i> , 2013, 8, e56400.	1.1	9
213	Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009). <i>PLoS ONE</i> , 2013, 8, e59787.	1.1	27
214	Determinants of Prevalent HIV Infection and Late HIV Diagnosis among Young Women with Two or More Sexual Partners in Beira, Mozambique. <i>PLoS ONE</i> , 2013, 8, e63427.	1.1	17
215	Awareness and Willingness to Use HIV Pre-Exposure Prophylaxis amongst Gay and Bisexual Men in Scotland: Implications for Biomedical HIV Prevention. <i>PLoS ONE</i> , 2013, 8, e64038.	1.1	58
216	Awareness of and Willingness to Use Oral Pre-Exposure Prophylaxis for HIV Prevention among HIV-Serodiscordant Heterosexual Couples: A Cross-Sectional Survey in Xinjiang, China. <i>PLoS ONE</i> , 2013, 8, e67392.	1.1	13
217	Disinhibition in Risky Sexual Behavior in Men, but Not Women, during Four Years of Antiretroviral Therapy in Rural, Southwestern Uganda. <i>PLoS ONE</i> , 2013, 8, e69634.	1.1	16
218	Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e74314.	1.1	69
219	Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures. <i>PLoS ONE</i> , 2013, 8, e76482.	1.1	32
220	Acceptability of Pre-Exposure Prophylaxis among Men Who Have Sex with Men and Transgender Women in Northern Thailand. <i>PLoS ONE</i> , 2013, 8, e76650.	1.1	63
221	Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study. <i>PLoS ONE</i> , 2013, 8, e59549.	1.1	40
222	Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. <i>International Journal of Women's Health</i> , 2013, 5, 695.	1.1	73

#	ARTICLE	IF	CITATIONS
223	Sexually Transmitted Infections and Sexual Function in Relation to Male Fertility. Korean Journal of Urology, 2013, 54, 149.	1.2	34
224	Prevention of Sexually Transmitted HIV Infection. , 2013, , .		0
225	'Getting to zero' in Asia and the Pacific through more strategic use of antiretrovirals for HIV prevention. Sexual Health, 2014, 11, 107.	0.4	4
226	How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework towards an Effective Response to HIV. PLoS ONE, 2014, 9, e111956.	1.1	67
227	High rates of sexually transmissible infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. Sexual Health, 2014, 11, 291.	0.4	5
228	Effectiveness and Cost Effectiveness of Oral Pre-Exposure Prophylaxis in a Portfolio of Prevention Programs for Injection Drug Users in Mixed HIV Epidemics. PLoS ONE, 2014, 9, e86584.	1.1	47
229	Abriendo Puertas: Baseline Findings from an Integrated Intervention to Promote Prevention, Treatment and Care among FSW Living with HIV in the Dominican Republic. PLoS ONE, 2014, 9, e88157.	1.1	63
230	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). PLoS ONE, 2014, 9, e83736.	1.1	125
231	Food Insecurity Is Associated with Increased Risk of Non-Adherence to Antiretroviral Therapy among HIV-Infected Adults in the Democratic Republic of Congo: A Cross-Sectional Study. PLoS ONE, 2014, 9, e85327.	1.1	72
232	HIV Pre-Exposure Prophylaxis Interest among Female Sex Workers in Guangxi, China. PLoS ONE, 2014, 9, e86200.	1.1	41
233	Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy. PLoS ONE, 2014, 9, e88509.	1.1	86
234	Preparing for PrEP: Perceptions and Readiness of Canadian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis. PLoS ONE, 2014, 9, e105283.	1.1	54
235	A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate. PLoS ONE, 2014, 9, e106196.	1.1	28
236	Access to Healthcare, HIV/STI Testing, and Preferred Pre-Exposure Prophylaxis Providers among Men Who Have Sex with Men and Men Who Engage in Street-Based Sex Work in the US. PLoS ONE, 2014, 9, e112425.	1.1	59
237	MABGEL 1: First Phase 1 Trial of the Anti-HIV-1 Monoclonal Antibodies 2F5, 4E10 and 2G12 as a Vaginal Microbicide. PLoS ONE, 2014, 9, e116153.	1.1	26
238	Can treatment-based HIV prevention curb the epidemic among gay and other men who have sex with men? A narrative synthesis of increasing evidence for moderating and countervailing effects. Sexual Health, 2014, 11, 137.	0.4	7
239	HIV Treatment as Prevention: Contradictory Perspectives from Dynamic Mathematical Models. Scientific World Journal, The, 2014, 2014, 1-9.	0.8	2
240	Biomedical HIV prevention research and epidemic control in Thailand: two sides of the same coin. Sexual Health, 2014, 11, 180.	0.4	19



#	ARTICLE	IF	CITATIONS
241	Acceptability of Condoms, Circumcision and PrEP among Young Black Men Who Have Sex with Men: A Descriptive Study Based on Effectiveness and Cost. <i>Vaccines</i> , 2014, 2, 129-137.	2.1	18
242	Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICEâ€™ qualitative study in Johannesburg, South Africa. <i>Journal of the International AIDS Society</i> , 2014, 17, 19146.	1.2	111
243	ARV-based HIV prevention for women â€œ where we are in 2014. <i>Journal of the International AIDS Society</i> , 2014, 17, 19154.	1.2	17
244	HIV preâ€™exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. <i>Journal of the International AIDS Society</i> , 2014, 17, 18899.	1.2	31
245	The potential for bridging: HIV status awareness and risky sexual behaviour of injection drug users who have nonâ€™injecting permanent partners in Ukraine. <i>Journal of the International AIDS Society</i> , 2014, 17, 18825.	1.2	16
246	Provider Attitudes toward Discussing Fertility Intentions with HIV-Infected Women and Serodiscordant Couples in the USA. <i>Journal of AIDS &amp; Clinical Research</i> , 2014, 05, 1000307.	0.5	8
247	Role of male partners in the prevention of mother-to-child HIV transmission. <i>Research and Reports in Neonatology</i> , 2014, , 131.	0.2	4
248	Attitudes and Barriers towards Pre-Exposure Prophylaxis (Prep) among High-Risk HIV-Seronegative Men who have Sex with Men. <i>Journal of AIDS &amp; Clinical Research</i> , 2014, 05, .	0.5	7
249	Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24â€™month prospective study in CÃ´te d'Ivoire. <i>Journal of the International AIDS Society</i> , 2014, 17, 18977.	1.2	11
250	Widow cleansing and inheritance among the Luo in Kenya: the need for additional womenâ€™centred HIV prevention options. <i>Journal of the International AIDS Society</i> , 2014, 17, 19010.	1.2	32
251	Sources of HIV incidence among stable couples in subâ€™Saharan Africa. <i>Journal of the International AIDS Society</i> , 2014, 17, 18765.	1.2	60
252	Women and ARV-based prevention: opportunities and challenges. <i>Journal of the International AIDS Society</i> , 2014, 17, 19419.	1.2	1
253	Cost-Effectiveness of PrEP in HIV/AIDS Control in Zambia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 221-228.	0.9	25
254	Will Risk Compensation Accompany Pre-Exposure Prophylaxis for HIV?. <i>AMA Journal of Ethics</i> , 2014, 16, 909-915.	0.4	48
255	Assessing the Public Health Impact of HIV Interventions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, e60-e62.	0.9	1
256	Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 206-212.	0.9	26
257	Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa. <i>Nature Communications</i> , 2014, 5, 5454.	5.8	30
258	A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 314-323.	2.3	97

#	ARTICLE	IF	CITATIONS
259	Perspectives on HIV Prevention Among Urban Black Women: A Potential Role for HIV Pre-Exposure Prophylaxis. <i>AIDS Patient Care and STDs</i> , 2014, 28, 635-642.	1.1	85
260	Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. <i>BMC Pharmacology &amp; Toxicology</i> , 2014, 15, 77.	1.0	16
261	Modeling the Implementation of Universal Coverage for HIV Treatment as Prevention and its Impact on the HIV Epidemic. <i>Current HIV/AIDS Reports</i> , 2014, 11, 459-467.	1.1	16
262	Optimizing ART Adherence: Update for HIV Treatment and Prevention. <i>Current HIV/AIDS Reports</i> , 2014, 11, 423-433.	1.1	42
263	Combination HIV Prevention Interventions: The Potential of Integrated Behavioral and Biomedical Approaches. <i>Current HIV/AIDS Reports</i> , 2014, 11, 363-375.	1.1	30
264	<i>My intention was a child but I was very afraid</i>: fertility intentions and HIV risk perceptions among HIV-serodiscordant couples experiencing pregnancy in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1283-1287.	0.6	53
265	Getting to zero the biomedical way in Africa: outcomes of deliberation at the 2013 Biomedical HIV Prevention Forum in Abuja, Nigeria. <i>BMC Proceedings</i> , 2014, 8, S1.	1.8	0
266	South Africans with recent pregnancy rarely know partner's HIV serostatus: implications for serodiscordant couples interventions. <i>BMC Public Health</i> , 2014, 14, 843.	1.2	32
267	Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1521-1525.	0.6	14
268	An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study. <i>BMC Public Health</i> , 2014, 14, 986.	1.2	25
269	Vaginally Delivered Tenofovir Disoproxil Fumarate Provides Greater Protection than Tenofovir against Genital Herpes in a Murine Model of Efficacy and Safety. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1153-1160.	1.4	22
270	Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. <i>Bioanalysis</i> , 2014, 6, 1907-1921.	0.6	15
271	Antiretroviral Chemoprophylaxis: State of Evidence and the Research Agenda. <i>Clinical Infectious Diseases</i> , 2014, 59, S47-S51.	2.9	17
272	HIV-1 Genital Shedding is Suppressed in the Setting of High Genital Antiretroviral Drug Concentrations Throughout the Menstrual Cycle. <i>Journal of Infectious Diseases</i> , 2014, 210, 736-744.	1.9	16
273	Oral Pre-Exposure Prophylaxis (PrEP) for Prevention of HIV in Serodiscordant Heterosexual Couples in the United States: Opportunities and Challenges. <i>AIDS Patient Care and STDs</i> , 2014, 28, 462-474.	1.1	66
274	Survey of HIV care providers on management of HIV serodiscordant couples – assessment of attitudes, knowledge, and practices. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1435-1439.	0.6	15
275	Multipurpose prevention technologies for reproductive and sexual health. <i>Reproductive Health Matters</i> , 2014, 22, 213-217.	1.3	10
276	Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5125-5135.	1.4	33



#	ARTICLE	IF	CITATIONS
277	HIV-1 Drug Resistance in Preexposure Prophylaxis Trials. , 2014, , 1-18.		0
278	Incident HIV during Pregnancy and Postpartum and Risk of Mother-to-Child HIV Transmission: A Systematic Review and Meta-Analysis. PLoS Medicine, 2014, 11, e1001608.	3.9	364
279	Antiretroviral Therapy for the Prevention of HIV Transmission: What Will It Take?. Clinical Infectious Diseases, 2014, 58, 1003-1011.	2.9	50
280	Neurology and the Global HIV Epidemic. Seminars in Neurology, 2014, 34, 070-077.	0.5	9
281	The Rise and Fall of HIV in High-Prevalence Countries: A Challenge for Mathematical Modeling. PLoS Computational Biology, 2014, 10, e1003459.	1.5	22
282	Gene Therapy Targeting HIV Entry. Viruses, 2014, 6, 1395-1409.	1.5	12
283	Early Experiences Implementing Pre-exposure Prophylaxis (PrEP) for HIV Prevention in San Francisco. PLoS Medicine, 2014, 11, e1001613.	3.9	213
284	Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. Frontiers in Immunology, 2014, 5, 202.	2.2	14
285	Antiviral Activity of Genital Tract Secretions After Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 65-73.	0.9	23
286	Committee Opinion No 595. Obstetrics and Gynecology, 2014, 123, 1133-1136.	1.2	38
287	Pre-Exposure Prophylaxis to Prevent HIV Infection: Why Do We Need It, What Are the Limitations, and Can We Successfully Provide It Today?. LGBT Health, 2014, 1, 250-252.	1.8	1
288	Considering Pre-Exposure Prophylaxis: Do the Pros Outweigh the Cons as an HIV Prevention Strategy?. LGBT Health, 2014, 1, 253-255.	1.8	2
289	Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning. Journal of the International AIDS Society, 2014, 17, 19162.	1.2	16
290	Communicating about microbicides with women in mind: tailoring messages for specific audiences. Journal of the International AIDS Society, 2014, 17, 19151.	1.2	11
291	An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal rings. Journal of the International AIDS Society, 2014, 17, 19158.	1.2	21
292	WHO guidance grounded in a comprehensive approach to sexual and reproductive health and human rights: topical pre-exposure prophylaxis. Journal of the International AIDS Society, 2014, 17, 19279.	1.2	5
293	Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention. JAMA - Journal of the American Medical Association, 2014, 312, 362.	3.8	110
294	Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 167-170.	0.7	5

#	ARTICLE	IF	CITATIONS
296	Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples. <i>The Lancet Global Health</i> , 2014, 2, e664-e671.	2.9	32
297	Antiretrovirals for HIV prevention: when should they be recommended?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 431-445.	2.0	1
298	Helping our patients take <sc>HIV</sc> pre-exposure prophylaxis (<sc>PrEP</sc>): a systematic review of adherence interventions. <i>HIV Medicine</i> , 2014, 15, 385-395.	1.0	52
299	Strategies for Preventing Mucosal Cell-Associated HIV Transmission. <i>Journal of Infectious Diseases</i> , 2014, 210, S674-S680.	1.9	12
300	Preventing HIV infection: Pre-exposure and postexposure prophylaxis. <i>IUBMB Life</i> , 2014, 66, 453-461.	1.5	3
301	The Medicalization of HIV Prevention: New Opportunities Beset by Old Challenges. <i>Milbank Quarterly</i> , 2014, 92, 434-437.	2.1	2
302	A Multilevel Understanding of HIV/AIDS Disease Burden Among African American Women. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2014, 43, 633-643.	0.2	37
303	Medication Adherence Among Men Who Have Sex with Men at Risk for HIV Infection in the United States: Implications for Pre-Exposure Prophylaxis Implementation. <i>AIDS Patient Care and STDs</i> , 2014, 28, 622-627.	1.1	34
304	Estimating the effectiveness in HIV prevention trials by incorporating the exposure process: Application to HPTN 035 data. <i>Biometrics</i> , 2014, 70, 742-750.	0.8	3
305	When is good good enough for HIV-1 prophylaxis?. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1024-1025.	4.6	1
306	Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use. <i>Journal of Medical Primatology</i> , 2014, 43, 364-369.	0.3	16
307	Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1055-1064.	4.6	94
308	Designing Preclinical Perceptibility Measures to Evaluate Topical Vaginal Gel Formulations: Relating User Sensory Perceptions and Experiences to Formulation Properties. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 78-91.	0.5	31
309	Exposure Ethics: Does Hiv Pre-Exposure Prophylaxis Raise Ethical Problems for the Health Care Provider and Policy Maker?. <i>Bioethics</i> , 2014, 28, 269-274.	0.7	20
310	Pre-exposure Prophylaxis for Human Immunodeficiency Virus. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 563-583.	1.9	17
311	Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 150-160.	1.0	10
312	The Adolescent and Young Adult HIV Cascade of Care in the United States: Exaggerated Health Disparities. <i>AIDS Patient Care and STDs</i> , 2014, 28, 128-135.	1.1	348
313	The changing face of the <sc>HIV</sc> epidemic in sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2014, 19, 1015-1028.	1.0	31

#	ARTICLE	IF	CITATIONS
314	HIV infection. , 2014, , 167-184.		0
315	Topical microbicides and HIV prevention in the female genital tract. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 603-615.	1.0	21
317	Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. <i>Clinical Medicine Insights Women's Health</i> , 2014, 7, CMWH.S10353.	0.6	30
318	Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1020-1026.	2.9	132
319	Characteristics of sexually experienced HIV testers aged 18 to 32 in rural South Africa: baseline results from a community-based trial, NIMH Project Accept (HPTN 043). <i>BMC Public Health</i> , 2014, 14, 1164.	1.2	7
320	Engaging, Recruiting, and Retaining Black Men Who Have Sex With Men in Research Studies. <i>Journal of Public Health Management and Practice</i> , 2014, 20, E1-E9.	0.7	32
321	HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 340-348.	0.9	270
322	Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 528-537.	0.9	63
323	Oral preexposure prophylaxis to prevent HIV infection. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2014, 27, 10-17.	0.1	2
324	Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. <i>Aids</i> , 2014, 28, 1825-1830.	1.0	37
325	High Medication Adherence During Periconception Periods Among HIV-1-â€œUninfected Women Participating in a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 91-97.	0.9	33
326	An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 522-529.	0.9	56
327	HIV sexual transmission risk among serodiscordant couples. <i>Aids</i> , 2014, 28, 1521-1529.	1.0	56
328	Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. <i>Aids</i> , 2014, 28, 2771-2776.	1.0	38
329	Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men. <i>Aids</i> , 2014, 28, 1977-1982.	1.0	18
330	Perception of HIV Risk and Adherence to a Daily, Investigational Pill for HIV Prevention in FEM-PrEP. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 555-563.	0.9	65
331	Lost Opportunities to Reduce Periconception HIV Transmission. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, S210-S217.	0.9	45
332	Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight. <i>Aids</i> , 2014, 28, 1903-1910.	1.0	62

#	ARTICLE	IF	CITATIONS
333	Pregnancy Intent Among a Sample of Recently Diagnosed HIV-Positive Women and Men Practicing Unprotected Sex in Cape Town, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, S202-S209.	0.9	20
334	Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York. <i>Aids</i> , 2014, 28, 2683-2691.	1.0	56
335	Using the Number Needed to Treat to Assess Appropriate Antimicrobial Therapy as a Determinant of Outcome in Severe Sepsis and Septic Shock*. <i>Critical Care Medicine</i> , 2014, 42, 2342-2349.	0.4	88
336	Delay of Antiretroviral Therapy Initiation Is Common in East African HIV-Infected Individuals in Serodiscordant Partnerships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 436-442.	0.9	33
337	FEM-PrEP. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 324-331.	0.9	139
338	Implementation of a safer conception service for HIV-affected couples in South Africa. <i>Aids</i> , 2014, 28, S277-S285.	1.0	48
339	Emerging antiretroviral drug resistance in sub-Saharan Africa. <i>Aids</i> , 2014, 28, 2643-2648.	1.0	5
340	Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2470-2476.	1.3	19
341	HIV Prevention in Clinical Care Settings. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 390.	3.8	109
342	Pharmacokinetic and Safety Analyses of Tenofovir and Tenofovir-Emtricitabine Vaginal Tablets in Pigtailed Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2665-2674.	1.4	29
343	A Cost-effectiveness Analysis of HIV Preexposure Prophylaxis for Men Who Have Sex With Men in Australia. <i>Clinical Infectious Diseases</i> , 2014, 58, 1027-1034.	2.9	54
344	Human Immunodeficiency Viruses Types 1 and 2. , 2014, , 1001-1062.		0
345	Beyond the Ball: Implications for HIV Risk and Prevention Among the Constructed Families of African American Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2014, 18, 2156-2168.	1.4	27
346	Integrating HIV Prevention Into Practice. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 349.	3.8	5
347	HIV infection and high-risk behaviours in a Paraguayan military population. <i>International Journal of STD and AIDS</i> , 2014, 25, 866-877.	0.5	7
348	Cost-effectiveness of provider-based HIV partner notification in urban Malawi. <i>Health Policy and Planning</i> , 2014, 29, 115-126.	1.0	49
349	Systemic Preexposure Prophylaxis for HIV. <i>Annals of Pharmacotherapy</i> , 2014, 48, 507-518.	0.9	2
350	Lessons learnt from implementing an empirically informed recruitment approach for FEM-PrEP, a large HIV prevention clinical trial. <i>Open Access Journal of Clinical Trials</i> , 0, , 1.	1.5	0

#	ARTICLE	IF	CITATIONS
351	Herausforderungen in der Diagnostik und Prävention von Viruserkrankungen. <i>Laboratoriums Medizin</i> , 2014, 38, .	0.1	0
352	Pre-exposure prophylaxis for conception (PrEP-C) as a risk reduction strategy in HIV-positive men and HIV-negative women in the UK. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 332-336.	0.6	38
353	Estimating per-act HIV transmission risk. <i>Aids</i> , 2014, 28, 1509-1519.	1.0	609
354	Adherence to HIV postexposure prophylaxis. <i>Aids</i> , 2014, 28, 2721-2727.	1.0	65
355	The need for multipurpose prevention technologies in sub-Saharan Africa. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 27-34.	1.1	35
356	The future of multipurpose prevention technology product strategies: understanding the market in parallel with product development. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 15-18.	1.1	13
357	Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. <i>The Lancet Global Health</i> , 2014, 2, e267-e277.	2.9	141
358	Impact of Tenofovir gel as a PrEP on HIV infection: A mathematical model. <i>Journal of Theoretical Biology</i> , 2014, 347, 151-159.	0.8	6
359	HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 468-475.	4.6	128
360	Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. <i>Lancet</i> , The, 2014, 384, 272-279.	6.3	107
361	Factors Informing HIV Providers' Decisions to Start Antiretroviral Therapy for Young People Living With Behaviorally Acquired HIV. <i>Journal of Adolescent Health</i> , 2014, 55, 358-365.	1.2	19
362	Knowledge of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men in Denver, Colorado. <i>AIDS and Behavior</i> , 2014, 18, 340-347.	1.4	31
363	Adherence to Post-Exposure Prophylaxis for Non-forcible Sexual Exposure to HIV: A Systematic Review and Meta-Analysis. <i>AIDS and Behavior</i> , 2014, 18, 217-225.	1.4	31
364	Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 70-85.	1.0	43
365	Racial/Ethnic Differences in Trust in Health Care: HIV Conspiracy Beliefs and Vaccine Research Participation. <i>Journal of General Internal Medicine</i> , 2014, 29, 140-146.	1.3	43
366	High Rates of Relationship Dissolution Among Heterosexual HIV-Serodiscordant Couples in Kenya. <i>AIDS and Behavior</i> , 2014, 18, 189-193.	1.4	28
367	“Set it and Forget it” Women’s Perceptions and Opinions of Long-Acting Topical Vaginal Gels. <i>AIDS and Behavior</i> , 2014, 18, 862-870.	1.4	29
368	Sensitive Tenofovir Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 Tenofovir Gel Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1916-1920.	1.9	13

#	ARTICLE	IF	CITATIONS
369	Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. <i>BMC Infectious Diseases</i> , 2014, 14, 14.	1.3	28
370	Altitudinal Changes in Malaria Incidence in Highlands of Ethiopia and Colombia. <i>Science</i> , 2014, 343, 1154-1158.	6.0	270
371	Methods for Measuring, Enhancing, and Accounting for Medication Adherence in Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 617-626.	2.3	107
372	A control systems analysis of HIV prevention model using impulsive input. <i>Biomedical Signal Processing and Control</i> , 2014, 13, 123-131.	3.5	20
373	Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells. <i>Journal of Virological Methods</i> , 2014, 199, 17-24.	1.0	2
374	New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. <i>Drugs</i> , 2014, 74, 7-13.	4.9	35
375	Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2014, 58, 704-712.	2.9	158
376	Role of Oral Pre-exposure Prophylaxis (PrEP) in Current and Future HIV Prevention Strategies. <i>Current HIV/AIDS Reports</i> , 2014, 11, 393-403.	1.1	23
377	HIV pre-exposure prophylaxis. <i>Cmaj</i> , 2014, 186, E588-E588.	0.9	0
378	A Polyvalent Clade B Virus-Like Particle HIV Vaccine Combined with Partially Protective Oral Preexposure Prophylaxis Prevents Simianâ€”Human Immunodeficiency Virus Infection in Macaques and Primates for Virus-Amplified Immunity. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1072-1081.	0.5	6
379	Induction of Intestinal Immunity by Mucosal Vaccines As a Means of Controlling HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1027-1040.	0.5	16
380	An Overview of Antiretroviral Preâ€”Exposure Prophylaxis of <sc>HIV</sc> Infection. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 624-630.	1.2	23
381	HIV Providersâ€™ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study. <i>AIDS and Behavior</i> , 2014, 18, 1712-1721.	1.4	259
382	Pre-Exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE Study). <i>AIDS and Behavior</i> , 2014, 18, 1722-1725.	1.4	73
383	Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1483-1494.	2.9	33
384	Biomedical Prevention: State of the Science. <i>Clinical Infectious Diseases</i> , 2014, 59, S41-S46.	2.9	10
385	Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence. <i>Clinical Infectious Diseases</i> , 2014, 59, S55-S60.	2.9	108
386	Controlling the HIV Epidemic With Antiretrovirals: Moving From Consensus to Implementation. <i>Clinical Infectious Diseases</i> , 2014, 59, S1-S2.	2.9	10

#	ARTICLE	IF	CITATIONS
387	A Paradigm Shift: Focus on the HIV Prevention Continuum. <i>Clinical Infectious Diseases</i> , 2014, 59, S12-S15.	2.9	80
388	Advances in HIV Prevention for Serodiscordant Couples. <i>Current HIV/AIDS Reports</i> , 2014, 11, 434-446.	1.1	49
389	Moving HIV PrEP from research into practice. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 781-783.	4.6	3
390	Examining the Role of Serostatus Disclosure on Unprotected Sex Among People Living with HIV. <i>AIDS Patient Care and STDs</i> , 2014, 28, 677-684.	1.1	17
391	Advancing HIV prevention science: the roads from Cape Town. <i>Lancet</i> , The, 2014, 384, 1725-1727.	6.3	0
392	Innovations in HIV Prevention Research and Practice through Community Engagement. , 2014, , .		10
393	Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus. <i>Science</i> , 2014, 343, 1151-1154.	6.0	145
394	Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 684-693.	0.6	65
395	The role of HIV serostatus disclosure on sexual risk behaviours among people living with HIV in steady partnerships in Rio de Janeiro, Brazil. <i>Global Public Health</i> , 2014, 9, 1093-1106.	1.0	7
396	Human Immunodeficiency Virus Vaccines. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 615-631.	1.9	5
398	Effects of Hormonal Contraception on Antiretroviral Drug Metabolism, Pharmacokinetics and Pharmacodynamics. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 523-530.	1.2	25
399	The case for transmissible antivirals to control population-wide infectious disease. <i>Trends in Biotechnology</i> , 2014, 32, 400-405.	4.9	25
400	HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model. <i>Virology</i> , 2014, 464-465, 253-263.	1.1	34
401	Challenges of infectious diseases in the USA. <i>Lancet</i> , The, 2014, 384, 53-63.	6.3	92
402	Moving the Bar to the Right Place: Positioning Interventions in HIV Prevention. <i>AIDS and Behavior</i> , 2014, 18, 634-637.	1.4	2
403	Optimizing Content for Pre-exposure Prophylaxis (PrEP) Counseling for Men Who Have Sex with Men: Perspectives of PrEP Users and High-Risk PrEP Na <sup>+</sup> ve Men. <i>AIDS and Behavior</i> , 2014, 18, 871-879.	1.4	68
404	The Impact of Patient Race on Clinical Decisions Related to Prescribing HIV Pre-Exposure Prophylaxis (PrEP): Assumptions About Sexual Risk Compensation and Implications for Access. <i>AIDS and Behavior</i> , 2014, 18, 226-240.	1.4	204
405	Prevalence and Public Health Implications of State Laws that Criminalize Potential HIV Exposure in the United States. <i>AIDS and Behavior</i> , 2014, 18, 997-1006.	1.4	97



#	ARTICLE	IF	CITATIONS
406	Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. <i>AIDS and Behavior</i> , 2014, 18, 841-848.	1.4	20
407	Willingness to Use HIV Pre-Exposure Prophylaxis Among Opiate Users. <i>AIDS and Behavior</i> , 2014, 18, 1694-1700.	1.4	71
408	Impact of Antiretroviral Therapy on Health-Related Quality of Life among South African Women in the CAPRISA 002 Acute Infection Study. <i>AIDS and Behavior</i> , 2014, 18, 1801-1807.	1.4	18
409	Preferences for Daily or Intermittent Pre-exposure Prophylaxis Regimens and Ability to Anticipate Sex Among HIV Uninfected Members of Kenyan HIV Serodiscordant Couples. <i>AIDS and Behavior</i> , 2014, 18, 1701-1711.	1.4	15
410	Effects of Messaging About Multiple Biomedical and Behavioral HIV Prevention Methods on Intentions to use Among US MSM: Results of an Experimental Messaging Study. <i>AIDS and Behavior</i> , 2014, 18, 1651-1660.	1.4	19
411	Adaptation of the African couples HIV testing and counseling model for men who have sex with men in the United States: an application of the ADAPT-ITT framework. <i>SpringerPlus</i> , 2014, 3, 249.	1.2	64
412	Electrospun Solid Dispersions of Maraviroc for Rapid Intravaginal Preexposure Prophylaxis of HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4855-4865.	1.4	62
413	A Lifecycle Approach to HIV Prevention in African Women and Children. <i>Current HIV/AIDS Reports</i> , 2014, 11, 119-127.	1.1	8
414	Pharmacokinetics of Antiretrovirals in Genital Secretions and Anatomic Sites of HIV Transmission: Implications for HIV Prevention. <i>Clinical Pharmacokinetics</i> , 2014, 53, 611-624.	1.6	46
415	Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: Results of a consultation with community stakeholders. <i>BMC Health Services Research</i> , 2014, 14, 231.	0.9	62
416	Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. <i>Trials</i> , 2014, 15, 68.	0.7	11
417	Renal Function of Participants in the Bangkok Tenofovir Study–Thailand, 2005-2012. <i>Clinical Infectious Diseases</i> , 2014, 59, 716-724.	2.9	58
418	Correlation between Plasma, Intracellular, and Cervical Tissue Levels of Raltegravir at Steady-State Dosing in Healthy Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3360-3365.	1.4	12
419	Systematic Review of Couple-Based HIV Intervention and Prevention Studies: Advantages, Gaps, and Future Directions. <i>AIDS and Behavior</i> , 2014, 18, 1864-1887.	1.4	115
420	Formulation and delivery of anti-HIV rectal microbicides: Advances and challenges. <i>Journal of Controlled Release</i> , 2014, 194, 278-294.	4.8	39
421	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	4.6	1,039
422	Considerations for Implementing Oral Preexposure Prophylaxis: A Literature Review. <i>Journal of the Association of Nurses in AIDS Care</i> , 2014, 25, 496-507.	0.4	13
423	Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery. <i>International Journal of Pharmaceutics</i> , 2014, 475, 282-291.	2.6	76



#	ARTICLE	IF	CITATIONS
424	Qualitative evaluation of a Positive Prevention training for health care providers in Mozambique. <i>Evaluation and Program Planning</i> , 2014, 43, 38-47.	0.9	7
425	Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?. <i>Contraception</i> , 2014, 90, 136-141.	0.8	5
426	Pre-exposure prophylaxis to intensify the fight against HIV. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 443-445.	4.6	7
427	HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227.	1.9	68
428	The development of rectal microbicides for HIV prevention. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 69-82.	2.4	43
429	HIV infection: epidemiology, pathogenesis, treatment, and prevention. <i>Lancet, The</i> , 2014, 384, 258-271.	6.3	616
430	Challenges and potential barriers to the uptake of antiretroviral-based prevention in Asia and the Pacific region. <i>Sexual Health</i> , 2014, 11, 126.	0.4	14
431	Daily Oral Tenofovir and Emtricitabine—Tenofovir Preexposure Prophylaxis Reduces Herpes Simplex Virus Type 2 Acquisition Among Heterosexual HIV-1–Uninfected Men and Women. <i>Annals of Internal Medicine</i> , 2014, 161, 11.	2.0	51
432	The key role of adherence for the effectiveness of antiretroviral-based prevention: state of the science and implications for the Asia-Pacific region. <i>Sexual Health</i> , 2014, 11, 155.	0.4	6
433	Acceptability of oral and topical HIV chemoprophylaxis in India: implications for at-risk women and men who have sex with men. <i>Sexual Health</i> , 2014, 11, 171.	0.4	11
434	Women and ARV–based HIV prevention – challenges and opportunities. <i>Journal of the International AIDS Society</i> , 2014, 17, 19356.	1.2	18
435	The Truvada wars. <i>BMJ, The</i> , 2014, 348, g3811-g3811.	3.0	18
436	Adolescent sexual health communication and condom use: A meta-analysis.. <i>Health Psychology</i> , 2014, 33, 1113-1124.	1.3	116
437	Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 33-41.	0.9	60
438	Knowledge and Attitudes About Preexposure Prophylaxis (PrEP) Among Sexually Active Men Who Have Sex with Men and Who Participate in New York City Gay Pride Events. <i>LGBT Health</i> , 2014, 1, 93-97.	1.8	22
439	Opportunity Knocks: HIV Prevention in Primary Care. <i>LGBT Health</i> , 2014, 1, 75-78.	1.8	8
440	Sexual Risk Trajectories Among MSM in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 579-586.	0.9	67
441	HIV Prevention for Adults With Criminal Justice Involvement: A Systematic Review of HIV Risk-Reduction Interventions in Incarceration and Community Settings. <i>American Journal of Public Health</i> , 2014, 104, e27-e53.	1.5	53

#	ARTICLE	IF	CITATIONS
442	Pregnancy Intentions Among Women Living With HIV in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 306-311.	0.9	41
443	Evidence-Based Programming for Adolescent HIV Prevention and Care. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, S228-S235.	0.9	11
444	Exploratory survey of Florida pharmacists's™ experience, knowledge, and perception of HIV pre-exposure prophylaxis. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 610-617.	0.7	37
445	Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. <i>Aids</i> , 2014, 28, 851-859.	1.0	123
446	Is preexposure prophylaxis ready for prime time use in HIV prevention research?. <i>Aids</i> , 2014, 28, 293-295.	1.0	5
447	CD4+ cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis. <i>Aids</i> , 2014, 28, 223-226.	1.0	22
448	The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. <i>Aids</i> , 2015, 29, 819-824.	1.0	77
449	Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. <i>Aids</i> , 2015, 29, 2035-2044.	1.0	39
450	Targeting Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in the United States and Peru. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 119-125.	0.9	25
451	HIV infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15035.	18.1	340
452	Challenges in the diagnosis and prevention of viral infections. <i>Laboratoriums Medizin</i> , 2015, 38, .	0.1	2
453	HIV in pregnant women and prevention of perinatal transmission. <i>Microbiology Australia</i> , 2015, 36, 182.	0.1	0
454	Preexposure Prophylaxis for HIV Prevention. <i>Annals of Internal Medicine</i> , 2015, 163, 941-948.	2.0	1
455	Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 278-281.	1.5	3
456	Passing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men. <i>Contemporary Clinical Trials</i> , 2015, 45, 244-251.	0.8	19
457	Predictors of couple HIV counseling and testing among adult residents of Bukomero sub-county, Kiboga district, rural Uganda. <i>BMC Public Health</i> , 2015, 15, 1171.	1.2	17
458	MSM and HIV-1 infection in China. <i>National Science Review</i> , 2015, 2, 388-391.	4.6	28
459	Pre-exposure Prophylaxis for the Prevention of HIV Disease in Heterosexuals. <i>Current Sexual Health Reports</i> , 2015, 7, 205-209.	0.4	0

#	ARTICLE	IF	CITATIONS
460	HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. <i>Aids</i> , 2015, 29, 2025-2033.	1.0	71
461	Strengthening HIV surveillance in the antiretroviral therapy era: rationale and design of a longitudinal study to monitor HIV prevalence and incidence in the uMgungundlovu District, KwaZulu-Natal, South Africa. <i>BMC Public Health</i> , 2015, 15, 1149.	1.2	33
462	A systematic review of the clinical and social epidemiological research among sex workers in Uganda. <i>BMC Public Health</i> , 2015, 15, 1226.	1.2	25
463	Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques. <i>Retrovirology</i> , 2015, 12, 69.	0.9	13
464	Protocol for a systematic review: understanding the motivations and barriers to uptake and use of female-initiated, primary biomedical HIV prevention technologies in sub-Saharan Africa. <i>Systematic Reviews</i> , 2015, 4, 111.	2.5	14
465	Fertility Decision-Making Among Kenyan HIV-Serodiscordant Couples Who Recently Conceived: Implications for Safer Conception Planning. <i>AIDS Patient Care and STDs</i> , 2015, 29, 510-516.	1.1	29
466	Data Collection and Harmonization in HIV Research: The Seek, Test, Treat, and Retain Initiative at the National Institute on Drug Abuse. <i>American Journal of Public Health</i> , 2015, 105, 2416-2422.	1.5	63
467	Beyond "getting drugs into bodies": social science perspectives on pre-exposure prophylaxis for HIV. <i>Journal of the International AIDS Society</i> , 2015, 18, 19983.	1.2	106
468	Cabotegravir long-acting for HIV-1 prevention. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 258-263.	1.5	50
469	Pharmacologic Prevention of Human Immunodeficiency Virus in Women. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 284-290.	0.2	8
470	Effectiveness of hormonal contraception in HIV-infected women using antiretroviral therapy. <i>Aids</i> , 2015, 29, 2353-2359.	1.0	43
471	How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores". <i>American Journal of Public Health</i> , 2015, 105, 1960-1964.	1.5	231
472	The road ahead: working towards effective clinical translation of biomedical HIV prevention strategies. <i>Future Virology</i> , 2015, 10, 271-282.	0.9	3
473	Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers. <i>Aids</i> , 2015, 29, 2149-2154.	1.0	16
474	Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 264-269.	0.9	67
475	Considerations for a Human Rights Impact Assessment of a Population Wide Treatment for HIV Prevention Intervention. <i>Developing World Bioethics</i> , 2015, 15, 115-124.	0.6	5
476	A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users. <i>Journal of Addiction Medicine</i> , 2015, 9, 226-232.	1.4	30
477	The current status of the use of oral medication to prevent HIV transmission. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 226-232.	1.5	26

#	ARTICLE	IF	CITATIONS
478	Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012. <i>Aids</i> , 2015, 29, 1077-1085.	1.0	59
479	Understanding HIV Care Provider Attitudes Regarding Intentions to Prescribe PrEP. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, 520-528.	0.9	61
480	Achieving Pregnancy Safely in HIV-Affected Individuals and Couples. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, e155-e159.	0.9	7
481	Sexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 36-43.	0.9	6
482	Antibodies for HIV prevention in young women. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 183-189.	1.5	9
483	Disclosure of pharmacokinetic drug results to understand nonadherence. <i>Aids</i> , 2015, 29, 2161-2171.	1.0	71
484	Injectable agents for pre-exposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 271-277.	1.5	13
485	Formulation and pharmacology of long-acting rilpivirine. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 233-238.	1.5	71
486	Defining success with HIV pre-exposure prophylaxis. <i>Aids</i> , 2015, 29, 1277-1285.	1.0	247
487	Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, 385-394.	0.9	8
488	A discussion of key values to inform the design and delivery of services for HIV-affected women and couples attempting pregnancy in resource-constrained settings. <i>Journal of the International AIDS Society</i> , 2015, 18, 20272.	1.2	17
489	Sex, human rights and AIDS: an analysis of new technologies for HIV prevention in the Brazilian context. <i>Revista Brasileira De Epidemiologia</i> , 2015, 18, 89-103.	0.3	20
490	Sexual and reproductive health and human rights of women living with HIV. <i>Journal of the International AIDS Society</i> , 2015, 18, 20834.	1.2	8
491	Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. <i>HIV/AIDS - Research and Palliative Care</i> , 2015, 7, 125.	0.4	34
492	Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence &ndash; a narrative review. <i>HIV/AIDS - Research and Palliative Care</i> , 2015, 7, 241.	0.4	78
493	HIV and adolescents: focus on young key populations. <i>Journal of the International AIDS Society</i> , 2015, 18, 20076.	1.2	56
494	Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. <i>Journal of the International AIDS Society</i> , 2015, 18, 20013.	1.2	59
495	Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. <i>Journal of the International AIDS Society</i> , 2015, 18, 19973.	1.2	34

#	ARTICLE	IF	CITATIONS
496	Safer disclosure of HIV serostatus for women living with HIV who experience or fear violence: a systematic review. <i>Journal of the International AIDS Society</i> , 2015, 18, 20292.	1.2	47
497	PRE-EXPOSURE PROPHYLAXIS (PREP) AS HIV PREVENTION STRATEGY AND PUBLIC HEALTH IMPLICATIONS. <i>International Research Journal of Pharmacy</i> , 2015, 6, 227-230.	0.0	0
498	What is the benefit of the biomedical and behavioral interventions in preventing HIV transmission?. <i>Revista Brasileira De Epidemiologia</i> , 2015, 18, 26-42.	0.3	3
499	Reclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceive. <i>Journal of the International AIDS Society</i> , 2015, 18, 19447.	1.2	13
500	Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. <i>Journal of the International AIDS Society</i> , 2015, 18, 20227.	1.2	109
501	Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. <i>Molecules</i> , 2015, 20, 11474-11489.	1.7	56
502	Client and Provider Perspectives on New HIV Prevention Tools for MSM in the Americas. <i>PLoS ONE</i> , 2015, 10, e0121044.	1.1	20
503	Frequency of False Positive Rapid HIV Serologic Tests in African Men and Women Receiving PrEP for HIV Prevention: Implications for Programmatic Roll-Out of Biomedical Interventions. <i>PLoS ONE</i> , 2015, 10, e0123005.	1.1	15
504	Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0125458.	1.1	66
505	Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. <i>PLoS ONE</i> , 2015, 10, e0128857.	1.1	25
506	Knowledge, Indications and Willingness to Take Pre-Exposure Prophylaxis among Transwomen in San Francisco, 2013. <i>PLoS ONE</i> , 2015, 10, e0128971.	1.1	47
507	Preparing for the Rollout of Pre-Exposure Prophylaxis (PrEP): A Vignette Survey to Identify Intended Sexual Behaviors among Women in Kenya and South Africa if Using PrEP. <i>PLoS ONE</i> , 2015, 10, e0129177.	1.1	9
508	Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England. <i>PLoS ONE</i> , 2015, 10, e0132398.	1.1	90
509	A Scoring Tool to Identify East African HIV-1 Serodiscordant Partnerships with a High Likelihood of Pregnancy. <i>PLoS ONE</i> , 2015, 10, e0145515.	1.1	4
510	Strategies to prevent HIV transmission to serodiscordant couples. <i>Revista Brasileira De Epidemiologia</i> , 2015, 18, 169-182.	0.3	7
511	Cost Effectiveness of "On Demand"™ Hiv Pre-Exposure Prophylaxis for Non-Injection Drug-Using Men Who Have Sex with Men in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2015, 26, 23-29.	0.7	39
512	Tailored combination prevention packages and PrEP for young key populations. <i>Journal of the International AIDS Society</i> , 2015, 18, 19434.	1.2	78
513	Pre-exposure prophylaxis for men and transgender women who have sex with men in Brazil: opportunities and challenges. <i>Journal of the International AIDS Society</i> , 2015, 18, 20010.	1.2	14

#	ARTICLE	IF	CITATIONS
514	Antiretroviral Therapy for Human Immunodeficiency Virus Infection. , 2015, , 1622-1641.e6.		7
515	PrEP Implementation Science: State-of-the-Art and Research Agenda. Journal of the International AIDS Society, 2015, 18, 20527.	1.2	10
516	The invisibility of heterosexuality in HIV/AIDS prevention for men. Revista Brasileira De Epidemiologia, 2015, 18, 143-155.	0.3	18
517	Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. Journal of the International AIDS Society, 2015, 18, 19980.	1.2	53
518	The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. Journal of the International AIDS Society, 2015, 18, 19949.	1.2	51
519	Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts. Journal of AIDS & Clinical Research, 2015, 6, 1-10.	0.5	54
520	The Art of HIV Elimination: Past and Present Science. Journal of AIDS & Clinical Research, 2015, 6, .	0.5	10
521	Pre-exposure prophylaxis in Southern Africa: feasible or not?. Journal of the International AIDS Society, 2015, 18, 19979.	1.2	12
522	Oral PrEP for HIV prevention. It works. Journal of Virus Eradication, 2015, 1, 168-172.	0.3	0
523	The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. Journal of Virus Eradication, 2015, 1, 245-249.	0.3	12
524	The Impact of Modern Antiretroviral Therapy on Lipid Metabolism of HIV-1 Infected Patients. , 2015, , .		1
525	Estimating HIV Protective Effects of Method Adherence With Combinations of Preexposure Prophylaxis and Condom Use Among African American Men Who Have Sex With Men. Sexually Transmitted Diseases, 2015, 42, 88-92.	0.8	30
526	HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 55-61.	0.9	10
527	Preexposure Prophylaxis. JAMA Internal Medicine, 2015, 175, 255.	2.6	1
528	Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. Infectious Diseases and Therapy, 2015, 4, 145-157.	1.8	31
529	Changes in Glomerular Kidney Function Among HIV-1 Uninfected Men and Women Receiving Emtricitabine Tenofovir Disoproxil Fumarate Preexposure Prophylaxis. JAMA Internal Medicine, 2015, 175, 246.	2.6	83
530	Management of Gender Dysphoria. , 2015, , .		11
531	Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitabine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. AIDS and Behavior, 2015, 19, 758-769.	1.4	31



#	ARTICLE	IF	CITATIONS
532	Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , 2015, 19, 2076-2086.	1.4	2
533	A Qualitative Study of Medical Mistrust, Perceived Discrimination, and Risk Behavior Disclosure to Clinicians by U.S. Male Sex Workers and Other Men Who Have Sex with Men: Implications for Biomedical HIV Prevention. <i>Journal of Urban Health</i> , 2015, 92, 667-686.	1.8	88
534	Mucosal Immunity and Vaccines Against Simian Immunodeficiency Virus and Human Immunodeficiency Virus. , 2015, , 1171-1182.		1
535	Population pharmacokinetics of tenofovir and tenofovir diphosphate in healthy women. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 629-638.	1.0	25
536	Determinants of HIV testing among Nigerian couples: a multilevel modelling approach. <i>Health Policy and Planning</i> , 2015, 30, 579-592.	1.0	23
537	Short Communication: <i>In Vitro</i> Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 851-858.	0.5	3
538	Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and <i>Ex Vivo</i> Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1089-1097.	0.5	12
539	Motivations for Reducing Other HIV Risk-Reduction Practices if Taking Pre-Exposure Prophylaxis: Findings from a Qualitative Study Among Women in Kenya and South Africa. <i>AIDS Patient Care and STDs</i> , 2015, 29, 503-509.	1.1	15
540	Optimizing Adherence to Preexposure and Postexposure Prophylaxis: The Need for an Integrated Biobehavioral Approach. <i>Clinical Infectious Diseases</i> , 2015, 60, S187-S190.	2.9	18
541	Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners. <i>Journal of Infectious Diseases</i> , 2015, 212, 1534-1543.	1.9	22
542	Pre-exposure and postexposure prophylaxes and the combination HIV prevention methods (The Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 Open, 2015, 5, e009021.	0.8	21
543	HIV knowledge, risk perception and pre-exposure prophylaxis interest among Thai university students. <i>International Journal of STD and AIDS</i> , 2015, 26, 1007-1016.	0.5	10
544	Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. <i>International Journal of STD and AIDS</i> , 2015, 26, 1040-1048.	0.5	70
545	Are couple-based interventions more effective than interventions delivered to individuals in promoting HIV protective behaviors? A meta-analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1361-1366.	0.6	118
546	Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner. <i>EBioMedicine</i> , 2015, 2, 1145-1152.	2.7	37
547	Perceptions among Dutch men who have sex with men and their willingness to use rectal microbicides and oral pre-exposure prophylaxis to reduce HIV risk – a preliminary study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1493-1500.	0.6	11
548	Combination HIV prevention for female sex workers: what is the evidence?. <i>Lancet, The</i> , 2015, 385, 72-87.	6.3	182
549	Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. <i>Journal of Infectious Diseases</i> , 2015, 211, 1943-1952.	1.9	15

#	ARTICLE	IF	CITATIONS
550	Pre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges. <i>Drugs</i> , 2015, 75, 243-251.	4.9	67
551	Antiretrovirals for Primary HIV Prevention: the Current Status of Pre- and Post-exposure Prophylaxis. <i>Current HIV/AIDS Reports</i> , 2015, 12, 127-138.	1.1	61
552	Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1473-1481.	1.3	30
553	Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. <i>AIDS and Behavior</i> , 2015, 19, 770-783.	1.4	12
554	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. <i>New England Journal of Medicine</i> , 2015, 372, 509-518.	13.9	1,094
555	Risk for HIV following a diagnosis of syphilis, gonorrhoea or chlamydia: 328,456 women in Florida, 2000-2011. <i>International Journal of STD and AIDS</i> , 2015, 26, 113-119.	0.5	56
556	Human rights violations against sex workers: burden and effect on HIV. <i>Lancet, The</i> , 2015, 385, 186-199.	6.3	253
557	Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. <i>AIDS and Behavior</i> , 2015, 19, 794-801.	1.4	39
558	It's Time: The Case for PrEP as an Active Comparator in HIV Biomedical Prevention Trials. <i>Journal of Bioethical Inquiry</i> , 2015, 12, 239-249.	0.9	3
559	Care of the HIV-infected pregnant woman in the developed world. <i>Obstetric Medicine</i> , 2015, 8, 13-17.	0.5	0
560	Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China, 2006 to 2012. <i>Clinical Infectious Diseases</i> , 2015, 61, 111-119.	2.9	19
561	The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. <i>Science Translational Medicine</i> , 2015, 7, 270ra5.	5.8	64
562	Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study. <i>AIDS and Behavior</i> , 2015, 19, 811-820.	1.4	21
563	Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting. <i>AIDS and Behavior</i> , 2015, 19, 752-757.	1.4	60
564	Intimacy, Condom Use, and Pre-Exposure Prophylaxis (PrEP) Acceptability among Men Who Have Sex with Men (MSM) in Primary Partnerships: a Comment on Gamarel and Golub. <i>Annals of Behavioral Medicine</i> , 2015, 49, 151-153.	1.7	20
565	Knowledge, Attitudes, and Likelihood of Pre-Exposure Prophylaxis (PrEP) Use Among US Women at Risk of Acquiring HIV. <i>AIDS Patient Care and STDs</i> , 2015, 29, 102-110.	1.1	299
566	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.	2.9	132
567	Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6080-6086.	1.4	19



#	ARTICLE	IF	CITATIONS
568	Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward. <i>AIDS Patient Care and STDs</i> , 2015, 29, 389-399.	1.1	54
569	Risk of Drug Resistance Among Persons Acquiring HIV Within a Randomized Clinical Trial of Single- or Dual-Agent Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1211-8.	1.9	80
570	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	1.9	62
571	Safer Conception Strategies for HIV-Serodiscordant Couples: How Safe Is Safe Enough?: Table 1.. <i>Journal of Infectious Diseases</i> , 2015, 212, 1525-1528.	1.9	9
572	The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention. <i>Clinical Infectious Diseases</i> , 2015, 60, S200-S204.	2.9	37
573	Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 211, 1202-4.	1.9	15
574	Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1077-1088.	0.5	17
575	Delayed linkage to care in one-third of HIV-positive individuals in the Netherlands. <i>Sexually Transmitted Infections</i> , 2015, 91, 603-609.	0.8	14
576	Empowering patients to link to care and treatment: qualitative findings about the role of a home-based HIV counselling, testing and linkage intervention in South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1162-1167.	0.6	22
577	Clinician Attitudes Toward CDC Interim Pre-Exposure Prophylaxis (PrEP) Guidance and Operationalizing PrEP for Adolescents. <i>AIDS Patient Care and STDs</i> , 2015, 29, 193-203.	1.1	47
578	Hormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis. <i>PLoS Medicine</i> , 2015, 12, e1001778.	3.9	170
579	A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. <i>Science Translational Medicine</i> , 2015, 7, 270ra4.	5.8	83
580	Optimal Treatment Strategies in the Context of "Treatment for Prevention"™ against HIV-1 in Resource-Poor Settings. <i>PLoS Computational Biology</i> , 2015, 11, e1004200.	1.5	17
581	Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3913-3919.	1.4	147
582	Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. <i>Contraception</i> , 2015, 91, 248-252.	0.8	12
583	Inclusion of trans women in pre-exposure prophylaxis trials: a review. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 637-641.	0.6	52
584	Tenofovir alafenamide for HIV infection: is less more?. <i>Lancet, The</i> , 2015, 385, 2559-2560.	6.3	14
585	Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 253-259.	1.3	0

#	ARTICLE	IF	CITATIONS
586	Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP. <i>AIDS and Behavior</i> , 2015, 19, 802-810.	1.4	155
587	“I don’t use a condom   I would be stressed in my heart that I’ve done something wrong” Routine Prevention Messages Preclude Safer Conception Counseling for HIV-Infected Men and Women in South Africa. <i>AIDS and Behavior</i> , 2015, 19, 1666-1675.	1.4	28
588	Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs. <i>Current HIV/AIDS Reports</i> , 2015, 12, 145-163.	1.1	18
589	Measuring the Cost Effectiveness of HIV Prevention Interventions in the US: Pitfalls and Problems. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 129-133.	1.0	1
590	Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. <i>Current Treatment Options in Infectious Diseases</i> , 2015, 7, 101-112.	0.8	22
591	Dispelling myths and focusing on notable concepts in HIV pathogenesis. <i>Trends in Molecular Medicine</i> , 2015, 21, 341-353.	3.5	12
592	“Why should I take drugs for your infection?” outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria. <i>BMC Public Health</i> , 2015, 15, 349.	1.2	18
593	Pre-exposure prophylaxis works—it’s time to deliver. <i>Lancet</i> , The, 2015, 385, 1482-1484.	6.3	19
594	HIV-Negative Partnered Men’s Willingness to Use Pre-Exposure Prophylaxis and Associated Factors Among an Internet Sample of U.S. HIV-Negative and HIV-Discordant Male Couples. <i>LGBT Health</i> , 2015, 2, 35-40.	1.8	28
595	HIV-serodiscordant couples desiring a child: “treatment as prevention,” preexposure prophylaxis, or medically assisted procreation?. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 341.e1-341.e12.	0.7	13
596	Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Adults and Adolescents: A Systematic Review. <i>Clinical Infectious Diseases</i> , 2015, 60, S170-S176.	2.9	35
597	Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 1128-1136.	0.6	37
598	Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial. <i>Clinical Trials</i> , 2015, 12, 394-402.	0.7	9
599	Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. <i>Aids</i> , 2015, 29, 331-337.	1.0	37
600	Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 13-20.	0.9	72
601	High Interest in Preexposure Prophylaxis Among Men Who Have Sex With Men at Risk for HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 439-448.	0.9	171
602	The Science of Being a Study Participant. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 578-584.	0.9	52
603	HIV Therapy—The State of ART. <i>Current Topics in Microbiology and Immunology</i> , 2015, 389, 1-29.	0.7	19

#	ARTICLE	IF	CITATIONS
604	Longitudinal Trends in HIV Nonoccupational Postexposure Prophylaxis Use at a Boston Community Health Center Between 1997 and 2013. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, 97-101.	0.9	21
605	Evaluating Respondent-Driven Sampling as an Implementation Tool for Universal Coverage of Antiretroviral Studies Among Men Who Have Sex With Men Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, S107-S113.	0.9	52
606	Models for Predicting Effective HIV Chemoprevention in Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, 369-376.	0.9	17
607	Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2015, 212, 754-759.	1.9	36
608	Pharmacokinetics of antiretrovirals in mucosal tissue. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 893-905.	1.5	30
609	Antiretroviral Drug Exposures Reported to Texas Poison Centers. <i>Journal of Pharmacy Technology</i> , 2015, 31, 276-281.	0.5	0
610	Transitioning to HIV Pre-Exposure Prophylaxis (PrEP) from Non-Occupational Post-Exposure Prophylaxis (nPEP) in a Comprehensive HIV Prevention Clinic: A Prospective Cohort Study. <i>AIDS Patient Care and STDs</i> , 2015, 29, 431-436.	1.1	20
611	A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs. <i>AIDS Patient Care and STDs</i> , 2015, 29, 597-605.	1.1	48
612	Estimating Efficacy in a Randomized Trial With Product Nonadherence: Application of Multiple Methods to a Trial of Preexposure Prophylaxis for HIV Prevention. <i>American Journal of Epidemiology</i> , 2015, 182, 848-856.	1.6	21
613	Cultural Conundrums: The Ethics of Epidemiology and the Problems of Population in Implementing Pre-Exposure Prophylaxis. <i>Developing World Bioethics</i> , 2015, 15, 27-39.	0.6	8
614	Defeating AIDS—advancing global health. <i>Lancet, The</i> , 2015, 386, 171-218.	6.3	234
615	Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention. <i>Pharmaceutical Research</i> , 2015, 32, 3768-3781.	1.7	16
616	Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7762-7770.	1.4	15
617	Multipurpose prevention technologies: the future of HIV and STI protection. <i>Trends in Microbiology</i> , 2015, 23, 429-436.	3.5	64
618	Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia. <i>Clinical Infectious Diseases</i> , 2015, 61, 1590-1597.	2.9	253
619	<i>Editorial Commentary</i> : Scaling Up Antiretroviral Preexposure Prophylaxis: Moving From Trials to Implementation. <i>Clinical Infectious Diseases</i> , 2015, 61, 1598-1600.	2.9	21
620	A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02). <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1098-1108.	0.5	20
621	Primary Care for Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2015, 373, 854-862.	13.9	23

#	ARTICLE	IF	CITATIONS
622	Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv126.	0.4	9
623	An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. <i>International Journal of Pharmaceutics</i> , 2015, 495, 579-587.	2.6	21
624	On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2237-2246.	13.9	1,302
625	Injectable and implantable antiretroviral strategies for HIV prevention. <i>Future Virology</i> , 2015, 10, 1163-1176.	0.9	9
626	Invited Commentary: Every Good Randomization Deserves Observation. <i>American Journal of Epidemiology</i> , 2015, 182, 857-860.	1.6	13
627	Awareness of Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) Is Low but Interest Is High Among Men Engaging in Condomless Anal Sex With Men in Boston, Pittsburgh, and San Juan. <i>AIDS Education and Prevention</i> , 2015, 27, 289-297.	0.6	77
628	Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. <i>Future Microbiology</i> , 2015, 10, 1773-1782.	1.0	34
629	Periconception HIV Risk Behavior Among Men and Women Reporting HIV-Serodiscordant Partners in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , 2015, 19, 2291-2303.	1.4	24
630	Tailoring biomedical interventions for key populations. <i>Lancet HIV</i> , 2015, 2, e8-e9.	2.1	4
631	A call to action for evidence-based safer conception interventions for HIV-affected couples desiring children in Sub-Saharan Africa. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 128, 73-74.	1.0	8
632	Blood salvage device for use during ruptured ectopic pregnancy in low-resource countries. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 128, 74-75.	1.0	4
633	Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. <i>AIDS and Behavior</i> , 2015, 19, 743-751.	1.4	62
634	Attitudes of Serodiscordant Couples Towards Antiretroviral-Based HIV Prevention Strategies in Kenya: A Qualitative Study. <i>AIDS Patient Care and STDs</i> , 2015, 29, 33-42.	1.1	7
635	The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 182-194.	1.1	123
636	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. <i>Annual Review of Medicine</i> , 2015, 66, 423-437.	5.0	150
637	Mind the gap: An empirical study of post-trial access in HIV biomedical prevention trials. <i>Developing World Bioethics</i> , 2015, 15, 85-97.	0.6	14
638	Intimacy Motivations and Pre-exposure Prophylaxis (PrEP) Adoption Intentions Among HIV-Negative Men Who Have Sex with Men (MSM) in Romantic Relationships. <i>Annals of Behavioral Medicine</i> , 2015, 49, 177-186.	1.7	125
639	Global implementation of PrEP as part of combination HIV prevention - Unsolved challenges. <i>Journal of the International AIDS Society</i> , 2016, 19, 21479.	1.2	0

#	ARTICLE	IF	CITATIONS
640	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-155.	0.3	63
641	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016, 2, 67-77.	0.3	7
642	Sexual Behavior Patterns and PrEP Dosing Preferences in a Large Sample of North American Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 94-101.	0.9	14
644	Perceived Advantages and Disadvantages of Using Pre-Exposure Prophylaxis (PrEP) among Sexually Active Black Women: An Exploratory Study. <i>Journal of Black Sexuality and Relationships</i> , 2016, 3, 1-24.	0.2	39
645	Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. <i>Journal of the International AIDS Society</i> , 2016, 19, 20903.	1.2	192
646	“Since both of us are using antiretrovirals, we have been supportive to each other” facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya. <i>Journal of the International AIDS Society</i> , 2016, 19, 21134.	1.2	47
647	Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE (MTN003D) study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20875.	1.2	65
648	HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. <i>Open AIDS Journal</i> , 2016, 10, 34-48.	0.1	595
649	Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw125.	0.4	9
650	An HIV Prevention and Treatment Strategy for Serodiscordant Black Men who have Sex with Men Couples: Using Pre-Exposure Prophylaxis (PrEP) and Antiretroviral Treatment (ART) to Reduce Infections in the Present and the Future. <i>Journal of AIDS &amp; Clinical Research</i> , 2016, 7, .	0.5	0
651	Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. <i>HIV/AIDS - Research and Palliative Care</i> , 2016, Volume 8, 157-164.	0.4	29
652	Recent Insights into the HIV/AIDS Pandemic. <i>Microbial Cell</i> , 2016, 3, 450-474.	1.4	41
653	A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy. <i>Journal of the International AIDS Society</i> , 2016, 19, 20990.	1.2	5
654	PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa. <i>Journal of the International AIDS Society</i> , 2016, 19, 21104.	1.2	25
655	Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN003 (VOICE) study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20642.	1.2	45
656	New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections. <i>Journal of Sexually Transmitted Diseases</i> , 2016, 2016, 1-10.	1.0	1
657	Therapeutic Drug Monitoring of Antiretrovirals. , 2016, , 135-163.		0
658	Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20791.	1.2	24

#	ARTICLE	IF	CITATIONS
659	Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America. <i>Journal of the International AIDS Society</i> , 2016, 19, 21113.	1.2	32
660	Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1 Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. <i>PLoS Medicine</i> , 2016, 13, e1002099.	3.9	166
661	Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters. <i>Journal of the International AIDS Society</i> , 2016, 19, 21165.	1.2	20
662	Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings. <i>Evidence-Based Medicine</i> , 2016, 21, 99-99.	0.6	0
663	Views of HIV-negative partners in heterosexual serodiscordant relationships regarding HIV pre-exposure prophylaxis: a qualitative study. <i>Sexual Health</i> , 2016, 13, 345.	0.4	4
664	Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?. <i>PLoS Biology</i> , 2016, 14, e1002372.	2.6	12
665	Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption. <i>PLoS Medicine</i> , 2016, 13, e1002132.	3.9	70
666	HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost. <i>PLoS ONE</i> , 2016, 11, e0145637.	1.1	20
667	The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi. <i>PLoS ONE</i> , 2016, 11, e0147662.	1.1	41
668	"How I Wish This Thing Was Initiated 100 Years Ago" Willingness to Take Daily Oral Pre-Exposure Prophylaxis among Men Who Have Sex with Men in Kenya. <i>PLoS ONE</i> , 2016, 11, e0151716.	1.1	50
669	PrEP Awareness and Attitudes in a National Survey of Primary Care Clinicians in the United States, 2009-2015. <i>PLoS ONE</i> , 2016, 11, e0156592.	1.1	139
670	Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures. <i>PLoS ONE</i> , 2016, 11, e0157061.	1.1	28
671	Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting. <i>PLoS ONE</i> , 2016, 11, e0157742.	1.1	60
672	Microbiome Composition and Function Drives Wound-Healing Impairment in the Female Genital Tract. <i>PLoS Pathogens</i> , 2016, 12, e1005889.	2.1	109
673	Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China. <i>BioScience Trends</i> , 2016, 10, 113-119.	1.1	57
674	HIV Infection and Infertility. , 0, , .		6
675	Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?. <i>F1000Research</i> , 2016, 5, 2328.	0.8	20
676	Factors associated with initiation of antiretroviral therapy among HIV-positive people who use injection drugs in a Canadian setting. <i>Aids</i> , 2016, 30, 925-932.	1.0	18



#	ARTICLE	IF	CITATIONS
677	Urinary $\beta_2$ microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. <i>Aids</i> , 2016, 30, 1563-1571.	1.0	19
678	The Safety of Tenofovir+Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 281-286.	0.9	25
679	Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 374-380.	0.9	57
680	Low Receipt and Uptake of Safer Conception Messages in Routine HIV Care. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 105-113.	0.9	22
681	Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 18-26.	1.5	94
682	Nondaily preexposure prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 94-101.	1.5	36
683	What people want from sex and preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 3-9.	1.5	66
684	What do we know about the cost-effectiveness of HIV preexposure prophylaxis, and is it affordable?. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 56-66.	1.5	37
685	Planning for HIV preexposure prophylaxis introduction. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 87-93.	1.5	47
686	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 191.	3.8	533
687	Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1287-1294.	1.0	5
688	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. <i>Clinical Infectious Diseases</i> , 2016, 63, 836-843.	2.9	37
689	The promise and pitfalls of long-acting injectable agents for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 122-128.	1.5	91
690	Human Immunodeficiency Virus Prevention With Preexposure Prophylaxis in Sexually Transmitted Disease Clinics. <i>Sexually Transmitted Diseases</i> , 2016, 43, 277-282.	0.8	11
691	A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. <i>Aids</i> , 2016, 30, 743-751.	1.0	27
692	Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 287-294.	0.9	42
693	Statistical issues in trials of preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 116-121.	1.5	5
694	A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 498-505.	0.9	63



#	ARTICLE	IF	CITATIONS
695	PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 444-451.	0.9	33
696	Guidance for Providing Informed-Choice Counseling on Sexual Health for Women Interested in Pre-Exposure Prophylaxis in Kenya and South Africa. <i>AIDS Patient Care and STDs</i> , 2016, 30, 106-109.	1.1	7
697	The preexposure prophylaxis revolution; from clinical trials to programmatic implementation. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 80-86.	1.5	84
698	The History of the HIV/AIDS Epidemic in Africa. <i>Current HIV/AIDS Reports</i> , 2016, 13, 187-193.	1.1	22
699	Healthcare providers' knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection. <i>HIV Medicine</i> , 2016, 17, 133-142.	1.0	51
700	The role of tenofovir alafenamide in future HIV management. <i>HIV Medicine</i> , 2016, 17, 4-16.	1.0	40
701	Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. <i>Aids</i> , 2016, 30, 31-35.	1.0	24
702	Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, e115-e118.	0.9	29
703	Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3759-3766.	1.4	22
704	Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 49-55.	1.5	54
705	Risk factors associated with incident sexually transmitted infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. <i>HIV Medicine</i> , 2016, 17, 623-630.	1.0	4
706	Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 148-154.	0.5	32
707	High Willingness to Use HIV Pre-Exposure Prophylaxis Among Transgender Women in Argentina. <i>Transgender Health</i> , 2016, 1, 266-273.	1.2	22
708	Preventing HIV among Women – A Step Forward, but Much Farther to Go. <i>New England Journal of Medicine</i> , 2016, 375, 2195-2196.	13.9	4
709	Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2133-2143.	13.9	368
710	Dual contraceptive method use in HIV-serodiscordant Kenyan couples. <i>Journal of Family Planning and Reproductive Health Care</i> , 2016, 42, 264-270.	0.9	4
711	The Shift to High-Impact HIV Prevention by Health Departments in the United States. <i>Public Health Reports</i> , 2016, 131, 7-10.	1.3	15
712	Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles. <i>AIDS and Behavior</i> , 2016, 20, 1315-1326.	1.4	23

#	ARTICLE	IF	CITATIONS
713	Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. <i>Sexual Health</i> , 2016, 13, 465.	0.4	23
714	Condom deserts: geographical disparities in condom availability and their relationship with rates of sexually transmitted infections. <i>Sexually Transmitted Infections</i> , 2016, 92, 194-199.	0.8	12
715	Treatment and Prevention for female sex workers in South Africa: protocol for the TAPS Demonstration Project. <i>BMJ Open</i> , 2016, 6, e011595.	0.8	15
716	Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. <i>BMJ Open</i> , 2016, 6, e012179.	0.8	19
717	The effect of HIV counselling and testing on HIV acquisition in sub-Saharan Africa: a systematic review. <i>Sexually Transmitted Infections</i> , 2016, 92, 579-586.	0.8	17
718	Pre-Exposure Prophylaxis for HIV Prevention. <i>North Carolina Medical Journal</i> , 2016, 77, 361-362.	0.1	1
719	Preexposure tenofovir/emtricitabine reduced HIV infection in men who have unprotected anal sex with men. <i>Annals of Internal Medicine</i> , 2016, 164, JC3.	2.0	0
720	Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. <i>Annals of Internal Medicine</i> , 2016, 165, 10.	2.0	45
721	Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the Cresting Wave. <i>BMJ Global Health</i> , 2016, 1, e000004.	2.0	115
722	ACOG. <i>Obstetrics and Gynecology</i> , 2016, 128, 1-1.	1.2	21
723	Clinical Research Involving Pregnant Women. <i>Research Ethics Forum</i> , 2016, , .	0.1	6
724	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 317-327.	3.7	80
725	Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.. <i>AIDS and Behavior</i> , 2016, 20, 1390-1399.	1.4	82
726	Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates. <i>Journal of Virology</i> , 2016, 90, 5315-5328.	1.5	12
727	Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. <i>Journal of Infectious Diseases</i> , 2016, 214, 1050-1057.	1.9	40
728	Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection. <i>Medical Clinics of North America</i> , 2016, 100, 927-950.	1.1	11
729	Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda: Implications for sample size estimates. <i>Vaccine</i> , 2016, 34, 1778-1785.	1.7	26
730	Pre-exposure Prophylaxis Awareness Among Gay and Other Men who have Sex with Men in Vancouver, British Columbia, Canada. <i>AIDS and Behavior</i> , 2016, 20, 1408-1422.	1.4	35

#	ARTICLE	IF	CITATIONS
731	An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. <i>Trials</i> , 2016, 17, 163.	0.7	36
732	PrEP as Peri-conception HIV Prevention for Women and Men. <i>Current HIV/AIDS Reports</i> , 2016, 13, 131-139.	1.1	52
734	A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. <i>Journal of Infectious Diseases</i> , 2016, 214, 55-64.	1.9	251
735	Awareness of Pre-exposure Prophylaxis for HIV, Willingness to Use It and Potential Barriers or Facilitators to Uptake Among Men Who Have Sex with Men in Spain. <i>AIDS and Behavior</i> , 2016, 20, 1423-1433.	1.4	29
736	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 1523-1531.	1.9	39
737	Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). <i>Biochemical Pharmacology</i> , 2016, 119, 1-7.	2.0	119
738	Evaluating the Impact of the US National HIV/AIDS Strategy, 2010–2015. <i>AIDS and Behavior</i> , 2016, 20, 1383-1389.	1.4	13
739	<i>I Knew I Would Be Safer</i> . Experiences of Kenyan HIV Serodiscordant Couples Soon After Pre-Exposure Prophylaxis (PrEP) Initiation. <i>AIDS Patient Care and STDs</i> , 2016, 30, 78-83.	1.1	44
740	Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4140-4150.	1.4	23
741	A shot at AIDS. <i>Current Opinion in Biotechnology</i> , 2016, 42, 147-151.	3.3	9
742	Perceived HIV risk, actual sexual HIV risk and willingness to take pre-exposure prophylaxis among men who have sex with men in Toronto, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1378-1385.	0.6	56
743	UK guideline for the use of HIV Post-Exposure Prophylaxis Following Sexual Exposure, 2015. <i>International Journal of STD and AIDS</i> , 2016, 27, 713-738.	0.5	54
744	Uncertainty in Online U.S. News Coverage of Truvada. <i>Health Communication</i> , 2016, 31, 1250-1257.	1.8	19
745	Antiretroviral chemoprophylaxis: PROUD and pragmatism. <i>Lancet, The</i> , 2016, 387, 6-7.	6.3	18
746	Stage-Based Computer-Delivered Interventions to Increase Condom Use in Young Men. <i>International Journal of Sexual Health</i> , 2016, 28, 176-186.	1.2	5
747	Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. <i>Aids</i> , 2016, 30, 1973-1983.	1.0	721
748	The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. <i>AIDS and Behavior</i> , 2016, 20, 1527-1534.	1.4	41
749	HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis. <i>Journal of Virology</i> , 2016, 90, 9855-9861.	1.5	12

#	ARTICLE	IF	CITATIONS
750	Preexposure Prophylaxis and Patient Centeredness. American Journal of Men's Health, 2016, 10, 353-358.	0.7	2
751	HIV-1 drug resistance and resistance testing. Infection, Genetics and Evolution, 2016, 46, 292-307.	1.0	215
752	HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection. Journal of Antimicrobial Chemotherapy, 2016, 71, 3185-3194.	1.3	12
753	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV, the, 2016, 3, e521-e528.	2.1	66
754	Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing. Biochemical Pharmacology, 2016, 116, 162-175.	2.0	15
755	Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions. Human Vaccines and Immunotherapeutics, 2016, 12, 3202-3211.	1.4	9
756	What Community-Based HIV Prevention Organizations Say About Their Role in Biomedical HIV Prevention. AIDS Education and Prevention, 2016, 28, 426-439.	0.6	14
757	Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. Infectious Diseases and Therapy, 2016, 5, 407-416.	1.8	15
758	Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection. Journal of Infectious Diseases, 2016, 214, 1787-1789.	1.9	5
759	Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Case-Control Study. AIDS Research and Human Retroviruses, 2016, 32, 1016-1021.	0.5	4
760	Against Permitted Exploitation in Developing World Research Agreements. Developing World Bioethics, 2016, 16, 36-44.	0.6	4
761	A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. Clinical Infectious Diseases, 2016, 63, 1495-1504.	2.9	53
762	Multiscale Systems Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 377-387.	1.3	27
763	Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. Journal of Clinical Virology, 2016, 83, 48-53.	1.6	5
764	Rectal Infection With <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> in Men in the United States. Clinical Infectious Diseases, 2016, 63, 1325-1331.	2.9	16
765	The benefits and risks of PrEP and kidney function. Lancet HIV, the, 2016, 3, e501-e502.	2.1	1
766	Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Research and Human Retroviruses, 2016, 32, 981-991.	0.5	66
767	Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue. Journal of Pharmaceutical and Biomedical Analysis, 2016, 131, 333-344.	1.4	13

#	ARTICLE	IF	CITATIONS
768	Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?. <i>Clinical Microbiology and Infection</i> , 2016, 22, 757-767.	2.8	10
769	Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination Protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 2016, 214, 1058-1062.	1.9	28
770	Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6692-6697.	1.4	59
771	Combination HIV prevention options for young women in Africa. <i>African Journal of AIDS Research</i> , 2016, 15, 109-121.	0.3	39
772	Expanding the relationship context for couple-based HIV prevention: Elucidating women's perspectives on non-traditional sexual partnerships. <i>Social Science and Medicine</i> , 2016, 166, 169-176.	1.8	20
773	HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 579-584.	0.9	68
774	Antiretrovirals for HIV Treatment and Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 151.	3.8	7
775	Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. <i>American Journal of Epidemiology</i> , 2016, 184, 239-248.	1.6	13
776	Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth. <i>AIDS Patient Care and STDs</i> , 2016, 30, 339-348.	1.1	41
777	Condomless Sex With Virologically Suppressed HIV-Infected Individuals. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 149.	3.8	7
779	Synergy, Salary, and Satisfaction: Benefits of Training in Critical Care Medicine and Infectious Diseases Gleaned From a National Pilot Survey of Dually Trained Physicians. <i>Clinical Infectious Diseases</i> , 2016, 63, 868-875.	2.9	8
780	HIV Infection, Tenofovir, and Urine $\beta$ 2-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 571-581.	2.1	34
781	Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study. <i>Lancet HIV</i> , 2016, 3, e289-e296.	2.1	62
782	Impact of Population Recruitment on the HIV Epidemics and the Effectiveness of HIV Prevention Interventions. <i>Bulletin of Mathematical Biology</i> , 2016, 78, 2057-2090.	0.9	2
783	Human Immunodeficiency Virus, Other Sexually Transmitted Infections, and Sexual and Reproductive Health in Lesbian, Gay, Bisexual, Transgender Youth. <i>Pediatric Clinics of North America</i> , 2016, 63, 1027-1055.	0.9	29
784	National leadership needed on HIV Pre-exposure Prophylaxis (PrEP) access in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2016, 40, 504-505.	0.8	2
785	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525.	1.9	40
786	Potential impact of pre-exposure prophylaxis for female sex workers and men who have sex with men in Bangalore, India: a mathematical modelling study. <i>Journal of the International AIDS Society</i> , 2016, 19, 20942.	1.2	18

#	ARTICLE	IF	CITATIONS
787	Church-Based HIV Screening in Racial/Ethnic Minority Communities of California, 2011-2012. <i>Public Health Reports</i> , 2016, 131, 676-684.	1.3	7
788	Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment. <i>BMJ Open</i> , 2016, 6, e010682.	0.8	20
789	An Approach to Achieving the Health Equity Goals of the National HIV/AIDS Strategy for the United States Among Racial/Ethnic Minority Communities. <i>Public Health Reports</i> , 2016, 131, 526-530.	1.3	17
790	A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population. <i>Scientific Reports</i> , 2016, 6, 22183.	1.6	6
791	Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 606-608.	0.9	81
792	Modeling HIV vaccine trials of the future. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 620-627.	1.5	5
793	Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention. <i>BMC Infectious Diseases</i> , 2016, 16, 571.	1.3	23
794	“People say that we are already dead much as we can still walk”: a qualitative investigation of community and couples’ understanding of HIV serodiscordance in rural Uganda. <i>BMC Infectious Diseases</i> , 2016, 16, 665.	1.3	5
795	Individuals motivated to participate in adherence, care and treatment (imPACT): development of a multi-component intervention to help HIV-infected recently incarcerated individuals link and adhere to HIV care. <i>BMC Public Health</i> , 2016, 16, 935.	1.2	9
796	Condom use and incarceration among STI clinic attendees in the Deep South. <i>BMC Public Health</i> , 2016, 16, 971.	1.2	13
797	How do HIV-negative individuals in sub-Saharan Africa change their sexual risk behaviour upon learning their serostatus? A systematic review. <i>Sexually Transmitted Infections</i> , 2016, 92, 571-578.	0.8	15
798	Perceptions of pre-exposure prophylaxis (PrEP) among HIV-negative and HIV-positive men who have sex with men (MSM). <i>Cogent Medicine</i> , 2016, 3, 1256850.	0.7	45
799	Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex. <i>Aids</i> , 2016, 30, 2753-2756.	1.0	37
800	Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 365-373.	0.9	11
801	Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 556-563.	0.9	10
802	Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers. <i>Medicine (United States)</i> , 2016, 95, e4511.	0.4	36
803	Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis. <i>Sexually Transmitted Diseases</i> , 2016, 43, 471-475.	0.8	8
804	Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S145-S153.	0.9	29



#	ARTICLE	IF	CITATIONS
805	Design Issues in Transgender Studies. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, S248-S251.	0.9	16
806	Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, S226-S229.	0.9	33
807	Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 73, 313-322.	0.9	89
808	Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, S230-S234.	0.9	17
809	Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 73, 540-546.	0.9	238
810	Use of an HIV risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. <i>Journal of the International AIDS Society</i> , 2016, 19, 20777.	1.2	97
811	Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. <i>Journal of the International AIDS Society</i> , 2016, 19, 21108.	1.2	34
812	The role of healthcare providers in the roll out of preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 41-48.	1.5	116
813	Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa. <i>Aids</i> , 2016, 30, 1121-1129.	1.0	54
814	Feasibility of HIV Pre-Exposure Prophylaxis as Part of Routine Care in Toronto, Canada. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, e80-e81.	0.9	7
815	Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. <i>AIDS and Behavior</i> , 2016, 20, 1535-1540.	1.4	33
816	Attitudes Toward HIV Pre-Exposure Prophylaxis in a United States Urban Clinic Population. <i>AIDS and Behavior</i> , 2016, 20, 1443-1450.	1.4	47
817	Pre-exposure prophylaxis as HIV prevention in the UK. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 150-152.	1.1	3
818	Differences in Attitudes About HIV Pre-Exposure Prophylaxis Use Among Stimulant Versus Alcohol Using Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2016, 20, 1451-1460.	1.4	46
819	HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. <i>International Journal of STD and AIDS</i> , 2016, 27, 873-881.	0.5	25
820	Public Health Ethics: Cases Spanning the Globe. <i>Public Health Ethics Analysis</i> , 2016, , .	0.1	26
821	Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?. <i>Journal of Infectious Diseases</i> , 2016, 213, 1519-1520.	1.9	7
822	â€œI never thought that it would happenâ€   â€œExperiences of HIV seroconverters among HIV-discordant partnerships in a prospective HIV prevention study in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1586-1589.	0.6	8



#	ARTICLE	IF	CITATIONS
823	Current concepts for PrEP adherence in the PrEP revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 10-17.	1.5	147
824	A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. <i>Pharmaceutical Research</i> , 2016, 33, 1649-1656.	1.7	87
825	An ethnographic exploration of drug markets in Kisumu, Kenya. <i>International Journal of Drug Policy</i> , 2016, 30, 82-90.	1.6	20
826	When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. <i>Culture, Health and Sexuality</i> , 2016, 18, 1081-1091.	1.0	52
827	Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers. <i>Epidemics</i> , 2016, 14, 62-70.	1.5	17
828	Acceptability and preferences for safer conception HIV prevention strategies: a qualitative study. <i>International Journal of STD and AIDS</i> , 2016, 27, 984-992.	0.5	29
829	Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis. <i>Lancet HIV</i> , 2016, 3, e275-e282.	2.1	20
830	Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. <i>BMC Infectious Diseases</i> , 2016, 16, 189.	1.3	21
831	Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda. <i>BMC Research Notes</i> , 2016, 9, 217.	0.6	12
832	The Potential of Pre-Exposure Prophylaxis for Women in Violent Relationships. <i>AIDS Patient Care and STDs</i> , 2016, 30, 274-281.	1.1	61
833	Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. <i>Clinical Infectious Diseases</i> , 2016, 63, 539-547.	2.9	24
834	Early Adopters: Correlates of HIV Chemoprophylaxis Use in Recent Online Samples of US Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2016, 20, 1489-1498.	1.4	36
835	Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial. <i>AIDS and Behavior</i> , 2016, 20, 2639-2643.	1.4	7
836	Framing HIV Pre-Exposure Prophylaxis (PrEP) for the General Public: How Inclusive Messaging May Prevent Prejudice from Diminishing Public Support. <i>AIDS and Behavior</i> , 2016, 20, 1499-1513.	1.4	41
837	Estimating effectiveness in HIV prevention trials with a Bayesian hierarchical compound Poisson frailty model. <i>Statistics in Medicine</i> , 2016, 35, 2609-2634.	0.8	6
838	HIV Prevention 2020: a framework for delivery and a call for action. <i>Lancet HIV</i> , 2016, 3, e323-e332.	2.1	54
839	Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5379-5386.	1.4	14
840	The preexposure prophylaxis revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 67-73.	1.5	25

#	ARTICLE	IF	CITATIONS
841	Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 452-461.	0.9	92
842	Regulatory T-Cell Activity But Not Conventional HIV-Specific T-Cell Responses Are Associated With Protection From HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 119-128.	0.9	18
843	Evidence and the Politics of Deimplementation: The Rise and Decline of the "Counseling and Testing" Paradigm for HIV Prevention at the US Centers for Disease Control and Prevention. <i>Milbank Quarterly</i> , 2016, 94, 126-162.	2.1	25
844	Performing Drug Safety Research During Pregnancy and Lactation: Biomedical HIV Prevention Research as a Template. <i>Journal of Women's Health</i> , 2016, 25, 761-766.	1.5	8
845	High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013. <i>AIDS and Behavior</i> , 2016, 20, 1556-1563.	1.4	5
846	Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions. <i>AIDS and Behavior</i> , 2016, 20, 1541-1548.	1.4	12
847	Explaining the Efficacy of Pre-exposure Prophylaxis (PrEP) for HIV Prevention: A Qualitative Study of Message Framing and Messaging Preferences Among US Men Who have Sex with Men. <i>AIDS and Behavior</i> , 2016, 20, 1514-1526.	1.4	46
848	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	2.9	40
849	Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective. <i>Journal of the American Board of Family Medicine</i> , 2016, 29, 143-151.	0.8	27
850	Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. <i>Infectious Diseases and Therapy</i> , 2016, 5, 65-71.	1.8	19
851	Use of Pharmacokinetic Data in Novel Analyses to Determine the Effect of Topical Microbicides as Preexposure Prophylaxis Against HIV Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 329-331.	1.9	4
852	Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2016, 27, 608-616.	0.5	15
853	Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 265-273.	1.0	31
854	New Approach for Inhibition of HIV Entry: Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives. <i>Pathology and Oncology Research</i> , 2016, 22, 617-623.	0.9	2
855	PrEP: A Review for Mental Health Professionals. <i>Journal of Gay and Lesbian Mental Health</i> , 2016, 20, 4-12.	0.8	5
856	People living with HIV and procreation: 30 years of progress from prohibition to freedom?. <i>Human Reproduction</i> , 2016, 31, 918-925.	0.4	8
858	HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. <i>AIDS and Behavior</i> , 2016, 20, 2983-2995.	1.4	5
859	ASHP Guidelines on Pharmacist Involvement in HIV Care. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 468-494.	0.5	47

#	ARTICLE	IF	CITATIONS
860	The European preexposure prophylaxis revolution. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 74-79.	1.5	19
861	Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings. <i>Current HIV/AIDS Reports</i> , 2016, 13, 116-124.	1.1	76
862	HIV providers'™ likelihood to prescribe pre-exposure prophylaxis (PrEP) for HIV prevention differs by patient type: a short report. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1154-1158.	0.6	95
863	A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1586-1596.	1.3	28
864	Gendered differences in the perceived risks and benefits of oral PrEP among HIV-serodiscordant couples in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1000-1006.	0.6	21
865	Ancient Disease, Modern Epidemiology: A Century of Progress in Understanding and Fighting Tuberculosis. <i>American Journal of Epidemiology</i> , 2016, 183, 407-414.	1.6	9
866	Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 48-55.	0.6	66
867	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , 2016, 375, 2121-2132.	13.9	624
868	Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv221.	0.4	11
869	Pre-Exposure Prophylaxis (PrEP) for Safer Conception Among Serodifferent Couples: Findings from Healthcare Providers Serving Patients with HIV in Seven US Cities. <i>AIDS Patient Care and STDs</i> , 2016, 30, 125-133.	1.1	22
870	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. <i>Mucosal Immunology</i> , 2016, 9, 821-833.	2.7	22
871	The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept. <i>Journal of Sex Research</i> , 2016, 53, 417-456.	1.6	151
872	Blocking CXCL9 Decreases HIV-1 Replication and Enhances the Activity of Prophylactic Antiretrovirals in Human Cervical Tissues. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 474-482.	0.9	8
873	Emerging Technologies to Prevent Pregnancy and Sexually Transmitted Infections in Women. <i>Seminars in Reproductive Medicine</i> , 2016, 34, 159-167.	0.5	4
874	Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2765-2770.	1.4	9
875	The male factor: Outcomes from a cluster randomized field experiment with a couples-based HIV prevention intervention in a South African township. <i>Drug and Alcohol Dependence</i> , 2016, 161, 307-315.	1.6	30
876	Modeling and Cost-Effectiveness in HIV Prevention. <i>Current HIV/AIDS Reports</i> , 2016, 13, 64-75.	1.1	25
877	Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates" proof of concept for HIV mucosal pre-exposure prophylaxis. <i>Drug Delivery and Translational Research</i> , 2016, 6, 1-16.	3.0	12

#	ARTICLE	IF	CITATIONS
878	Optimizing Delivery of Preexposure Prophylaxis—The Next Frontier. <i>JAMA Internal Medicine</i> , 2016, 176, 85.	2.6	5
879	On the extinction probability in models of within-host infection: the role of latency and immunity. <i>Journal of Mathematical Biology</i> , 2016, 73, 787-813.	0.8	17
880	Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis. <i>Virology</i> , 2016, 489, 173-178.	1.1	8
881	HIV protection with PrEP — implications for controlling other STIs. <i>Nature Reviews Urology</i> , 2016, 13, 72-74.	1.9	1
882	HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. <i>Infection</i> , 2016, 44, 151-158.	2.3	173
883	Low-Cost Method to Monitor Patient Adherence to HIV Antiretroviral Therapy Using Multiplex Cathepsin Zymography. <i>Molecular Biotechnology</i> , 2016, 58, 56-64.	1.3	6
884	Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. <i>JAMA Internal Medicine</i> , 2016, 176, 75.	2.6	535
885	Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). <i>AIDS and Behavior</i> , 2016, 20, 1478-1488.	1.4	38
886	Diffusion of Newer HIV Prevention Innovations: Variable Practices of Frontline Infectious Diseases Physicians. <i>Clinical Infectious Diseases</i> , 2016, 62, 99-105.	2.9	33
887	HIV Treatment and Prevention. <i>Medical Decision Making</i> , 2016, 36, 391-409.	1.2	22
888	Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. <i>Clinical Infectious Diseases</i> , 2016, 62, 375-382.	2.9	20
889	Psychological Issues and PrEP in Private Practice. <i>Journal of Gay and Lesbian Mental Health</i> , 2016, 20, 34-40.	0.8	2
890	Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 201-208.	1.9	7
891	Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 489-499.	0.7	61
892	Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. <i>Lancet, The</i> , 2016, 387, 53-60.	6.3	1,493
893	Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 32-43.	0.5	148
894	Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial. <i>AIDS and Behavior</i> , 2016, 20, 2565-2577.	1.4	8
895	Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 335-342.	1.9	40

#	ARTICLE	IF	CITATIONS
896	Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 178-186.	0.5	5
897	Prediction of HIV Sexual Risk Behaviors Among Disadvantaged African American Adults Using a Syndemic Conceptual Framework. <i>AIDS and Behavior</i> , 2016, 20, 449-460.	1.4	20
898	Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes. <i>AIDS and Behavior</i> , 2016, 20, 1461-1469.	1.4	131
899	Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework. <i>AIDS and Behavior</i> , 2017, 21, 1361-1375.	1.4	109
900	“Life-Steps” for PrEP Adherence: Demonstration of a CBT-Based Intervention to Increase Adherence to Preexposure Prophylaxis (PrEP) Medication Among Sexual-Minority Men at High Risk for HIV Acquisition. <i>Cognitive and Behavioral Practice</i> , 2017, 24, 38-49.	0.9	35
901	Getting the balance right: Scaling-up treatment and prevention. <i>Global Public Health</i> , 2017, 12, 483-497.	1.0	4
902	Polarised press reporting about HIV prevention: Social representations of pre-exposure prophylaxis in the UK press. <i>Health (United Kingdom)</i> , 2017, 21, 478-497.	0.9	35
903	“PrEP is not ready for our community, and our community is not ready for PrEP”: pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response. <i>Addiction</i> , 2017, 112, 572-578.	1.7	34
904	Current views on the potential for development of a HIV vaccine. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 295-303.	1.4	23
905	Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. <i>Lancet HIV</i> , 2017, 4, e83-e92.	2.1	78
906	Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment. <i>AIDS and Behavior</i> , 2017, 21, 3100-3110.	1.4	31
907	Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. <i>AIDS and Behavior</i> , 2017, 21, 1299-1308.	1.4	52
908	Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. <i>Scientific Reports</i> , 2017, 7, 41098.	1.6	8
909	Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. <i>Drug Safety</i> , 2017, 40, 273-283.	1.4	51
910	Long-acting slow effective release antiretroviral therapy. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1281-1291.	2.4	53
911	PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study. <i>Lancet HIV</i> , 2017, 4, e214-e222.	2.1	37
912	Adolescent Sexuality. <i>Pediatric Clinics of North America</i> , 2017, 64, 389-411.	0.9	27
913	Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. <i>Drug and Alcohol Dependence</i> , 2017, 173, 107-116.	1.6	57

#	ARTICLE	IF	CITATIONS
914	Acceptability of microbicide vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1453-1457.	0.6	31
915	Science, technology, power and sex: PrEP and HIV-positive gay men in Paris. <i>Culture, Health and Sexuality</i> , 2017, 19, 1066-1077.	1.0	16
916	Progress in HIV vaccine development. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1018-1030.	1.4	80
917	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 377-383.	0.3	11
918	Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 866-869.	0.6	53
919	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.	0.5	52
920	HIV Pre-Exposure Prophylaxis and Postexposure Prophylaxis in Japan: Context of Use and Directions for Future Research and Action. <i>AIDS Patient Care and STDs</i> , 2017, 31, 60-77.	1.1	3
921	Sexual Behavior and Vaginal Practices During Pregnancy and Postpartum: Implications for HIV Prevention Strategies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 142-149.	0.9	30
922	Importance of Drug Pharmacokinetics at the Site of Action. <i>Clinical and Translational Science</i> , 2017, 10, 133-142.	1.5	86
923	US Black Women and Human Immunodeficiency Virus Prevention: Time for New Approaches to Clinical Trials. <i>Clinical Infectious Diseases</i> , 2017, 65, 324-327.	2.9	18
924	A cross-sectional analysis of <i>Trichomonas vaginalis</i> infection among heterosexual HIV-1 serodiscordant African couples. <i>Sexually Transmitted Infections</i> , 2017, 93, 520-529.	0.8	12
925	Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. <i>Annals of Medicine</i> , 2017, 49, 534-544.	1.5	14
926	Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. <i>Clinical Trials</i> , 2017, 14, 201-210.	0.7	4
927	Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 184-188.	1.1	3
928	The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 175-183.	0.9	48
929	Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	25
930	Perspectives on HIV Pre- and Post-Exposure Prophylaxes (PrEP and PEP) Among Female and Male Sex Workers in Mombasa, Kenya: Implications for Integrating Biomedical Prevention into Sexual Health Services. <i>AIDS Education and Prevention</i> , 2017, 29, 141-153.	0.6	58
931	Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract. <i>Scientific Reports</i> , 2017, 7, 45725.	1.6	20



#	ARTICLE	IF	CITATIONS
932	Disparities in HIV knowledge and attitudes toward biomedical interventions among the non-medical HIV workforce in the United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1576-1584.	0.6	6
933	Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. <i>HIV Medicine</i> , 2017, 18, 412-418.	1.0	57
934	Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis. <i>Journal of the Association of Nurses in AIDS Care</i> , 2017, 28, 612-621.	0.4	9
935	Reproductive health counseling delivered to women living with HIV in the United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 928-935.	0.6	12
936	Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. <i>Journal of Women's Health</i> , 2017, 26, 670-676.	1.5	5
937	Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	15
938	Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 184-189.	0.9	5
939	Is it time to start new HIV prevention strategies in Spain?. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )</i> , 2017, 35, 271-272.	0.2	1
940	PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists. <i>AIDS and Behavior</i> , 2017, 21, 1256-1267.	1.4	229
941	Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. <i>Drug Delivery and Translational Research</i> , 2017, 7, 805-816.	3.0	28
942	Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxil Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. <i>Journal of Infectious Diseases</i> , 2017, 215, 907-910.	1.9	8
943	Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 535-539.	0.9	16
944	Defining the HIV pre-exposure prophylaxis care continuum. <i>Aids</i> , 2017, 31, 731-734.	1.0	245
945	Examination of HIV infection through heterosexual contact with partners who are known to be HIV infected in the United States. <i>Aids</i> , 2017, 31, 1641-1644.	1.0	8
946	Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S17-S26.	0.9	80
947	Awareness, Willingness, and Use of Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Washington, DC and Miami-Dade County, FL: National HIV Behavioral Surveillance, 2011 and 2014. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S375-S382.	0.9	44
948	Acceptability and use of a dapivirine vaginal ring in a phase III trial. <i>Aids</i> , 2017, 31, 1159-1167.	1.0	97
949	Tackling HIV and AIDS: contributions by non-human primate models. <i>Lab Animal</i> , 2017, 46, 259-270.	0.2	25



#	ARTICLE	IF	CITATIONS
950	Stabilization and Sustained Release of HIV Inhibitors by Encapsulation in Silk Fibroin Disks. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 1654-1665.	2.6	19
951	The global HIV epidemic: What the pathologist needs to know. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 314-317.	1.0	25
952	Comparison of the vaginal environment in rhesus and cynomolgus macaques pre- and post-lactobacillus colonization. <i>Journal of Medical Primatology</i> , 2017, 46, 232-238.	0.3	5
953	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. <i>Science</i> , 2017, 356, 938-945.	6.0	348
954	HIV preexposure prophylaxis for adolescents and young adults. <i>Current Opinion in Pediatrics</i> , 2017, 29, 399-406.	1.0	33
955	Correlates of Preexposure Prophylaxis (PrEP) Use among Men Who Have Sex with Men (MSM) in Los Angeles, California. <i>Journal of Urban Health</i> , 2017, 94, 710-715.	1.8	55
956	Differences in Awareness of Pre-exposure Prophylaxis and Post-exposure Prophylaxis Among Groups At-Risk for HIV in New York State: New York City and Long Island, NY, 2011-2013. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, S383-S391.	0.9	56
958	Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1731-1740.	1.3	50
959	Prevention of Sexually Transmitted Diseases in HIV-Infected Individuals. <i>Current HIV/AIDS Reports</i> , 2017, 14, 41-46.	1.1	6
960	¿Es el momento de poner en marcha nuevas estrategias de prevención de la infección por VIH en España?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017, 35, 271-272.	0.3	3
961	The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 467-481.	2.0	3
962	Time to Make the Jump: Translating HIV Pre-exposure Prophylaxis Research Into Real-World Public Health Impact. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, e144-e146.	0.9	3
963	HIV Prevention and Treatment: The Evolving Role of the Emergency Department. <i>Annals of Emergency Medicine</i> , 2017, 70, 562-572.e3.	0.3	25
964	Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure Prophylaxis. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 606-615.	1.0	7
965	Reaching Key Populations: PrEP Uptake in an Urban Health Care System in the Bronx, New York. <i>AIDS and Behavior</i> , 2017, 21, 1309-1314.	1.4	23
966	Maximizing the benefits of ART and PrEP in resource-limited settings. <i>Epidemiology and Infection</i> , 2017, 145, 942-956.	1.0	15
967	Safe sex includes knowing your partner's HIV Status. <i>Journal of Perinatology</i> , 2017, 37, 1-1.	0.9	3
968	Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system. <i>Sexual Health</i> , 2017, 14, 179.	0.4	3

#	ARTICLE	IF	CITATIONS
969	Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	5
970	Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 8-15.	0.3	0
971	Moral conflict and competing duties in the initiation of a biomedical HIV prevention trial with minor adolescents. <i>AJOB Empirical Bioethics</i> , 2017, 8, 145-152.	0.8	19
972	Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1288-1298.	1.4	115
973	HIV prevention trial design in an era of effective pre-exposure prophylaxis. <i>HIV Clinical Trials</i> , 2017, 18, 177-188.	2.0	19
974	Perceived message effectiveness to evaluate updated concepts for a national HIV testing campaign for African American women. <i>Journal of Communication in Healthcare</i> , 0, , 1-11.	0.8	1
975	Brief Report: Context Matters: PrEP Adherence is Associated With Sexual Behavior Among HIV Serodiscordant Couples in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 488-492.	0.9	16
976	Delivering safer conception services to HIV serodiscordant couples in Kenya: perspectives from healthcare providers and HIV serodiscordant couples. <i>Journal of the International AIDS Society</i> , 2017, 20, 21309.	1.2	31
977	Comprehensive Primary Health Care for HIV Positive Gay Men. , 2017, , 27-50.		0
978	Willingness to use HIV pre-exposure prophylaxis among gay men, other men who have sex with men and transgender women in Myanmar. <i>Journal of the International AIDS Society</i> , 2017, 20, 21885.	1.2	38
979	Dealing with pre-exposure prophylaxis-associated condom migration: changing the paradigm for men who have sex with men. <i>Sexual Health</i> , 2017, 14, 106.	0.4	11
980	Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2017, 20, 21580.	1.2	119
981	Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model. <i>Pharmaceutical Research</i> , 2017, 34, 2749-2755.	1.7	32
982	Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. <i>BMJ Open</i> , 2017, 7, e015142.	0.8	19
983	The social value of candidate HIV cures: actualism versus possibilism. <i>Journal of Medical Ethics</i> , 2017, 43, 118-123.	1.0	14
984	Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. <i>Journal of the International AIDS Society</i> , 2017, 20, 21579.	1.2	107
985	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	1.0	47
986	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	2.0	29

#	ARTICLE	IF	CITATIONS
987	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, e104-e106.	0.9	64
988	Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. <i>Lancet HIV</i> ,the, 2017, 4, e522-e528.	2.1	69
989	Factors Contributing to the Antiviral Effectiveness of Tenofovir. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 363, 156-163.	1.3	17
990	Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. <i>JAMA Pediatrics</i> , 2017, 171, 1063.	3.3	178
991	Pre-exposure prophylaxis for MSM and transgender persons in early adopting countries. <i>Aids</i> , 2017, 31, 2179-2191.	1.0	51
992	Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. <i>Lancet HIV</i> ,the, 2017, 4, e449-e456.	2.1	44
993	Challenges and emerging opportunities for the HIV prevention, treatment and care cascade in men who have sex with men in Asia Pacific. <i>Sexually Transmitted Infections</i> , 2017, 93, 356-362.	0.8	27
994	Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. <i>Lancet HIV</i> ,the, 2017, 4, e402-e410.	2.1	379
995	Vaginal dysbiosis and pre-exposure prophylaxis efficacy. <i>Lancet HIV</i> ,the, 2017, 4, e427-e429.	2.1	2
996	The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. <i>Aids</i> , 2017, 31, 2007-2016.	1.0	75
997	Two, three, and four-drug regimens for HIV post-exposure prophylaxis in a North American sexual assault victim population. <i>American Journal of Emergency Medicine</i> , 2017, 35, 1798-1803.	0.7	7
998	Infecci3n por el VIH/sida: El principio del fin de la primera gran pandemia contempornea?. <i>Revista Clinica Espanola</i> , 2017, 217, 468-472.	0.2	2
999	HIV/AIDS infection: The beginning of the end for today's greatest pandemic?. <i>Revista Cl&amp;#x00ed;nica Espan&amp;#x00f5;la</i> , 2017, 217, 468-472.	0.3	0
1000	Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. <i>AIDS Patient Care and STDs</i> , 2017, 31, 348-355.	1.1	22
1001	Humanized Mouse Models for Human Immunodeficiency Virus Infection. <i>Annual Review of Virology</i> , 2017, 4, 393-412.	3.0	65
1002	Repeated administration of high-dose depot medroxyprogesterone acetate does not alter <scp>SHIV</sub>SF</sub></scp> <sub>162p3</sub> viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings. <i>Journal of Medical Primatology</i> , 2017, 46, 129-136.	0.3	2
1003	HIV pre-exposure prophylaxis (PrEP): effective but controversial. <i>Trends in Urology &amp; Men's Health</i> , 2017, 8, 9-12.	0.2	8
1004	How Do We Get Partners to Test for HIV?: Predictors of Uptake of Partner HIV Testing Following Individual Outpatient Provider Initiated HIV Testing in Rural Uganda. <i>AIDS and Behavior</i> , 2017, 21, 2497-2508.	1.4	7

#	ARTICLE	IF	CITATIONS
1005	When Science and Values Collide: Recalling the Lessons of Evidence-Based HIV Prevention. <i>AIDS and Behavior</i> , 2017, 21, 2807-2810.	1.4	0
1006	Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. <i>Aids</i> , 2017, 31, 469-476.	1.0	45
1007	Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa. <i>Aids</i> , 2017, 31, 2193-2197.	1.0	30
1008	Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 38-43.	0.9	3
1009	Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 343-347.	0.9	9
1010	Routine Inpatient Human Immunodeficiency Virus Screening. <i>Clinical Nurse Specialist</i> , 2017, 31, 45-51.	0.3	0
1011	Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. <i>Aids</i> , 2017, 31, 461-467.	1.0	37
1012	Sexual Behaviors and HIV Status: A Population-Based Study Among Older Adults in Rural South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, e9-e17.	0.9	59
1013	Counseling Framework for HIV-Serodiscordant Couples on the Integrated Use of Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, S15-S22.	0.9	37
1014	Social Disequilibrium and the Risk of HIV Acquisition: A Multilevel Study in Rural KwaZulu-Natal Province, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 164-174.	0.9	19
1015	Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 330-337.	0.9	16
1016	Where next with preexposure prophylaxis?. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 44-49.	1.3	2
1017	Decoding HIV resistance: from genotype to therapy. <i>Future Medicinal Chemistry</i> , 2017, 9, 1529-1538.	1.1	9
1018	Multipurpose tenofovir disoproxil fumarate electrospun fibers for the prevention of HIV-1 and HSV-2 infections in vitro. <i>International Journal of Pharmaceutics</i> , 2017, 531, 118-133.	2.6	18
1019	Antiretroviral combination use during pregnancy and the risk of major congenital malformations. <i>Aids</i> , 2017, 31, 2267-2277.	1.0	10
1020	Individual Versus Community-Level Risk Compensation Following Preexposure Prophylaxis of HIV. <i>American Journal of Public Health</i> , 2017, 107, 1568-1571.	1.5	48
1021	The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women. <i>Current HIV/AIDS Reports</i> , 2017, 14, 153-160.	1.1	23
1022	Sero-discovering versus sero-cognisant: initial challenges and needs of HIV-serodiscordant couples in Porto Alegre, Brazil. <i>Culture, Health and Sexuality</i> , 2017, 19, 888-902.	1.0	3

#	ARTICLE	IF	CITATIONS
1023	Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus-Infected Persons in Serodiscordant Partnerships. <i>Sexually Transmitted Diseases</i> , 2017, 44, 58-62.	0.8	8
1024	Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3142-3154.	3.0	24
1025	HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults. <i>AIDS Patient Care and STDs</i> , 2017, 31, 504-516.	1.1	52
1026	Extensive Homeostatic T Cell Phenotypic Variation within the Collaborative Cross. <i>Cell Reports</i> , 2017, 21, 2313-2325.	2.9	42
1027	Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. <i>Cmaj</i> , 2017, 189, E1448-E1458.	0.9	149
1028	Acute Alcohol Consumption Directly Increases HIV Transmission Risk: A Randomized Controlled Experiment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 493-500.	0.9	34
1029	Test-and-treat approach to HIV/AIDS: a primer for mathematical modeling. <i>Theoretical Biology and Medical Modelling</i> , 2017, 14, 16.	2.1	14
1030	Prevalence and Correlates of Use of Safer Conception Methods in a Prospective Cohort of Ugandan HIV-Affected Couples with Fertility Intentions. <i>AIDS and Behavior</i> , 2017, 21, 2479-2487.	1.4	16
1031	Jaboya (â€œSex for Fishâ€): A Qualitative Analysis of Contextual Risk Factors for Extramarital Partnerships in the Fishing Communities in Western Kenya. <i>Archives of Sexual Behavior</i> , 2017, 46, 1877-1890.	1.2	11
1032	Brief Report: Hormonal Contraception Is Not Associated With Reduced ART Effectiveness Among Women Initiating ART: Evidence From Longitudinal Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 91-96.	0.9	6
1033	HIV pre-exposure prophylaxis: the primary care implications of prescribing restrictions. <i>British Journal of General Practice</i> , 2017, 67, 324-325.	0.7	1
1034	A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective. <i>Infectious Diseases and Therapy</i> , 2017, 6, 363-382.	1.8	37
1035	Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis. <i>Aids</i> , 2017, 31, 1647-1650.	1.0	6
1036	Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. <i>Harm Reduction Journal</i> , 2017, 14, 40.	1.3	95
1037	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 21-29.	0.9	235
1038	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182.	0.9	25
1039	Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda. <i>Reproductive Health</i> , 2017, 14, 36.	1.2	3
1040	Disparities in Awareness of HIV Postexposure and Preexposure Prophylaxis Among Notified Partners of HIV-Positive Individuals, New York City 2015â€“2017. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 132-140.	0.9	35

#	ARTICLE	IF	CITATIONS
1041	Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2017, 35, 377-383.	0.2	0
1042	Assessment of HIV Screening Tests for Pre-Exposure Prophylaxis Programs. <i>Journal of Infectious Diseases</i> , 2017, 216, 382-386.	1.9	25
1043	Substance Use Disorders, Violence, Mental Health, and HIV: Differentiating a Syndemic Factor by Gender and Sexuality. <i>AIDS and Behavior</i> , 2017, 21, 2270-2282.	1.4	32
1044	Entonjeniâ€”A Structural Intervention to Integrate Sexual and Reproductive Health into Public Sector HIV Care in Cape Town, South Africa: Results of a Phase II Study. <i>AIDS and Behavior</i> , 2017, 21, 905-922.	1.4	13
1045	Drugs for HIV Infection. , 2017, , 1293-1308.e2.		17
1046	Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Personsâ€”United States, 2010â€”2014. <i>Clinical Infectious Diseases</i> , 2017, 64, 144-149.	2.9	109
1047	Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care. <i>Journal of General Internal Medicine</i> , 2017, 32, 192-198.	1.3	88
1048	Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. <i>AIDS and Behavior</i> , 2017, 21, 2173-2179.	1.4	14
1049	Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2017, 21, 1336-1349.	1.4	103
1050	A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. <i>Journal of General Internal Medicine</i> , 2017, 32, 62-70.	1.3	131
1051	Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 734-740.	0.6	6
1052	Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 339-346.	0.5	32
1053	Epithelium-innate immune cell axis in mucosal responses to SIV. <i>Mucosal Immunology</i> , 2017, 10, 508-519.	2.7	35
1054	The â€œSafe Sexâ€”Conundrum: Anticipated Stigma From Sexual Partners as a Barrier to PrEP Use Among Substance Using MSM Engaging in Transactional Sex. <i>AIDS and Behavior</i> , 2017, 21, 300-306.	1.4	62
1055	The Impact of HIV Pre-exposure Prophylaxis (PrEP) Use on the Sexual Health of Men Who Have Sex with Men: A Qualitative Study in Seattle, WA. <i>International Journal of Sexual Health</i> , 2017, 29, 55-68.	1.2	63
1056	Mathematical assessment of the role of pre-exposure prophylaxis on HIV transmission dynamics. <i>Applied Mathematics and Computation</i> , 2017, 293, 168-193.	1.4	15
1057	Healthcare Provider Contact and Pre-exposure Prophylaxis in Baltimore Men Who Have Sex With Men. <i>American Journal of Preventive Medicine</i> , 2017, 52, 55-63.	1.6	29
1058	Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil. <i>AIDS and Behavior</i> , 2017, 21, 1278-1287.	1.4	76



#	ARTICLE	IF	CITATIONS
1059	Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 478-485.	1.3	37
1060	Bio-behavioral Interventions to Prevent HIV Transmission. , 2017, , 824-828.e2.		0
1061	HIV/AIDS-Related Problems in Low- and Middle-Income Countries. , 2017, , 888-895.e1.		0
1062	Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study. <i>Lancet HIV</i> ,the, 2017, 4, e59-e66.	2.1	46
1063	Commitment issues: PrEP adherence in injecting drug users. <i>Lancet HIV</i> ,the, 2017, 4, e52-e53.	2.1	4
1064	Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP" AIDS and Behavior, 2017, 21, 1350-1360.	1.4	72
1065	Top Questions in ID: Pre-exposure Prophylaxis for HIV. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx185.	0.4	1
1066	Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature. <i>Antiviral Therapy</i> , 2017, 23, 379-382.	0.6	0
1067	Recent advances in pre-exposure prophylaxis for HIV. <i>BMJ: British Medical Journal</i> , 2017, 359, j5011.	2.4	101
1068	Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+T cells. <i>Scientific Reports</i> , 2017, 7, 17697.	1.6	10
1069	Sociodemographic and Clinical Factors Associated With Increasing Bacterial Sexually Transmitted Infection Diagnoses in Men Who Have Sex With Men Accessing Care at a Boston Community Health Center (2005-2015). <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx214.	0.4	26
1070	Preventing the Spread of HIV/AIDS in Botswana. , 0, , 998-1019.		0
1071	Couples HIV counselling and couple relationships in India, Georgia and the Dominican Republic. <i>BMC Public Health</i> , 2017, 17, 901.	1.2	5
1072	Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy Is Not Associated With Adverse Perinatal Outcomes Among HIV-infected East African Women: A Prospective Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 1561-1568.	1.9	25
1074	New Antiretrovirals for HIV and Antivirals for HBV. , 2017, , 628-664.		1
1075	Editorial: HIV and Antiretroviral Drugs: Current Status and New Challenges. <i>Current Pharmaceutical Design</i> , 2017, 23, 2551.	0.9	0
1076	The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. <i>Vaccines</i> , 2017, 5, 13.	2.1	11
1077	Nurturing the continuum of HIV testing, treatment and prevention matrix cascade in reducing HIV transmission. <i>Ethiopian Journal of Health Sciences</i> , 2017, 27, 621.	0.2	1



#	ARTICLE	IF	CITATIONS
1078	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
1079	Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. <i>Frontiers in Immunology</i> , 2017, 8, 561.	2.2	25
1080	Hepatitis C Virus (HCV) Treatment as Prevention: Epidemic and Cost-Effectiveness Modeling. <i>Handbook of Statistics</i> , 2017, 37, 93-119.	0.4	0
1081	Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 137-148.	0.7	20
1082	Feasibility and acceptability of HIV self-testing among pre-exposure prophylaxis users in Kenya. <i>Journal of the International AIDS Society</i> , 2017, 20, 21234.	1.2	66
1083	Pre-exposure prophylaxis for HIV prevention in women: current perspectives. <i>International Journal of Women's Health</i> , 2017, Volume 9, 391-401.	1.1	41
1084	Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study. <i>PLoS ONE</i> , 2017, 12, e0175596.	1.1	6
1085	Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. <i>PLoS ONE</i> , 2017, 12, e0178170.	1.1	25
1086	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017, 12, e0181433.	1.1	9
1087	Low HIV incidence in pregnant and postpartum women receiving a community-based combination HIV prevention intervention in a high HIV incidence setting in South Africa. <i>PLoS ONE</i> , 2017, 12, e0181691.	1.1	18
1088	Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. <i>PLoS ONE</i> , 2017, 12, e0185946.	1.1	26
1089	Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. <i>PLoS ONE</i> , 2017, 12, e0184303.	1.1	18
1090	Long-Acting HIV Treatment and Prevention: Closer to the Threshold. <i>Global Health, Science and Practice</i> , 2017, 5, 182-187.	0.6	23
1091	Incident HIV during pregnancy and early postpartum period: a population-based cohort study in a rural area in KwaZulu-Natal, South Africa. <i>BMC Pregnancy and Childbirth</i> , 2017, 17, 248.	0.9	28
1092	The role of male partners in women's participation in research during pregnancy: a case study from the partners demonstration project. <i>Reproductive Health</i> , 2017, 14, 160.	1.2	12
1093	Ethical considerations in developing an evidence base for pre-exposure prophylaxis in pregnant women. <i>Reproductive Health</i> , 2017, 14, 171.	1.2	1
1094	A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. <i>BMC Infectious Diseases</i> , 2017, 17, 496.	1.3	20
1095	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017, 17, 734.	1.3	4

#	ARTICLE	IF	CITATIONS
1096	High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. <i>Journal of the International AIDS Society</i> , 2017, 20, 21472.	1.2	98
1097	Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. <i>Journal of AIDS &amp; Clinical Research</i> , 2017, 08, .	0.5	128
1098	Prescribing of Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis by HIV Medical Providers in the United States, 2013-2014. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx003.	0.4	11
1099	Pre-exposure prophylaxis for HIV prevention in East and Southern Africa. <i>Canadian Journal of Public Health</i> , 2017, 108, e643-e645.	1.1	3
1100	The role of family planning in achieving safe pregnancy for serodiscordant couples: commentary from the United States government's interagency task force on family planning and HIV service integration. <i>Journal of the International AIDS Society</i> , 2017, 20, 21312.	1.2	8
1101	Summary of Guidelines for the Use of Pre-Exposure Prophylaxis for HIV in Korea. <i>Infection and Chemotherapy</i> , 2017, 49, 243.	1.0	7
1102	Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 1534-1540.	1.9	18
1103	Anti-Retroviral-Based HIV Pre-Exposure Prophylaxis for Women: Recent Advances and Next Steps. , 0, , .		0
1104	Preexposure Prophylaxis—a New Addition to the Armamentarium Against Human Immunodeficiency Virus. <i>Clinical Medicine Insights Therapeutics</i> , 2017, 9, 1179559X1771524.	0.4	0
1105	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 175-179.	0.9	34
1106	Concordance of self-reported hormonal contraceptive use and presence of exogenous hormones in serum among African women. <i>Contraception</i> , 2018, 97, 357-362.	0.8	15
1107	“Where Did This [PrEP] Come From?” African American Mother/Daughter Perceptions Related to Adolescent Preexposure Prophylaxis (PrEP) Utilization and Clinical Trial Participation. <i>Journal of Empirical Research on Human Research Ethics</i> , 2018, 13, 173-184.	0.6	29
1108	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. <i>Nature Medicine</i> , 2018, 24, 491-496.	15.2	123
1109	HIV Coinfection Among Persons Diagnosed As Having Sexually Transmitted Diseases, San Francisco, 2007 to 2014. <i>Sexually Transmitted Diseases</i> , 2018, 45, 563-572.	0.8	11
1110	Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. <i>Sexually Transmitted Infections</i> , 2018, 94, 457-462.	0.8	60
1111	US Guidelines That Empower Women to Prevent HIV With Preexposure Prophylaxis. <i>Sexually Transmitted Diseases</i> , 2018, 45, e38-e39.	0.8	13
1112	Amplifying the Population Health Benefits of PrEP for HIV Prevention. <i>Journal of Infectious Diseases</i> , 2018, 217, 1509-1511.	1.9	9
1113	Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 67, 676-686.	2.9	326

#	ARTICLE	IF	CITATIONS
1114	Alcohol use, expectancies and HIV-related sexual risk: a cross-sectional survey of male migrant workers in South India. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 656-662.	0.6	5
1115	Meta-Analysis of Alcohol and Serodiscordant Condomless Sex Among People Living with HIV. <i>Archives of Sexual Behavior</i> , 2018, 47, 1351-1366.	1.2	7
1116	Sex Differences in HIV Infection. <i>Current HIV/AIDS Reports</i> , 2018, 15, 136-146.	1.1	128
1117	Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners. <i>Journal of Infectious Diseases</i> , 2018, 218, 16-25.	1.9	198
1118	Impact of Improved HIV Care and Treatment on PrEP Effectiveness in the United States, 2016â€“2020. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 399-405.	0.9	31
1119	Access to Fertility Treatment for Mixed-Status Couples With Human Immunodeficiency Virus. <i>Obstetrics and Gynecology</i> , 2018, 131, 875-878.	1.2	4
1120	Biomedical Approaches to HIV Prevention in Women. <i>Current Infectious Disease Reports</i> , 2018, 20, 11.	1.3	7
1121	HIV prevention strategies. <i>Medicine</i> , 2018, 46, 293-299.	0.2	1
1122	Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City. <i>AIDS and Behavior</i> , 2018, 22, 3627-3636.	1.4	79
1123	A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. <i>AIDS Patient Care and STDs</i> , 2018, 32, 104-111.	1.1	68
1124	Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 413-420.	1.9	28
1125	Reported Primary and Secondary Syphilis Cases in the United States: Implications for HIV Infection. <i>Sexually Transmitted Diseases</i> , 2018, 45, S42-S47.	0.8	28
1126	HIV Pre-exposure Prophylaxis Program Implementation Using Intervention Mapping. <i>American Journal of Preventive Medicine</i> , 2018, 54, 519-529.	1.6	7
1127	Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 554-564.	4.6	175
1128	Simultaneous quantitation of multiple contraceptive hormones in human serum by LCâ€“MS/MS. <i>Contraception</i> , 2018, 97, 363-369.	0.8	43
1129	Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction. <i>Health Policy</i> , 2018, 122, 237-242.	1.4	11
1130	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	2.9	50
1131	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1712-1721.	2.9	48

#	ARTICLE	IF	CITATIONS
1132	Correlates of Linkage to HIV Preexposure Prophylaxis Among HIV-Testing Clients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 365-372.	0.9	20
1133	“Get an early check” Chrysanthemum tea™: An outcome evaluation of a multimedia campaign promoting HIV testing among men who have sex with men in Hong Kong. <i>HIV Medicine</i> , 2018, 19, 347-354.	1.0	2
1134	Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs. <i>Aids</i> , 2018, 32, 663-672.	1.0	15
1135	Temporal Fluctuations in Behavior, Perceived HIV Risk, and Willingness to Use Pre-Exposure Prophylaxis (PrEP). <i>Archives of Sexual Behavior</i> , 2018, 47, 2109-2121.	1.2	44
1136	Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States. <i>AIDS Patient Care and STDs</i> , 2018, 32, 16-23.	1.1	105
1137	The Etiology of Vaginal Discharge Syndrome in Zimbabwe: Results from the Zimbabwe STI Etiology Study. <i>Sexually Transmitted Diseases</i> , 2018, 45, 422-428.	0.8	23
1139	Vaginal microbiota and susceptibility to HIV. <i>Aids</i> , 2018, 32, 687-698.	1.0	70
1140	Preventing New Human Immunodeficiency Virus Infections With Pre-exposure Prophylaxis. <i>Journal for Nurse Practitioners</i> , 2018, 14, 376-382.	0.4	3
1141	Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategies. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 95-101.	1.5	11
1142	Who Starts the Conversation and Who Receives Preexposure Prophylaxis (PrEP)? A Brief Online Survey of Medical Providers’ PrEP Practices. <i>Health Education and Behavior</i> , 2018, 45, 723-729.	1.3	20
1143	Intimate Partner Violence and Self-Reported Pre-exposure Prophylaxis Interruptions Among HIV-Negative Partners in HIV Serodiscordant Couples in Kenya and Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 154-159.	0.9	47
1144	Implementing Generalized Additive Models to Estimate the Expected Value of Sample Information in a Microsimulation Model: Results of Three Case Studies. <i>Medical Decision Making</i> , 2018, 38, 189-199.	1.2	6
1145	Do You PrEP? A Review of Primary Care Provider Knowledge of PrEP and Attitudes on Prescribing PrEP. <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 83-92.	0.4	48
1146	No. 354-Canadian HIV Pregnancy Planning Guidelines. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 94-114.	0.3	34
1147	No 354 “Lignes directrices canadiennes en matière de planification de la grossesse en présence du VIH. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 115-137.	0.3	0
1148	Generic antiretroviral drug use in HIV-infected patients: A cohort study from the French health insurance database. <i>Thérapie</i> , 2018, 73, 257-266.	0.6	1
1149	Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States. <i>AIDS and Behavior</i> , 2018, 22, 3540-3549.	1.4	39
1150	Body/Selves and Beyond: Men’s Narratives of Sexual Behavior on PrEP. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2018, 37, 387-400.	0.6	27

#	ARTICLE	IF	CITATIONS
1151	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.	2.9	82
1152	Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value. <i>AIDS and Behavior</i> , 2018, 22, 1165-1173.	1.4	51
1153	The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase. <i>Journal of Infectious Diseases</i> , 2018, 217, 790-801.	1.9	12
1154	Identifying "corridors of HIV transmission" in a severely affected rural South African population: a case for a shift toward targeted prevention strategies. <i>International Journal of Epidemiology</i> , 2018, 47, 537-549.	0.9	44
1155	Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 350-357.	0.9	3
1156	Evaluating the impact of DREAMS on HIV incidence among young women who sell sex: protocol for a non-randomised study in Zimbabwe. <i>BMC Public Health</i> , 2018, 18, 203.	1.2	22
1157	Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities. <i>AIDS and Behavior</i> , 2018, 22, 3649-3657.	1.4	25
1158	Physiologically-based pharmacokinetic model of vaginally administered dapivirine ring and film formulations. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1950-1969.	1.1	16
1159	Missed Opportunities to Prescribe HIV Pre-Exposure Prophylaxis by Primary Care Providers in Saint Louis, Missouri. <i>LGBT Health</i> , 2018, 5, 250-256.	1.8	23
1160	Editorial. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 291-293.	1.5	8
1161	Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517.	1.3	38
1162	Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City. <i>AIDS and Behavior</i> , 2018, 22, 421-436.	1.4	11
1163	Subsequent HIV Diagnosis Risk After Syphilis in a Southern Black Population. <i>Sexually Transmitted Diseases</i> , 2018, 45, 643-647.	0.8	8
1164	HIV Preexposure Prophylaxis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1261.	3.8	206
1165	An Information-Motivation-Behavioral Skills Model of PrEP Uptake. <i>AIDS and Behavior</i> , 2018, 22, 3603-3616.	1.4	70
1166	Implementing preexposure prophylaxis among key populations. <i>Aids</i> , 2018, 32, 829-830.	1.0	6
1167	Correlation of Adherence by Pill Count, Self-report, MEMS and Plasma Drug Levels to Treatment Response Among Women Receiving ARV Therapy for PMTCT in Kenya. <i>AIDS and Behavior</i> , 2018, 22, 918-928.	1.4	14
1168	Prevention Strategies Against HIV Transmission: A Proactive Approach. <i>Journal of Pharmacy Practice</i> , 2018, 31, 82-90.	0.5	3

#	ARTICLE	IF	CITATIONS
1169	Effects of Brief Messages About Antiretroviral Therapy and Condom Use Benefits Among Black and Latino MSM in Three U.S. Cities. <i>Journal of Homosexuality</i> , 2018, 65, 154-166.	1.3	7
1170	Consensus statement: Supporting Safer Conception and Pregnancy For Men And Women Living with and Affected by HIV. <i>AIDS and Behavior</i> , 2018, 22, 1713-1724.	1.4	50
1171	Behavioral intention to take up different types of HIV testing among men who have sex with men who were never-testers in Hong Kong. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 95-102.	0.6	11
1172	How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe. <i>AIDS and Behavior</i> , 2018, 22, 877-886.	1.4	7
1173	Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. <i>Lancet HIV,the</i> , 2018, 5, e68-e78.	2.1	96
1174	Working towards HIV prevention choices for women. <i>Lancet HIV,the</i> , 2018, 5, e60-e61.	2.1	1
1175	Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data. <i>AIDS and Behavior</i> , 2018, 22, 1174-1183.	1.4	36
1176	The Effect of PrEP on HIV Incidence Among Men Who Have Sex With Men in the Context of Condom Use, Treatment as Prevention, and Seroadaptive Practices. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 31-40.	0.9	54
1177	Sexual Identity Disclosure and Awareness of HIV Prevention Methods Among Black Men Who Have Sex With Men. <i>Journal of Sex Research</i> , 2018, 55, 975-983.	1.6	23
1178	Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued. <i>Aids</i> , 2018, 32, 179-188.	1.0	12
1179	Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 193-198.	0.9	35
1180	HIV Preexposure Prophylaxis Implementation at Local Health Departments: A Statewide Assessment of Activities and Barriers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 72-77.	0.9	26
1181	HIV/AIDS conspiracy beliefs and intention to adopt preexposure prophylaxis among black men who have sex with men in Los Angeles. <i>International Journal of STD and AIDS</i> , 2018, 29, 375-381.	0.5	46
1182	A Randomized Controlled Trial Evaluating Efficacy of Promoting a Home-Based HIV Self-Testing with Online Counseling on Increasing HIV Testing Among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2018, 22, 190-201.	1.4	94
1183	Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 191-198.	0.6	49
1184	Perceived need of, and interest in, HIV pre-exposure prophylaxis amongst men who have sex with men attending three sexual health clinics in London, UK. <i>International Journal of STD and AIDS</i> , 2018, 29, 435-442.	0.5	15
1185	Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	17
1186	A cross-sectional study examining associations between substance use frequency, problematic use and STIs among youth living with HIV. <i>Sexually Transmitted Infections</i> , 2018, 94, 304-308.	0.8	15



#	ARTICLE	IF	CITATIONS
1187	Pre-Exposure Prophylaxis (PrEP) Use and Condomless Anal Sex: Evidence of Risk Compensation in a Cohort of Young Men Who Have Sex with Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 358-364.	0.9	90
1188	Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. <i>Epidemics</i> , 2018, 23, 34-41.	1.5	8
1189	High percentage of undiagnosed HIV cases within a hyperendemic South African community: a population-based study. <i>Journal of Epidemiology and Community Health</i> , 2018, 72, 168-172.	2.0	25
1190	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	182
1191	Evolving Models and Ongoing Challenges for HIV Preexposure Prophylaxis Implementation in the United States. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 119-127.	0.9	108
1192	The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue. <i>Aids</i> , 2018, 32, 11-15.	1.0	8
1193	HIV Prevention Among Young Women in South Africa: Understanding Multiple Layers of Risk. <i>Archives of Sexual Behavior</i> , 2018, 47, 1969-1982.	1.2	21
1194	Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 206-211.	0.9	23
1195	Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 175-182.	0.9	23
1196	Predictors of HIV, HIV Risk Perception, and HIV Worry Among Adolescent Girls and Young Women in Lilongwe, Malawi. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 53-63.	0.9	61
1197	Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. <i>AIDS and Behavior</i> , 2018, 22, 1228-1238.	1.4	31
1198	Dyadic Qualitative Analysis of Condom Use Scripts Among Emerging Adult Gay Male Couples. <i>Journal of Sex and Marital Therapy</i> , 2018, 44, 269-280.	1.0	13
1199	Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV. <i>Sexually Transmitted Infections</i> , 2018, 94, 163-168.	0.8	36
1200	Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 9-17.	0.6	76
1201	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. <i>Aids</i> , 2018, 32, 2189-2194.	1.0	14
1202	Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 330-338.	0.9	20
1203	Pre-exposure prophylaxis rollout in a national public sector program: the Kenyan case study. <i>Sexual Health</i> , 2018, 15, 578.	0.4	60
1204	Canadian guidelines on HIV pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP): Discussion beyond the guidelines and commentary on the role of infectious diseases specialists. <i>Jammi</i> , 2018, 3, 165-177.	0.3	3



#	ARTICLE	IF	CITATIONS
1205	Role of Preexposure Prophylaxis in the Reproductive Health of Women at Risk for Human Immunodeficiency Virus Infection. <i>Obstetrics and Gynecology</i> , 2018, 132, 687-691.	1.2	14
1206	Advancing HIV Biomedical Prevention Research for At-Risk Adolescents. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 535-542.	0.9	7
1207	PrEP: pre-exposure prophylaxis for HIV prevention. <i>Trends in Urology &amp; Men's Health</i> , 2018, 9, 22-24.	0.2	0
1208	HIV Preexposure Prophylaxis, by Race and Ethnicity – United States, 2014–2016. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 1147-1150.	9.0	318
1209	Acceptability and tolerability of and adherence to HIV preexposure prophylaxis among Toronto gay and bisexual men: a pilot study. <i>CMAJ Open</i> , 2018, 6, E611-E617.	1.1	4
1210	Female Sex Workers Often Incorrectly Interpret HIV Self-Test Results in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, e42-e45.	0.9	29
1211	The DREAMS core package of interventions: A comprehensive approach to preventing HIV among adolescent girls and young women. <i>PLoS ONE</i> , 2018, 13, e0208167.	1.1	198
1212	Awareness and use of pre-exposure and postexposure prophylaxes among Nigerian university students. <i>Medicine (United States)</i> , 2018, 97, e12226.	0.4	28
1213	PrEParing for the unexpected: mechanisms and management of HIV pre-exposure prophylaxis failure. <i>Future Virology</i> , 2018, 13, 747-759.	0.9	3
1214	Prevençã³n primaria. <i>Enfermedades Infecciosas Y MicrobiologÃa ClÃnica</i> , 2018, 36, 31-34.	0.3	0
1215	Redefining Prevention and Care: A Status-Neutral Approach to HIV. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy097.	0.4	79
1216	Sources of social support and sexual behaviour advice for young adults in rural South Africa. <i>BMJ Global Health</i> , 2018, 3, e000955.	2.0	13
1217	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. <i>Journal of Virus Eradication</i> , 2018, 4, 143-159.	0.3	39
1219	Delivery of TDF/FTC for Pre-exposure Prophylaxis to Prevent HIV-1 Acquisition in Young Adult Men Who Have Sex With Men and Transgender Women of Color Using a Urine Adherence Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 173-178.	0.9	22
1220	Evaluation of the awareness, knowledge and use of pre-exposure prophylaxis (PrEP) among the serodiscordant partners of HIV infected individuals on ART in an urban HIV clinic. <i>Cogent Medicine</i> , 2018, 5, 1475124.	0.7	1
1221	Outcomes of Preexposure Prophylaxis Referrals From Public STI Clinics and Implications for the Preexposure Prophylaxis Continuum. <i>Sexually Transmitted Diseases</i> , 2018, 45, 50-55.	0.8	32
1222	Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. <i>Sexual Health</i> , 2018, 15, 556.	0.4	90
1223	Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States. <i>Aids</i> , 2018, 32, 2787-2798.	1.0	7

#	ARTICLE	IF	CITATIONS
1224	Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002690.	3.9	126
1225	A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?. <i>BMC Infectious Diseases</i> , 2018, 18, 581.	1.3	146
1226	“Don't Need PrEP Right Now” A Qualitative Exploration of the Barriers to PrEP Care Engagement Through the Application of the Health Belief Model. <i>AIDS Education and Prevention</i> , 2018, 30, 369-381.	0.6	28
1227	Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. <i>Aids</i> , 2018, 32, 2161-2169.	1.0	45
1228	Knowledge, interest, and anticipated barriers of pre-exposure prophylaxis uptake and adherence among gay, bisexual, and men who have sex with men who are incarcerated. <i>PLoS ONE</i> , 2018, 13, e0205593.	1.1	35
1229	Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men. <i>PLoS ONE</i> , 2018, 13, e0209484.	1.1	23
1230	Serodiscordant partnerships and opportunities for pre-exposure prophylaxis among partners of women and men living with HIV in St. Petersburg, Russia. <i>PLoS ONE</i> , 2018, 13, e0207402.	1.1	3
1231	Power to participants: a call for person-centred HIV prevention services and research. <i>Journal of the International AIDS Society</i> , 2018, 21, e25167.	1.2	21
1232	PrEP Eligibility and Interest Among Clinic- and Community-Recruited Young Black Women in Atlanta, Georgia, USA. <i>Current HIV Research</i> , 2018, 16, 250-255.	0.2	24
1233	Project ECHO: telementoring to educate and support prescribing of HIV pre-exposure prophylaxis by community medical providers. <i>Sexual Health</i> , 2018, 15, 601.	0.4	32
1234	Use of antiretroviral drugs to prevent the transmission and acquisition of HIV. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 544-545.	0.2	0
1235	A Group-Based Trajectory Model for Changes in Pre-Exposure Prophylaxis and Condom Use Among Men Who Have Sex with Men Participating in the ANRS IPERGAY Trial. <i>AIDS Patient Care and STDs</i> , 2018, 32, 495-510.	1.1	8
1236	Midwest pharmacists' familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV. <i>PLoS ONE</i> , 2018, 13, e0207372.	1.1	20
1237	Higher prevalence of viral control in HIV-1-infected women in serodiscordant relationships. <i>PLoS ONE</i> , 2018, 13, e0208401.	1.1	1
1238	Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. <i>Emerging Infectious Diseases</i> , 2018, 24, .	2.0	38
1239	Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. <i>Sexual Health</i> , 2018, 15, 501.	0.4	25
1240	Perceptions of HIV transmission and pre-exposure prophylaxis among health care workers and community members in Rwanda. <i>PLoS ONE</i> , 2018, 13, e0207650.	1.1	24
1241	Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and examples of successful health service models of PrEP implementation. <i>Sexual Health</i> , 2018, 15, 481.	0.4	13

#	ARTICLE	IF	CITATIONS
1242	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. <i>HIV Clinical Trials</i> , 2018, 19, 129-138.	2.0	51
1243	PrEP Continuation, HIV and STI Testing Rates, and Delivery of Preventive Care in a Clinic-Based Cohort. <i>AIDS Education and Prevention</i> , 2018, 30, 393-405.	0.6	25
1244	Acceptability of HIV self-testing to support pre-exposure prophylaxis among female sex workers in Uganda and Zambia: results from two randomized controlled trials. <i>BMC Infectious Diseases</i> , 2018, 18, 503.	1.3	37
1245	A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 818-828.	1.3	11
1246	Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial. <i>PLoS Medicine</i> , 2018, 15, e1002655.	3.9	27
1247	Ultra-long-acting removable drug delivery system for HIV treatment and prevention. <i>Nature Communications</i> , 2018, 9, 4156.	5.8	70
1248	Gaps in Preexposure Prophylaxis Uptake for HIV Prevention in the Veterans Health Administration. <i>American Journal of Public Health</i> , 2018, 108, S305-S310.	1.5	21
1249	A systematic evaluation of mobile apps to improve the uptake of and adherence to HIV pre-exposure prophylaxis. <i>Sexual Health</i> , 2018, 15, 587.	0.4	24
1250	Vaginal washing and lubrication among female sex workers in the Mexico-US border region: implications for the development of vaginal PrEP for HIV prevention. <i>BMC Public Health</i> , 2018, 18, 1009.	1.2	6
1251	Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice. <i>The Open Virology Journal</i> , 2018, 12, 1-13.	1.8	11
1252	Ending the HIV/AIDS Pandemic1. <i>Emerging Infectious Diseases</i> , 2018, 24, 413-416.	2.0	109
1253	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. <i>EClinicalMedicine</i> , 2018, 2-3, 22-28.	3.2	42
1254	Scale-Up of PrEP integrated in public health HIV care clinics: a protocol for a stepped-wedge cluster-randomized rollout in Kenya. <i>Implementation Science</i> , 2018, 13, 118.	2.5	25
1255	Adherence to pre-exposure prophylaxis among men who have sex with men: A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2018, 75, 52-59.	1.5	30
1256	Lessons from a decade of voluntary medical male circumcision implementation and their application to HIV pre-exposure prophylaxis scale up. <i>International Journal of STD and AIDS</i> , 2018, 29, 1432-1443.	0.5	13
1257	<scp>HIV</scp> Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1082-1097.	2.3	21
1258	Stigma and Shame Experiences by MSM Who Take PrEP for HIV Prevention: A Qualitative Study. <i>American Journal of Men's Health</i> , 2018, 12, 1843-1854.	0.7	134
1259	Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea. <i>Journal of Korean Medical Science</i> , 2018, 33, e91.	1.1	4

#	ARTICLE	IF	CITATIONS
1260	Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. <i>Aids</i> , 2018, 32, 2353-2361.	1.0	10
1261	A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 245-251.	1.3	14
1262	Patterns of Oral PrEP Adherence and HIV Risk Among Eastern African Women in HIV Serodiscordant Partnerships. <i>AIDS and Behavior</i> , 2018, 22, 3718-3725.	1.4	21
1263	Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women. <i>AIDS and Behavior</i> , 2018, 22, 3044-3056.	1.4	78
1264	Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 169-174.	0.9	20
1265	Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 175-182.	0.9	9
1266	Reasons for nonadherence to the dapivirine vaginal ring. <i>Aids</i> , 2018, 32, 1517-1525.	1.0	33
1267	Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques. <i>Drug Delivery and Translational Research</i> , 2018, 8, 1180-1190.	3.0	7
1268	Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. <i>Aids</i> , 2018, 32, 1707-1713.	1.0	32
1269	HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability. <i>Aids</i> , 2018, 32, 1613-1623.	1.0	5
1270	Preventing Mother-to-Child Transmission (PMTCT): Prevention of HIV. , 2018, , 1698-1704.		0
1271	Response to the Hammoud et al paper on "the new MTV generation". <i>International Journal of Drug Policy</i> , 2018, 55, 205-206.	1.6	2
1272	Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to serodiscordant couples in East Africa: a qualitative evaluation study in Uganda. <i>Journal of the International AIDS Society</i> , 2018, 21, e25113.	1.2	19
1273	Early Adopters of Human Immunodeficiency Virus Preexposure Prophylaxis in a Population-based Combination Prevention Study in Rural Kenya and Uganda. <i>Clinical Infectious Diseases</i> , 2018, 67, 1853-1860.	2.9	30
1274	Medical students reflect on the future of Pre-Exposure Prophylaxis use among adolescents and young adults. <i>Preventive Medicine</i> , 2018, 113, 122-123.	1.6	2
1275	Preventing HIV Infection in High-Risk Adolescents Using Preexposure Prophylaxis (PrEP). <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 770-774.	0.4	6
1276	Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling. <i>PLoS ONE</i> , 2018, 13, e0195499.	1.1	4
1277	Advancing independent adolescent consent for participation in HIV prevention research. <i>Journal of Medical Ethics</i> , 2018, 44, 431-433.	1.0	9

#	ARTICLE	IF	CITATIONS
1278	Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. <i>Annals of Epidemiology</i> , 2018, 28, 833-840.	0.9	168
1279	Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. <i>PLoS ONE</i> , 2018, 13, e0195764.	1.1	12
1280	Understanding willingness to use oral pre-exposure prophylaxis for HIV prevention among men who have sex with men in China. <i>PLoS ONE</i> , 2018, 13, e0199525.	1.1	21
1281	Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment. <i>Frontiers in Public Health</i> , 2018, 6, 195.	1.3	33
1282	HIV Prevention After Discontinuing Pre-Exposure Prophylaxis: Conclusions From a Case Study. <i>Frontiers in Public Health</i> , 2018, 6, 137.	1.3	8
1283	HIV. <i>Lancet, The</i> , 2018, 392, 685-697.	6.3	219
1284	Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 835-837.	0.5	12
1285	HIV Pre-Exposure Prophylaxis and Women: Survey of the Knowledge, Attitudes, and Beliefs in an Urban Obstetrics/Gynecology Clinic. <i>AIDS Patient Care and STDs</i> , 2018, 32, 490-494.	1.1	53
1287	Pharmaceutical Approaches to HIV Treatment and Prevention. <i>Advanced Therapeutics</i> , 2018, 1, 1800054.	1.6	14
1289	Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol. <i>BMC Health Services Research</i> , 2018, 18, 513.	0.9	23
1290	Statewide Evaluation of New HIV Diagnoses in Rhode Island: Implications for Prevention. <i>Public Health Reports</i> , 2018, 133, 489-496.	1.3	2
1291	How to do it: setting up a PrEP service in an integrated sexual reproductive health service setting. <i>Sexually Transmitted Infections</i> , 2018, 94, 327-330.	0.8	3
1292	Women and HIV in the Twenty-First Century: How Can We Reach the UN 2030 Goal?. <i>AIDS Education and Prevention</i> , 2018, 30, 213-224.	0.6	4
1293	PrEParing Women to Prevent HIV: An Integrated Theoretical Framework to PrEP Black Women in the United States. <i>Journal of the Association of Nurses in AIDS Care</i> , 2018, 29, 835-848.	0.4	48
1294	Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 125-162.	0.8	12
1295	Tailoring combination HIV prevention for female sex workers. <i>Lancet HIV,the</i> , 2018, 5, e406-e407.	2.1	5
1296	Prevalence and correlates of non-disclosure of maternal HIV status to male partners: a national survey in Kenya. <i>BMC Public Health</i> , 2018, 18, 671.	1.2	28
1297	Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?. <i>Drugs and Aging</i> , 2018, 35, 485-491.	1.3	16

#	ARTICLE	IF	CITATIONS
1298	Where Are They Now? Assessing if Persons Returned to HIV Care Following Loss to Follow-Up by Public Health Case Workers Were Engaged in Care in Follow-Up Years. <i>AIDS Patient Care and STDs</i> , 2018, 32, 181-190.	1.1	12
1299	Seroconversion on preexposure prophylaxis. <i>Aids</i> , 2018, 32, 1199-1200.	1.0	0
1300	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
1301	Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults. <i>Current Pediatrics Reports</i> , 2018, 6, 114-122.	1.7	11
1302	Cabotegravir. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 334-340.	1.5	14
1303	Healthcare providers' understanding of HIV serodiscordance in South Africa and Uganda: implications for HIV prevention in sub-Saharan Africa. <i>African Journal of AIDS Research</i> , 2018, 17, 137-144.	0.3	4
1304	The intention to use HIV-pre-exposure prophylaxis (PrEP) among men who have sex with men in Switzerland: testing an extended explanatory model drawing on the unified theory of acceptance and use of technology (UTAUT). <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2018, 26, 247-259.	0.8	7
1305	Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1566-1572.	2.9	77
1306	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 645-656.	0.5	23
1307	Acceptability of Injectable and On-Demand Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in California. <i>LGBT Health</i> , 2018, 5, 341-349.	1.8	19
1308	<scp>FAME</scp>: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. <i>Journal of the International AIDS Society</i> , 2018, 21, e25156.	1.2	27
1309	Implementation of a Test, Treat, and Prevent HIV program among men who have sex with men and transgender women in Thailand, 2015-2016. <i>PLoS ONE</i> , 2018, 13, e0201171.	1.1	30
1310	Positive sexuality: HIV disclosure, gender, violence and the law—A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0202776.	1.1	26
1311	Progress and pitfalls in measuring HIV preexposure prophylaxis coverage in the United States. <i>Annals of Epidemiology</i> , 2018, 28, 830-832.	0.9	13
1312	Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. <i>Journal of the International AIDS Society</i> , 2018, 21, e25129.	1.2	25
1313	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2018, 286, 315-325.	4.8	66
1314	Antiretroviral therapy interruptions: impact on HIV treatment and transmission. <i>HIV/AIDS - Research and Palliative Care</i> , 2018, Volume 10, 91-101.	0.4	12
1316	Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland. <i>Aids</i> , 2018, 32, 1541-1542.	1.0	9



#	ARTICLE	IF	CITATIONS
1317	Lessons learned from the experiences of informal PrEP users in France: results from the ANRS-PrEPAGE study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 48-53.	0.6	14
1318	Emerging Trends in Clinical Research With Implications for Population Health and Health Policy. <i>Milbank Quarterly</i> , 2018, 96, 369-401.	2.1	5
1319	Preexposure Prophylaxis Is for Women, Too. <i>Mayo Clinic Proceedings</i> , 2018, 93, 395-396.	1.4	0
1320	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.	1.1	18
1321	HIV Risk Characteristics Associated with Violence Against Women: A Longitudinal Study Among Women in the United States. <i>Journal of Women's Health</i> , 2018, 27, 1317-1326.	1.5	1
1322	Improving PrEP Implementation Through Multilevel Interventions: A Synthesis of the Literature. <i>AIDS and Behavior</i> , 2018, 22, 3681-3691.	1.4	158
1323	The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents. <i>Lancet HIV</i> , 2018, 5, e329-e334.	2.1	22
1324	Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1381-1395.	1.0	14
1325	Enhancing HIV Pre-exposure Prophylaxis Practices via an Educational Intervention. <i>American Journal of Therapeutics</i> , 2019, 26, e462-e468.	0.5	14
1326	Persistent stigmatizing and negative perceptions of pre-exposure prophylaxis (PrEP) users: implications for PrEP adoption among Latino men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 427-435.	0.6	33
1327	Factors Associated with Sexual Risks and Risk of STIs, HIV and Other Blood-Borne Viruses Among Women Using Heroin and Other Drugs: A Systematic Literature Review. <i>AIDS and Behavior</i> , 2019, 23, 222-251.	1.4	21
1328	Preexposure prophylaxis comprehension and the certainty of willingness to use preexposure prophylaxis among men who have sex with men in China. <i>International Journal of STD and AIDS</i> , 2019, 30, 4-11.	0.5	17
1329	Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies. <i>AIDS and Behavior</i> , 2019, 23, 252-258.	1.4	1
1330	Natural Conception is Safe for HIV-Serodiscordant Couples with Persistent Suppressive Antiretroviral Therapy for the Infected Partner. <i>Journal of Women's Health</i> , 2019, 28, 1555-1562.	1.5	2
1331	Topical Inserts: A Versatile Delivery Form for HIV Prevention. <i>Pharmaceutics</i> , 2019, 11, 374.	2.0	22
1332	Empowerment Evaluation: A Case Study of Citywide Implementation Within an HIV Prevention Context. <i>American Journal of Evaluation</i> , 2019, 40, 318-334.	0.6	5
1333	Impact of Tenofovir-Based Pre-exposure Prophylaxis on Biomarkers of Bone Formation, Bone Resorption, and Bone Mineral Metabolism in HIV-Negative Adults. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz338.	0.4	3
1334	The power of partners: positively engaging networks of people with HIV in testing, treatment and prevention. <i>Journal of the International AIDS Society</i> , 2019, 22, e25314.	1.2	14

#	ARTICLE	IF	CITATIONS
1335	Implementation of "Treat-All" at adult <scp>HIV</scp> care and treatment sites in the Global le<scp>DEA</scp> Consortium: results from the Site Assessment Survey. Journal of the International AIDS Society, 2019, 22, e25331.	1.2	32
1336	Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. Journal of the International AIDS Society, 2019, 22, e25373.	1.2	6
1337	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE, 2019, 14, e0219142.	1.1	58
1338	Acceptability and Feasibility of a Pharmacist-Led Human Immunodeficiency Virus Pre-Exposure Prophylaxis Program in the Midwestern United States. Open Forum Infectious Diseases, 2019, 6, .	0.4	56
1339	Electronic health record tools to catalyse PrEP conversations. Lancet HIV, the, 2019, 6, e644-e645.	2.1	7
1340	PrEP for HIV: grade A for evidence but pending for impact. Nature Reviews Urology, 2019, 16, 570-571.	1.9	1
1341	Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. PLoS ONE, 2019, 14, e0221281.	1.1	24
1342	Perceptions of pregnancy occurring among HIV-serodiscordant couples in Kenya. Reproductive Health, 2019, 16, 85.	1.2	8
1343	Historical and Current Trends in HIV Criminalization in South Carolina: Implications for the Southern HIV Epidemic. AIDS and Behavior, 2019, 23, 233-241.	1.4	12
1344	Biopolitiken "Regierungen des Lebens heute. Politologische Aufklärung - Konstruktivistische Perspektiven, 2019, , .	0.4	1
1345	HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya. Trials, 2019, 20, 396.	0.7	20
1346	Expanding Knowledge About Implementation of Pre-exposure Prophylaxis (PrEP): A Methodological Review. AIDS and Behavior, 2019, 23, 2761-2778.	1.4	30
1347	Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study. Journal of the International AIDS Society, 2019, 22, e25338.	1.2	66
1348	Incidence of cutaneous adverse events after exposure to tenofovir-emtricitabine in <scp>HIV</scp>-uninfected vs <scp>HIV</scp>-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e470-e471.	1.3	1
1349	Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions. Drugs, 2019, 79, 1263-1276.	4.9	53
1350	Antiretroviral Therapy Administration in Healthy Rhesus Macaques Is Associated with Transient Shifts in Intestinal Bacterial Diversity and Modest Immunological Perturbations. Journal of Virology, 2019, 93, .	1.5	13
1351	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. Viruses, 2019, 11, 607.	1.5	12
1352	Antiretroviral Medications for the Prevention of HIV Infection. Infectious Disease Clinics of North America, 2019, 33, 629-646.	1.9	6

#	ARTICLE	IF	CITATIONS
1353	Gender-based violence and engagement in biomedical HIV prevention, care and treatment: a scoping review. <i>BMC Public Health</i> , 2019, 19, 897.	1.2	68
1354	Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP). <i>Pharmaceutics</i> , 2019, 11, 315.	2.0	62
1355	Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 1599.	2.2	14
1356	Is knowledge of HIV status associated with sexual behaviours? A fixed effects analysis of a female sex worker cohort in urban Uganda. <i>Journal of the International AIDS Society</i> , 2019, 22, e25336.	1.2	11
1357	Protocol for a randomized clinical trial exploring the effect of antimicrobial agents on the penile microbiota, immunology and HIV susceptibility of Ugandan men. <i>Trials</i> , 2019, 20, 443.	0.7	7
1358	Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review. <i>Journal of Women's Health</i> , 2019, 28, 1272-1285.	1.5	57
1359	Comparing Self-Report Pre-Exposure Prophylaxis Adherence Questions to Pharmacologic Measures of Recent and Cumulative Pre-Exposure Prophylaxis Exposure. <i>Frontiers in Pharmacology</i> , 2019, 10, 721.	1.6	28
1360	HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. <i>Journal of the International AIDS Society</i> , 2019, 22, e25298.	1.2	150
1361	Twenty Years Of Antiretroviral Therapy For People Living With HIV: Global Costs, Health Achievements, Economic Benefits. <i>Health Affairs</i> , 2019, 38, 1163-1172.	2.5	68
1362	Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	1
1363	Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz310.	0.4	47
1364	Infrared Matrix-Assisted Laser Desorption Electrospray Ionization Mass Spectrometry Imaging of Human Hair to Characterize Longitudinal Profiles of the Antiretroviral Maraviroc for Adherence Monitoring. <i>Analytical Chemistry</i> , 2019, 91, 10816-10822.	3.2	17
1365	Controlling HIV in adolescents: solutions for engagement, access and retention. <i>Future Virology</i> , 2019, 14, 383-385.	0.9	0
1366	Contextual drivers of HIV risk among young African women. <i>Journal of the International AIDS Society</i> , 2019, 22, e25302.	1.2	17
1367	Integrating PrEP into HIV care clinics could improve partner testing services and reinforce mutual support among couples: provider views from a PrEP implementation project in Kenya. <i>Journal of the International AIDS Society</i> , 2019, 22, e25303.	1.2	13
1368	Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis. <i>Viruses</i> , 2019, 11, 569.	1.5	2
1369	NZPrEP Demonstration Project: protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) to determine feasibility, acceptability, adverse and behavioural effects of PrEP provision to gay and bisexual men in publicly funded sexual health clinics in Auckland, New Zealand. <i>BMJ Open</i> , 2019, 9, e026363.	0.8	6
1370	Cohort profile: Actual Pre-Exposure Prophylaxis (PrEP) Cohort study in Montreal, Canada. <i>BMJ Open</i> , 2019, 9, e028768.	0.8	40

#	ARTICLE	IF	CITATIONS
1371	Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?. PLoS ONE, 2019, 14, e0218556.	1.1	15
1372	Pre-Exposure Prophylaxis Counseling in a Community Sexual Health Clinic for Men Who Have Sex with Men in Lisbon, Portugal. Acta Medica Portuguesa, 2019, 32, 441.	0.2	4
1373	Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. Bioconjugate Chemistry, 2019, 30, 2216-2227.	1.8	13
1374	Development and validation of an automated HIV prediction algorithm to identify candidates for pre-exposure prophylaxis: a modelling study. Lancet HIV, 2019, 6, e696-e704.	2.1	87
1375	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. BMJ Open, 2019, 9, e030283.	0.8	12
1376	Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. Journal of the International AIDS Society, 2019, 22, e25355.	1.2	85
1377	Attitudes and referral practices for pre-exposure prophylaxis (PrEP) among HIV rapid testers and case managers in Philadelphia: A mixed methods study. PLoS ONE, 2019, 14, e0223486.	1.1	4
1378	Give PrEP a chance: moving on from the "risk compensation" concept. Journal of the International AIDS Society, 2019, 22, e25351.	1.2	57
1379	HIV and sexually transmitted infections: reconciling estranged bedfellows in the U.S. and PrEP era. Journal of the International AIDS Society, 2019, 22, e25357.	1.2	6
1380	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. Journal of the International AIDS Society, 2019, 22, e25381.	1.2	13
1381	The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward. Journal of the International AIDS Society, 2019, 22, e25390.	1.2	24
1382	Pre-exposure prophylaxis awareness and interest among participants in a medications for addiction treatment program in a unified jail and prison setting in Rhode Island. Journal of Substance Abuse Treatment, 2019, 106, 73-78.	1.5	16
1383	"The Drug Will Help Protect My Tomorrow": Perceptions of Integrating PrEP into HIV Prevention Behaviors Among Female Sex Workers in Lilongwe, Malawi. AIDS Education and Prevention, 2019, 31, 421-432.	0.6	13
1384	Acceptability and Barriers to HIV Pre-Exposure Prophylaxis in Atlanta's Adolescents and Their Parents. AIDS Patient Care and STDs, 2019, 33, 425-433.	1.1	14
1385	Global implementation of PrEP for HIV prevention: setting expectations for impact. Journal of the International AIDS Society, 2019, 22, e25370.	1.2	45
1386	Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical trial (HPTN 076). Journal of the International AIDS Society, 2019, 22, e25408.	1.2	33
1387	Transactional Sex, Substance Use, and Sexual Risk: Comparing Pay Direction for an Internet-Based U.S. Sample of Men Who Have Sex with Men. Sexuality Research and Social Policy, 2019, 16, 255-267.	1.4	30
1388	Cure and Control: What Will It Take to Eliminate HCV?. Topics in Medicinal Chemistry, 2019, , 447-490.	0.4	2

#	ARTICLE	IF	CITATIONS
1389	Electronic Health Record Use in Public Health Infectious Disease Surveillance, USA, 2018–2019. <i>Current Infectious Disease Reports</i> , 2019, 21, 32.	1.3	17
1391	Factors associated with vaccination completion and retention among HIV negative female sex workers enrolled in a simulated vaccine efficacy trial in Kampala, Uganda. <i>BMC Infectious Diseases</i> , 2019, 19, 725.	1.3	7
1392	Iowa TelePrEP: A Public-Health-Partnered Telehealth Model for Human Immunodeficiency Virus Preexposure Prophylaxis Delivery in a Rural State. <i>Sexually Transmitted Diseases</i> , 2019, 46, 507-512.	0.8	83
1393	Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program. <i>Sexual Health</i> , 2019, 16, 180-186.	0.4	12
1394	Perceived barriers to pre-exposure prophylaxis use among HIV-negative men who have sex with men in Tijuana, Mexico: A latent class analysis. <i>PLoS ONE</i> , 2019, 14, e0221558.	1.1	14
1395	Experiences of Pre-Exposure Prophylaxis Stigma, Social Support, and Information Dissemination Among Black and Latina Transgender Women Who Are Using Pre-Exposure Prophylaxis. <i>Transgender Health</i> , 2019, 4, 188-196.	1.2	30
1396	Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya. <i>PLoS Medicine</i> , 2019, 16, e1002885.	3.9	105
1397	Factors associated with knowledge of pre-exposure prophylaxis in pregnant women in Cape Town, South Africa. <i>International Journal of STD and AIDS</i> , 2019, 30, 1063-1070.	0.5	4
1398	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. <i>PLoS ONE</i> , 2019, 14, e0222183.	1.1	1
1399	HIV control strategies for sex worker–client contact networks. <i>Journal of the Royal Society Interface</i> , 2019, 16, 20190497.	1.5	1
1400	Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. <i>Lancet HIV</i> , 2019, 6, e788-e799.	2.1	79
1401	What will it take for the Global Plan priority countries in Sub-Saharan Africa to eliminate mother-to-child transmission of HIV?. <i>BMC Infectious Diseases</i> , 2019, 19, 783.	1.3	19
1402	Primary Care Physician Attitudes and Intentions Toward the Use of HIV Pre-exposure Prophylaxis in Adolescents in One Metropolitan Region. <i>Journal of Adolescent Health</i> , 2019, 64, 581-588.	1.2	26
1403	Decisional Balance and Contemplation Ladder to Support Interventions for HIV Pre-Exposure Prophylaxis Uptake and Persistence. <i>AIDS Patient Care and STDs</i> , 2019, 33, 67-78.	1.1	11
1404	US Guideline Criteria for Human Immunodeficiency Virus Preexposure Prophylaxis: Clinical Considerations and Caveats. <i>Clinical Infectious Diseases</i> , 2019, 69, 884-889.	2.9	20
1405	Understanding women’s motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence. <i>BMC Women’s Health</i> , 2019, 19, 18.	0.8	12
1406	In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate. <i>Current HIV Research</i> , 2019, 16, 322-337.	0.2	14
1407	How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. <i>AIDS and Behavior</i> , 2019, 23, 2146-2154.	1.4	11

#	ARTICLE	IF	CITATIONS
1408	Progress in the HIV epidemic: Identifying goals and measuring success. PLoS Medicine, 2019, 16, e1002729.	3.9	51
1409	2-Hydroxypropyl- $\beta$ -cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. Journal of Controlled Release, 2019, 306, 89-96.	4.8	49
1410	Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals. Current HIV/AIDS Reports, 2019, 16, 349-358.	1.1	47
1411	Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation. Current Infectious Disease Reports, 2019, 21, 28.	1.3	36
1412	Nonoccupational Postexposure Prophylaxis and Preexposure Prophylaxis for Human Immunodeficiency Virus Prevention in Adolescents and Young Adults. Advances in Pediatrics, 2019, 66, 245-261.	0.5	3
1413	HIV incidence, pregnancy, and implementation outcomes from the Sakh'umndeni safer conception project in South Africa: a prospective cohort study. Lancet HIV, 2019, 6, e438-e446.	2.1	27
1414	Preexposure Prophylaxis for the Prevention of HIV Infection. JAMA - Journal of the American Medical Association, 2019, 321, 2214.	3.8	172
1415	Preexposure Prophylaxis for the Prevention of HIV Infection. JAMA - Journal of the American Medical Association, 2019, 321, 2203.	3.8	219
1416	Confronting Rising STIs in the Era of PrEP and Treatment as Prevention. Current HIV/AIDS Reports, 2019, 16, 244-256.	1.1	47
1417	Summary of German and Austrian HIV PrEP guideline. HIV Medicine, 2019, 20, 368-376.	1.0	11
1418	A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS Research and Human Retroviruses, 2019, 35, 794-804.	0.5	5
1419	Characteristics of the Provider-Patient Encounter Associated With Awareness of and Willingness to Take PrEP Among Young Minority Urban Males in Baltimore City. AIDS Education and Prevention, 2019, 31, 237-245.	0.6	0
1420	Provider Knowledge Gaps in HIV PrEP Affect Practice Patterns in the US Navy. Military Medicine, 2019, 185, e117-e124.	0.4	4
1421	Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	2
1422	Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women. Frontiers in Pharmacology, 2019, 10, 401.	1.6	9
1423	The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis. AIDS Patient Care and STDs, 2019, 33, 207-213.	1.1	42
1424	Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. AIDS Patient Care and STDs, 2019, 33, 220-226.	1.1	4
1425	Interest in Pre-exposure Prophylaxis (PrEP) for HIV is Limited Among Women in a General Obstetrics & Gynecology Setting. AIDS and Behavior, 2019, 23, 2741-2748.	1.4	20



#	ARTICLE	IF	CITATIONS
1426	Acceptability and willingness of HIV pre-exposure prophylaxis amongst female sex workers in China. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1555-1564.	0.6	12
1427	Interpretation of the Individual Effect Under Treatment Spillover. <i>American Journal of Epidemiology</i> , 2019, 188, 1407-1409.	1.6	6
1428	Demographic characteristics associated with the use of HIV pre-exposure prophylaxis (PrEP) in an urban, community health center. <i>Preventive Medicine Reports</i> , 2019, 15, 100889.	0.8	12
1429	Rates of New Human Immunodeficiency Virus (HIV) Diagnoses After Reported Sexually Transmitted Infection in Women in Louisiana, 2000–2015: Implications for HIV Prevention. <i>Clinical Infectious Diseases</i> , 2020, 70, 1115-1120.	2.9	14
1430	Healthcare providers' knowledge, readiness, prescribing behaviors, and perceived barriers regarding routine HIV testing and pre-exposure prophylaxis in DeLand, Florida. <i>SAGE Open Medicine</i> , 2019, 7, 205031211983603.	0.7	8
1431	HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1234-1240.	0.6	29
1432	Current and emerging therapies to combat persistent intracellular pathogens. <i>Current Opinion in Pharmacology</i> , 2019, 48, 33-39.	1.7	9
1433	Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1228-1233.	0.6	17
1434	HIV prevalence, spatial distribution and risk factors for HIV infection in the Kenyan fishing communities of Lake Victoria. <i>PLoS ONE</i> , 2019, 14, e0214360.	1.1	21
1435	Awareness, knowledge, and attitudes towards human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) among pharmacy students. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 352-360.	0.4	23
1436	HIV Infection in Transgender Persons. <i>Contemporary Endocrinology</i> , 2019, , 239-281.	0.3	0
1437	Linking women experiencing incarceration to community-based HIV pre-exposure prophylaxis care: protocol of a pilot trial. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 8.	1.2	18
1438	Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children. <i>Medical Journal of Australia</i> , 2019, 210, 281-284.	0.8	2
1439	Public Awareness of HIV Pre-Exposure Prophylaxis in Durham, North Carolina. <i>North Carolina Medical Journal</i> , 2019, 80, 7-11.	0.1	3
1440	US Human Immunodeficiency Virus (HIV) Practitioners' Recommendations Regarding Condomless Sex in the Era of HIV Pre-Exposure Prophylaxis and Treatment as Prevention. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz082.	0.4	5
1441	HIV risk and pre-exposure prophylaxis interest among female bar workers in Dar es Salaam: cross-sectional survey. <i>BMJ Open</i> , 2019, 9, e023272.	0.8	20
1442	Using discrete choice experiments to inform the design of complex interventions. <i>Trials</i> , 2019, 20, 157.	0.7	16
1443	Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. <i>Journal of the International AIDS Society</i> , 2019, 22, e25247.	1.2	15

#	ARTICLE	IF	CITATIONS
1444	BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. <i>HIV Medicine</i> , 2019, 20, s2-s80.	1.0	30
1445	Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda. <i>Vaccine</i> , 2019, 37, 2065-2072.	1.7	14
1446	Tenofovir and emtricitabine resistance among antiretroviral-naïve patients in the Canadian Observational Cohort Collaboration: implications for PrEP. <i>Antiviral Therapy</i> , 2019, 24, 211-220.	0.6	2
1447	Implementation of a comprehensive safer conception intervention for HIV-serodiscordant couples in Kenya: uptake, use and effectiveness. <i>Journal of the International AIDS Society</i> , 2019, 22, e25261.	1.2	28
1448	Drug Resistance During HIV Pre-Exposure Prophylaxis. <i>Drugs</i> , 2019, 79, 609-619.	4.9	54
1449	Training health care providers to provide PrEP for HIV serodiscordant couples attending public health facilities in Kenya. <i>Global Public Health</i> , 2019, 14, 1524-1534.	1.0	12
1450	In-depth Sampling of High-risk Populations to Characterize HIV Transmission Epidemics Among Young MSM Using PrEP in France and Quebec. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz080.	0.4	12
1451	The epidemiology of HIV and other sexually transmitted infections in African, Caribbean and Black men in Toronto, Canada. <i>BMC Infectious Diseases</i> , 2019, 19, 294.	1.3	16
1452	Data-Driven Goals for Curbing the U.S. HIV Epidemic by 2030. <i>AIDS and Behavior</i> , 2019, 23, 557-563.	1.4	26
1453	Changes Over Time in HIV Prevalence and Sexual Behaviour Among Young Female Sex-Workers in 14 Sites in Zimbabwe, 2013-2016. <i>AIDS and Behavior</i> , 2019, 23, 1494-1507.	1.4	18
1454	Behavioral Intention to Initiate Antiretroviral Therapy (ART) Among Chinese HIV-Infected Men Who Have Sex With Men Having High CD4 Count in the Era of "Treatment for All". <i>American Journal of Men's Health</i> , 2019, 13, 155798831982861.	0.7	11
1455	Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?. <i>Current HIV/AIDS Reports</i> , 2019, 16, 141-150.	1.1	51
1456	HIV Prevention Interventions for Adolescents. <i>Current HIV/AIDS Reports</i> , 2019, 16, 120-128.	1.1	66
1457	Knowledge and willingness to use pre-exposure prophylaxis among men who have sex with men in Northeastern Brazil. <i>Global Public Health</i> , 2019, 14, 1098-1111.	1.0	20
1458	Lessons from PrEP: A Qualitative Study Investigating How Clinical and Policy Experts Weigh Ethics and Evidence When Evaluating Preventive Medications for Use in Pregnant and Breastfeeding Women. <i>AIDS and Behavior</i> , 2019, 23, 1858-1870.	1.4	9
1459	Acceptability and Predictors of Uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) Among Fishing Communities in Uganda: A Cross-Sectional Discrete Choice Experiment Survey. <i>AIDS and Behavior</i> , 2019, 23, 2674-2686.	1.4	24
1460	Patterns and clinical consequences of discontinuing HIV pre-exposure prophylaxis during primary care. <i>Journal of the International AIDS Society</i> , 2019, 22, e25250.	1.2	74
1461	Review of Real-World Implementation Data on Emtricitabine/Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. <i>Pharmacotherapy</i> , 2019, 39, 486-500.	1.2	19

#	ARTICLE	IF	CITATIONS
1462	Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. <i>Journal of the International AIDS Society</i> , 2019, 22, e25252.	1.2	99
1463	Substance Use and HIV Among Justice-Involved Youth: Intersecting Risks. <i>Current HIV/AIDS Reports</i> , 2019, 16, 37-47.	1.1	20
1464	Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells. <i>Scientific Reports</i> , 2019, 9, 1864.	1.6	8
1465	HIV-1 genetic diversity to estimate time of infection and infer adherence to preexposure prophylaxis. <i>Aids</i> , 2019, 33, 2299-2307.	1.0	3
1467	Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz463.	0.4	9
1468	Estimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States. <i>Journal of the International AIDS Society</i> , 2019, 22, e25433.	1.2	10
1469	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 72-77.	0.9	50
1470	Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa. <i>BMJ Open</i> , 2019, 9, e027227.	0.8	12
1471	Progreso en Salud: Findings from Two Adapted Social Network HIV Risk Reduction Interventions for Latina Seasonal Workers. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4530.	1.2	9
1472	Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants. <i>International Journal of Drug Policy</i> , 2019, 74, 246-254.	1.6	30
1473	Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
1474	Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 252-256.	0.9	12
1475	From surviving to thriving. <i>Aids</i> , 2019, 33, S1-S4.	1.0	13
1476	Differences Between Groups of Pre-exposure Prophylaxis (PrEP) Using Couples in HIV-Negative/Unknown Relationships. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 419-428.	0.9	9
1477	The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 542-550.	0.9	37
1478	HIV Pre-Exposure Prophylaxis Implementation Cascade Among Health Care Professionals in the United States: Implications from a Systematic Review and Meta-Analysis. <i>AIDS Patient Care and STDs</i> , 2019, 33, 507-527.	1.1	75
1479	Schistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007886.	1.3	2
1480	Sexual and reproductive health considerations among transgender and gender-expansive youth. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2019, 49, 100684.	0.8	25

#	ARTICLE	IF	CITATIONS
1481	Silver bullets and structural impediments to HIV prevention. <i>Lancet HIV</i> , 2019, 6, e729-e732.	2.1	3
1482	Unspeakable PrEP: a qualitative study of sexual communication, problematic integration, and uncertainty management among men who have sex with men in Taiwan. <i>Journal of Applied Communication Research</i> , 2019, 47, 611-627.	0.7	9
1483	Transformation of Australian Community Pharmacies Into Good Clinical Practice Compliant Trial Pharmacies for HIV Pre-Exposure Prophylaxis. <i>Frontiers in Pharmacology</i> , 2019, 10, 1269.	1.6	2
1484	Impact of Endemic Infections on HIV Susceptibility in Sub-Saharan Africa. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2019, 5, 22.	0.9	14
1485	Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings. <i>Epidemiology</i> , 2019, 30, 358-364.	1.2	5
1486	Behavioral Interventions to Enhance PrEP Uptake Among Black Men Who Have Sex With Men. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 151-163.	0.4	18
1487	Sociobehavioral and community predictors of unsuppressed HIV viral load. <i>Aids</i> , 2019, 33, 559-569.	1.0	14
1488	PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 265-274.	0.9	20
1489	Comprehensive HIV risk reduction interventions for 2020 and beyond. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 423-432.	1.5	16
1490	Pathways to HIV Pre-exposure Prophylaxis Among Women Prescribed PrEP at an Urban Sexual Health Clinic. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 321-329.	0.4	29
1491	Factors Associated With Increased Syphilis Screening Among People Living With Human Immunodeficiency Virus. <i>Sexually Transmitted Diseases</i> , 2019, 46, 521-526.	0.8	1
1492	A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda. <i>Aids</i> , 2019, 33, 1995-2004.	1.0	8
1493	Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. <i>Aids</i> , 2019, 33, 2189-2195.	1.0	55
1494	Brief Report: Pre-exposure Prophylaxis Awareness and Use Among Cisgender Women at a Sexually Transmitted Disease Clinic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 36-39.	0.9	34
1495	Comfort Discussing HIV Pre-exposure Prophylaxis With Patients Among Physicians in an Urban Emergency Department. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e49-e52.	0.9	7
1496	Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 406-413.	0.9	11
1497	High Incidence of Intended Partner Pregnancy Among Men Living With HIV in Rural Uganda: Implications for Safer Conception Services. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 497-507.	0.9	6
1498	A Field Evaluation of Point-of-Care Creatinine Testing Within a Large PrEP Implementation Program in Western Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e8-e10.	0.9	7

#	ARTICLE	IF	CITATIONS
1499	Pre-exposure Prophylaxis (PrEP) Uptake Among Older Individuals in Rural Western Kenya. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, e50-e53.	0.9	6
1500	Regulatory Perspectives for Streamlining HIV Prevention Trials. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	4
1501	Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 386-391.	0.9	14
1502	HIV Seroconversion in the Era of Pharmacologic Prevention: A Caseâ€“Control Study at a San Francisco STD Clinic. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 159-165.	0.9	7
1503	Study on Pre-Exposure Prophylaxis Regimens among Men Who Have Sex with Men: A Prospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4996.	1.2	4
1504	PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, S113-S117.	0.9	19
1505	Modelling the potential impact of providing preexposure prophylaxis in pregnant and breastfeeding women in South Africa. <i>Aids</i> , 2019, 33, 1391-1395.	1.0	29
1506	Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women. <i>Aids</i> , 2019, 33, 2125-2136.	1.0	5
1507	Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 166-174.	0.9	15
1508	Factors Associated With Sex-Related Pre-exposure Prophylaxis Adherence Among Men Who Have Sex With Men in New York City in HPTN 067. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 551-558.	0.9	24
1509	Brief Report: Impact of PrEP Training for Family Planning Providers on HIV Prevention Counseling and Patient Interest in PrEP in Atlanta, Georgia. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 81, 414-418.	0.9	35
1510	Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 427-430.	0.9	9
1511	Current and Future Challenges in Trial Design for Pre-Exposure Prophylaxis in HIV Prevention. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
1512	Global Epidemiologic Characteristics of Sexually Transmitted Infections Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection. <i>JAMA Network Open</i> , 2019, 2, e1917134.	2.8	102
1513	Incentivized Screening to Reduce Sexually Transmitted Infection Risk and Prevalence. <i>Sexually Transmitted Diseases</i> , 2019, 46, 654-656.	0.8	0
1514	Perceived Versus Calculated HIV Risk: Implications for Pre-exposure Prophylaxis Uptake in a Randomized Trial of Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, e23-e29.	0.9	55
1515	Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 82, 149-158.	0.9	12
1516	The arc of HIV epidemics in sub-Saharan Africa. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 354-365.	1.5	28

#	ARTICLE	IF	CITATIONS
1517	Implementing Pre-exposure Prophylaxis for HIV Prevention at an Urban Youth Clinic. <i>Journal of the Association of Nurses in AIDS Care</i> , 2019, 30, 232-237.	0.4	2
1518	HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa. <i>Aids</i> , 2019, 33, 735-744.	1.0	3
1519	Impact of Q-Griffithsin anti-HIV microbicide gel in non-human primates: In situ analyses of epithelial and immune cell markers in rectal mucosa. <i>Scientific Reports</i> , 2019, 9, 18120.	1.6	19
1521	Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region. <i>International Journal of STD and AIDS</i> , 2019, 30, 45-55.	0.5	15
1522	Applying the Informationâ€“Motivationâ€“Behavioral Skills Model to Understand PrEP Intentions and Use Among Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2019, 23, 1904-1916.	1.4	69
1523	Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 545-553.	0.6	54
1524	Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. <i>Journal of Controlled Release</i> , 2019, 294, 216-225.	4.8	37
1525	Short Message Service (SMS) Surveys Assessing Pre-exposure Prophylaxis (PrEP) Adherence and Sexual Behavior are Highly Acceptable Among HIV-Uninfected Members of Serodiscordant Couples in East Africa: A Mixed Methods Study. <i>AIDS and Behavior</i> , 2019, 23, 1267-1276.	1.4	13
1526	Stigma, the Media, and Pre-exposure Prophylaxis for HIV Prevention: Observations for Enhancing Knowledge Translation and Resisting Stigma in the Canadian Context. <i>AIDS and Behavior</i> , 2019, 23, 1877-1887.	1.4	15
1527	Cancer and AIDS. , 2019, , .		0
1528	HIV testing and counselling couples together for affordable HIV prevention in Africa. <i>International Journal of Epidemiology</i> , 2019, 48, 217-227.	0.9	17
1529	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246.	1.0	17
1530	Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood. <i>Scientific Reports</i> , 2019, 9, 82.	1.6	2
1531	Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e9-e13.	0.9	33
1532	Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir. <i>Pharmacogenomics</i> , 2019, 20, 105-111.	0.6	7
1533	Experiences of Anticipated and Enacted Pre-exposure Prophylaxis (PrEP) Stigma Among Latino MSM in Los Angeles. <i>AIDS and Behavior</i> , 2019, 23, 1964-1973.	1.4	61
1534	Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking. <i>Journal of NeuroVirology</i> , 2019, 25, 324-330.	1.0	11
1535	Adolescent Preexposure Prophylaxis Administration: An Education Curriculum for Health Care Providers. <i>Journal of Pediatric Health Care</i> , 2019, 33, 288-295.	0.6	8



#	ARTICLE	IF	CITATIONS
1536	Barriers to preexposure prophylaxis use among individuals with recently acquired HIV infection in Northern California. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 536-544.	0.6	45
1537	Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring. <i>Clinical Infectious Diseases</i> , 2019, 69, 523-529.	2.9	8
1538	The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour. <i>AIDS and Behavior</i> , 2019, 23, 1708-1720.	1.4	56
1539	A Review of Approaches Used to Increase Awareness of Pre-exposure Prophylaxis (PrEP) in the United States. <i>AIDS and Behavior</i> , 2019, 23, 1749-1770.	1.4	31
1540	Improving HIV Preexposure Prophylaxis Implementation for Women: Summary of Key Findings From a Discussion Series with Women's HIV Prevention Experts. <i>Women's Health Issues</i> , 2019, 29, 3-7.	0.9	32
1541	Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. <i>AIDS and Behavior</i> , 2019, 23, 1287-1296.	1.4	14
1542	Health Care Facility Characteristics are Associated with Variation in Human Immunodeficiency Virus Pre-exposure Prophylaxis Initiation in Veteran's Health Administration. <i>AIDS and Behavior</i> , 2019, 23, 1803-1811.	1.4	8
1543	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV</i> , 2019, 6, e43-e50.	2.1	43
1544	Adaptive non-inferiority margins under observable non-constancy. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3318-3332.	0.7	18
1545	Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 2010-2017.	2.9	96
1546	Institutional distrust among gay, bisexual, and other men who have sex with men as a barrier to accessing pre-exposure prophylaxis (PrEP). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 364-369.	0.6	25
1547	Beyond "Vessels and Vectors": A Global Review of Registered HIV-Related Clinical Trials with Pregnant Women. <i>Journal of Women's Health</i> , 2019, 28, 93-99.	1.5	10
1548	Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015. <i>AIDS and Behavior</i> , 2019, 23, 1833-1840.	1.4	34
1549	Considerable interest in pre-exposure prophylaxis uptake among men who have sex with men recruited from a popular geosocial-networking smartphone application in London. <i>Global Public Health</i> , 2019, 14, 112-121.	1.0	11
1550	Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 138, 3-10.	2.0	40
1551	Risk Behaviors Among Young Men Who Have Sex With Men in Bangkok: A Qualitative Study to Understand and Contextualize High HIV Incidence. <i>Journal of Homosexuality</i> , 2019, 66, 533-548.	1.3	7
1552	Viewpoint: Why you should provide HIV pre-exposure prophylaxis (PrEP) at your college health center. <i>Journal of American College Health</i> , 2020, 68, 119-123.	0.8	1
1553	Assessing Mozambicans' willingness and determinants to use pre-exposure prophylactic HIV medication. <i>Journal of Health Psychology</i> , 2020, 25, 1954-1964.	1.3	5

#	ARTICLE	IF	CITATIONS
1554	Correlations Between Human Immunodeficiency Virus (HIV) Infection and Rectal Gonorrhea Incidence in Men Who Have Sex With Men: Implications for Future HIV Preexposure Prophylaxis Trials. <i>Journal of Infectious Diseases</i> , 2020, 221, 214-217.	1.9	25
1555	Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067/ADAPT Study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 249-254.	0.6	25
1556	Experiences of Pre-Exposure Prophylaxis (PrEP)–Related Stigma among Black MSM PrEP Users in Los Angeles. <i>Journal of Urban Health</i> , 2020, 97, 679-691.	1.8	61
1557	Perceived barriers to pre-exposure prophylaxis use and the role of syndemic factors among female sex workers in the Mexico-United States border region: <i>a latent class analysis</i>. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 557-566.	0.6	17
1558	Next-Generation Preexposure Prophylaxis: Choices For Effective HIV Prevention. <i>Journal of Infectious Diseases</i> , 2020, 221, 1387-1389.	1.9	3
1559	Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 1-10.	1.5	16
1560	Hidden in Plain Sight: Identifying Women Living in the United States Who Could Benefit From HIV Preexposure Prophylaxis. <i>Journal of Infectious Diseases</i> , 2020, 222, 1428-1431.	1.9	11
1561	HIV Pre-exposure Prophylaxis for People Who Inject Drugs: The Context of Co-occurring Injection- and Sexual-Related HIV Risk in the U.S. Northeast. <i>Substance Use and Misuse</i> , 2020, 55, 525-533.	0.7	10
1562	Life Chaos is Associated with Reduced HIV Testing, Engagement in Care, and ART Adherence Among Cisgender Men and Transgender Women upon Entry into Jail. <i>AIDS and Behavior</i> , 2020, 24, 491-505.	1.4	13
1563	Human Immunodeficiency Virus Infection. , 2020, , 232-266.		3
1564	Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3. <i>Journal of Infectious Diseases</i> , 2020, 221, 1398-1406.	1.9	31
1565	Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). <i>Clinical Infectious Diseases</i> , 2020, 70, 2143-2151.	2.9	24
1566	Increasing PrEP uptake and adherence among MSM and TW sex workers in Lima, PerÃ: what and whom do different patients trust?. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 255-260.	0.6	11
1567	Increases in HIV Incidence Following Receptive Anal Intercourse Among Women: A Systematic Review and Meta-analysis. <i>AIDS and Behavior</i> , 2020, 24, 667-681.	1.4	12
1568	Predicted Effectiveness of Daily and Nondaily Preexposure Prophylaxis for Men Who Have Sex With Men Based on Sex and Pill-taking Patterns From the Human Immuno Virus Prevention Trials Network 067/ADAPT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 249-255.	2.9	7
1569	“Some of us, we don’t know where we’re going to be tomorrow.” Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 585-593.	0.6	19
1570	Preferences for Pre-exposure Prophylaxis Service Delivery Among Female Sex Workers in Malawi: A Discrete Choice Experiment. <i>AIDS and Behavior</i> , 2020, 24, 1294-1303.	1.4	21
1571	No Evidence of Sexual Risk Compensation Following PrEP Initiation Among Heterosexual HIV Serodiscordant Couples in Kenya and Uganda. <i>AIDS and Behavior</i> , 2020, 24, 1365-1375.	1.4	11

#	ARTICLE	IF	CITATIONS
1572	Prevention of HIV Transmission and the HPTN 052 Study. <i>Annual Review of Medicine</i> , 2020, 71, 347-360.	5.0	25
1573	Roadblocks to PrEP: What Medical Records Reveal About Access to HIV Pre-exposure Prophylaxis. <i>Journal of General Internal Medicine</i> , 2020, 35, 832-838.	1.3	30
1574	Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment. <i>AIDS and Behavior</i> , 2020, 24, 1443-1451.	1.4	22
1575	Topical Microbicides in HIV Prevention: State of the Promise. <i>Annual Review of Medicine</i> , 2020, 71, 361-377.	5.0	30
1576	Undetectable equals untransmittable (U=U): implications for preconception counseling for human immunodeficiency virus serodiscordant couples. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 53.e1-53.e4.	0.7	7
1577	Barriers and Facilitators to PrEP Use Among People Who Inject Drugs in Rural Appalachia: A Qualitative Study. <i>AIDS and Behavior</i> , 2020, 24, 1942-1950.	1.4	47
1578	Responsibilization and Sexual Stigma Under Austerity: Surveying Public Support for Government-Funded PrEP in England. <i>Sexuality Research and Social Policy</i> , 2020, 17, 643-653.	1.4	2
1579	Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. <i>Lancet HIV</i> , 2020, 7, e443-e448.	2.1	27
1580	The HIV Pre-exposure Prophylaxis (PrEP) Cascade at NYC Sexual Health Clinics: Navigation Is the Key to Uptake. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 357-364.	0.9	40
1581	Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. <i>Lancet HIV</i> , 2020, 7, e38-e48.	2.1	106
1582	HIV Preexposure Prophylaxis—The Role of Primary Care Clinicians in Ending the HIV Epidemic. <i>JAMA Internal Medicine</i> , 2020, 180, 126.	2.6	11
1583	Preferences for implementation of HIV pre-exposure prophylaxis (PrEP): Results from a survey of primary care providers. <i>Preventive Medicine Reports</i> , 2020, 17, 101012.	0.8	18
1584	Low Awareness of and Access to Pre-exposure Prophylaxis But High Interest Among Heterosexual Women in Cleveland, Ohio. <i>Sexually Transmitted Diseases</i> , 2020, 47, 96-99.	0.8	6
1585	The PrEP Care Continuum Among Cisgender Women Who Sell Sex and/or Use Drugs Globally: A Systematic Review. <i>AIDS and Behavior</i> , 2020, 24, 1312-1333.	1.4	44
1586	Introduction. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 1-3.	1.5	0
1587	Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk. <i>Clinical Biochemistry</i> , 2020, 82, 66-72.	0.8	0
1588	Predictors of Awareness, Accessibility and Acceptability of Pre-exposure Prophylaxis (PrEP) Among English- and Spanish-Speaking Latino Men Who have Sex with Men in Los Angeles, California. <i>Journal of Immigrant and Minority Health</i> , 2020, 22, 708-716.	0.8	18
1589	HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. <i>Aids</i> , 2020, 34, 699-706.	1.0	12

#	ARTICLE	IF	CITATIONS
1590	HIV treatment and prevention 2019. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 4-12.	1.5	52
1591	Bareback sex, PrEP, <i>National AIDS Trust</i> v <i>NHS England</i> and the reality of gay sex. <i>Sexualities</i> , 2020, 23, 1362-1377.	0.8	1
1592	Tenofovir Urine Assay to Monitor Adherence to HIV Pre-exposure Prophylaxis. <i>Current Clinical Pharmacology</i> , 2020, 15, 102-104.	0.2	6
1593	Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 61-65.	1.5	6
1594	Long-acting injectable cabotegravir for the prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 19-26.	1.5	71
1595	Topical delivery of long-acting antiretrovirals to prevent HIV acquisition. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 42-48.	1.5	12
1596	Knowledge, Attitudes, and Intentions towards HIV Pre-Exposure Prophylaxis among Nursing Students in Spain. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7151.	1.2	4
1597	Roles for Pharmacists in the "Ending the HIV Epidemic: A Plan for America" Initiative. <i>Public Health Reports</i> , 2020, 135, 547-554.	1.3	23
1598	Awareness and use of HIV pre-exposure prophylaxis among people who engage in sex work presenting to a sexually transmitted infection clinic. <i>International Journal of STD and AIDS</i> , 2020, 31, 1055-1062.	0.5	3
1599	Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal. <i>International Journal of STD and AIDS</i> , 2020, 31, 1063-1072.	0.5	26
1600	Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. <i>Cell Reports Medicine</i> , 2020, 1, 100096.	3.3	10
1601	Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen. <i>Drugs</i> , 2020, 80, 1881-1888.	4.9	5
1602	Exploring Changes in Racial/Ethnic Disparities of HIV Diagnosis Rates Under the "Ending the HIV Epidemic: A Plan for America" Initiative. <i>Public Health Reports</i> , 2020, 135, 685-690.	1.3	7
1604	Improving the HIV PrEP continuum of care using an intervention for healthcare providers: a stepped-wedge study protocol. <i>BMJ Open</i> , 2020, 10, e040734.	0.8	18
1605	Perceived male partner attitudes toward the female condom predict female university students'™ use of the female condom. <i>International Journal of STD and AIDS</i> , 2020, 31, 753-762.	0.5	4
1606	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 239-254.	6.3	245
1607	HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern. <i>Blood</i> , 2020, 136, 1351-1358.	0.6	32
1608	Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25491.	1.2	18

#	ARTICLE	IF	CITATIONS
1609	Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention. <i>Current HIV/AIDS Reports</i> , 2020, 17, 487-498.	1.1	19
1610	Profile of new HIV diagnoses and risk factors associated with late diagnosis in a specialized outpatient clinic during the 2014–2018 period. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 482-487.	0.1	3
1611	Adherence to recommendations for ART and targeted PrEP use among HIV serodiscordant couples in East Africa: the “PrEP as a bridge to ART” strategy. <i>BMC Public Health</i> , 2020, 20, 1621.	1.2	9
1612	Design of a care pathway for pharmacy-based PrEP delivery in Kenya: results from a collaborative stakeholder consultation. <i>BMC Health Services Research</i> , 2020, 20, 1034.	0.9	31
1613	Optimal strategies for mitigating the HIV/AIDS epidemic in the Philippines. <i>Mathematical Methods in the Applied Sciences</i> , 2020, 43, 10690-10710.	1.2	1
1614	Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men. <i>BMC Public Health</i> , 2020, 20, 1782.	1.2	33
1615	National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018. <i>Annals of Internal Medicine</i> , 2020, 173, 799-805.	2.0	18
1616	Willingness of female sex workers in Kampala, Uganda to participate in future HIV vaccine trials: a case control study. <i>BMC Public Health</i> , 2020, 20, 1789.	1.2	2
1617	Consensus statement on human immunodeficiency virus pre-exposure prophylaxis in China. <i>Chinese Medical Journal</i> , 2020, 133, 2840-2846.	0.9	8
1618	Inflammation, HIV, and Immune Quiescence: Leveraging on Immunomodulatory Products to Reduce HIV Susceptibility. <i>AIDS Research and Treatment</i> , 2020, 2020, 1-16.	0.3	3
1619	DISCOVER: much accomplished, but not yet for all. <i>Lancet, The</i> , 2020, 396, 214-215.	6.3	6
1620	Impact along the HIV pre-exposure prophylaxis “cascade of prevention” in western Kenya: a mathematical modelling study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25527.	1.2	6
1621	Abrocitinib for atopic dermatitis: a step forward. <i>Lancet, The</i> , 2020, 396, 215-217.	6.3	10
1622	HIV risk, risk perception, and PrEP interest among adolescent girls and young women in Lilongwe, Malawi: operationalizing the PrEP cascade. <i>Journal of the International AIDS Society</i> , 2020, 23, e25502.	1.2	31
1623	The pre-exposure prophylaxis (PrEP) consciousness of black college women and the perceived hesitancy of public health institutions to curtail HIV in black women. <i>BMC Public Health</i> , 2020, 20, 1172.	1.2	35
1624	HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. <i>AIDS Patient Care and STDs</i> , 2020, 34, 295-302.	1.1	5
1625	Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 149-152.	0.9	11
1626	Simulating the End of AIDS in New York: Using Participatory Dynamic Modeling to Improve Implementation of the Ending the Epidemic Initiative. <i>Public Health Reports</i> , 2020, 135, 158S-171S.	1.3	5

#	ARTICLE	IF	CITATIONS
1627	Highly synergistic drug combination prevents vaginal HIV infection in humanized mice. <i>Scientific Reports</i> , 2020, 10, 12995.	1.6	3
1628	Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. <i>Journal of Substance Abuse Treatment</i> , 2020, 117, 108058.	1.5	24
1629	Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol. <i>BMC Public Health</i> , 2020, 20, 1160.	1.2	8
1630	Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 423-429.	0.9	7
1631	Infección por el virus de la inmunodeficiencia humana (VIH). Síndrome de inmunodeficiencia adquirida. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2020, 27, 63-74.	0.0	1
1632	Does providing laboratory confirmed STI results impact uptake of HIV pre-exposure prophylaxis (PrEP) uptake among Kenyan adolescents girls and young women? A descriptive analysis. <i>Sexually Transmitted Infections</i> , 2021, 97, 467-468.	0.8	5
1633	Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. <i>Statistics in Biosciences</i> , 2020, 12, 468-494.	0.6	5
1634	HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016–2018. <i>Substance Use and Misuse</i> , 2020, 55, 2409-2419.	0.7	24
1635	Perceptions of black men who have sex with men about accessing and taking PrEP: A qualitative study. <i>Journal of HIV/AIDS and Social Services</i> , 2020, 19, 263-282.	0.7	3
1636	The paradox of HIV prevention: did biomedical prevention trials show how effective behavioral prevention can be?. <i>Aids</i> , 2020, 34, 2007-2011.	1.0	4
1637	Delivering PrEP to adults with low or no HIV risk and youth: experiences and perspectives of PrEP providers. <i>Culture, Health and Sexuality</i> , 2022, 24, 95-108.	1.0	6
1638	Comparative Effectiveness of Interventions to Improve the HIV Continuum of Care and HIV Preexposure Prophylaxis in Kenya: A Model-Based Analysis. <i>Journal of Infectious Diseases</i> , 2020, , .	1.9	0
1639	Brief Report: Discrepancies Between Self-Reported Adherence and a Biomarker of Adherence in Real-World Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 454-457.	0.9	17
1640	Meta-synthesis of Qualitative Research of Pre-exposure Prophylaxis (PrEP) Adherence Among Men Who Have Sex With Men (MSM). <i>AIDS Education and Prevention</i> , 2020, 32, 416-431.	0.6	13
1641	Strategies for increasing impact, engagement, and accessibility in HIV prevention programs: suggestions from women in urban high HIV burden counties in the Eastern United States (HPTN 064). <i>BMC Public Health</i> , 2020, 20, 1340.	1.2	6
1642	Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development. <i>Nature Communications</i> , 2020, 11, 4737.	5.8	31
1643	A stepped-wedge randomized trial and qualitative survey of HIV pre-exposure prophylaxis uptake in the Eswatini population. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	11
1644	The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. <i>Aids</i> , 2020, 34, 883-891.	1.0	18



#	ARTICLE	IF	CITATIONS
1645	Oral preexposure prophylaxis continuation, measurement and reporting. <i>Aids</i> , 2020, 34, 1801-1811.	1.0	31
1646	Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda. <i>Journal of the International AIDS Society</i> , 2020, 23, e25588.	1.2	32
1647	Evaluating family physicians' willingness to prescribe PrEP. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 606-610.	5.1	4
1648	Knowledge needs for implementing HIV pre-exposure prophylaxis among primary care providers in a safety-net health system. <i>Preventive Medicine Reports</i> , 2020, 20, 101266.	0.8	10
1649	Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV acquisition: a secondary analysis from a randomized, placebo-controlled trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25634.	1.2	49
1650	Utilizing emergency departments for pre-exposure prophylaxis (PrEP). <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1427-1435.	0.4	10
1651	Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25636.	1.2	41
1652	Multilevel Factors Shaping Awareness of and Attitudes Toward Pre-exposure Prophylaxis for HIV Prevention among Criminal Justice-Involved Women. <i>Archives of Sexual Behavior</i> , 2021, 50, 1743-1754.	1.2	17
1653	Patterns of PrEP Retention Among HIV Pre-exposure Prophylaxis Users in Baltimore City, Maryland. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 593-600.	0.9	13
1654	Understanding the role of nurse practitioners, physician assistants and other nursing staff in HIV pre-exposure prophylaxis care in the United States: a systematic review and meta-analysis. <i>BMC Nursing</i> , 2020, 19, 117.	0.9	11
1655	What's Sex Got to Do With It? Understanding Potential Confounding and Exposure Misclassification in Mechanistic Sexually Transmitted Infection Research. <i>Journal of Infectious Diseases</i> , 2021, 224, 137-140.	1.9	2
1656	Barriers and facilitators in pre-exposure prophylaxis (PrEP) use intention among Chinese homosexual men. <i>Global Health Journal (Amsterdam, Netherlands)</i> , 2020, 4, 79-86.	1.9	1
1657	Sexually transmitted infections among African women: an opportunity for combination sexually transmitted infection/HIV prevention. <i>Aids</i> , 2020, 34, 651-658.	1.0	16
1658	Sexual health needs of female sex workers in Côte d'Ivoire: a mixed-methods study to prepare the future implementation of pre-exposure prophylaxis (PrEP) for HIV prevention. <i>BMJ Open</i> , 2020, 10, e028508.	0.8	17
1659	The effect of a universal test and treat program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia. <i>AIDS Research and Therapy</i> , 2020, 17, 19.	0.7	31
1660	Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	9
1661	Am I doing this test so I can benefit from PrEP? exploring HIV testing barriers/facilitators and implementation of pre-exposure prophylaxis among South African adolescents. <i>African Journal of AIDS Research</i> , 2020, 19, 101-108.	0.3	5
1662	Influence of hair treatments on detection of antiretrovirals by mass spectrometry imaging. <i>Analyst, The</i> , 2020, 145, 4540-4550.	1.7	6

#	ARTICLE	IF	CITATIONS
1663	“A Good Habit”: Telehealth PrEP Users Find Benefit in Quarterly Monitoring Requirements. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595822091926.	0.6	12
1664	Integrating HIV Pre-Exposure Prophylaxis into Family Planning Care: A RE-AIM Framework Evaluation. <i>AIDS Patient Care and STDs</i> , 2020, 34, 259-266.	1.1	21
1665	PrEP rollout in Africa: status and opportunity. <i>Nature Medicine</i> , 2020, 26, 655-664.	15.2	71
1666	Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12368-12374.	3.3	34
1667	Lost in translation: College students’ knowledge of HIV and PrEP in relation to their sexual health behaviors. <i>Journal of American College Health</i> , 2022, 70, 561-567.	0.8	5
1668	HIV Antiretroviral Treatment and Pre-exposure Prophylaxis in Transgender Individuals. <i>Drugs</i> , 2020, 80, 965-972.	4.9	15
1669	Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 173-181.	0.9	18
1670	Views among Malawian women about joining HIV prevention clinical trials when pregnant. <i>AIDS Research and Therapy</i> , 2020, 17, 27.	0.7	6
1671	Attitude of infectious diseases physicians in Turkey about HIV pre-exposure prophylaxis: results of an online survey. <i>International Journal of STD and AIDS</i> , 2020, 31, 665-670.	0.5	3
1672	Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis. <i>Aids</i> , 2020, 34, 1181-1186.	1.0	16
1673	Perceived Knowledge of HIV-Negative Status Increases Condom Use Among Female Sex Workers in Zambian Transit Towns. <i>AIDS Patient Care and STDs</i> , 2020, 34, 184-192.	1.1	5
1674	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 323-330.	0.9	26
1675	Standardised patient encounters to improve quality of counselling for pre-exposure prophylaxis (PrEP) in adolescent girls and young women (AGYW) in Kenya: study protocol of a cluster randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035689.	0.8	11
1676	The incidence of HIV and associated risk factors among pregnant women in Kabarole District, Uganda. <i>PLoS ONE</i> , 2020, 15, e0234174.	1.1	10
1677	Perspectives on HIV PrEP care in Germany: qualitative insights from primary care physicians and specialists. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 994-1000.	0.6	5
1678	Unlocking HIV Pre-Exposure Prophylaxis Delivery: Examining the Role of HIV Providers in Pre-Exposure Prophylaxis Care. <i>AIDS Patient Care and STDs</i> , 2020, 34, 251-258.	1.1	4
1679	Health Care-Seeking Behaviors and Perceptions of Provider-Initiated Discussion of Pre-exposure Prophylaxis Among PrEP-Naïve HIV-Negative Men Who Have Sex With Men in Atlanta, Georgia. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa165.	0.4	3
1680	“I’m waiting for that”: Interest in the use of PrEP for safer conception in Botswana. <i>Global Public Health</i> , 2020, 15, 1200-1211.	1.0	4

#	ARTICLE	IF	CITATIONS
1681	Are PrEP services in France reaching all those exposed to HIV who want to take PrEP? MSM respondents who are eligible but not using PrEP (EMIS 2017). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 47-56.	0.6	32
1682	Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide. <i>Frontiers in Pharmacology</i> , 2020, 11, 286.	1.6	8
1683	The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25463.	1.2	115
1684	Educational Interventions Improved Knowledge, Attitude, and Practice to Prevent HIV Infection among HIV-Negative Heterosexual Partners of HIV-Infected Persons. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595821989953.	0.6	8
1685	Mapping and characterising areas with high levels of HIV transmission in sub-Saharan Africa: A geospatial analysis of national survey data. <i>PLoS Medicine</i> , 2020, 17, e1003042.	3.9	34
1686	The Ashodaya PrEP project: Lessons and implications for scaling up PrEP from a community-led demonstration project among female sex workers in Mysore, India. <i>Global Public Health</i> , 2020, 15, 889-904.	1.0	16
1687	Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. <i>AIDS and Behavior</i> , 2020, 24, 2520-2531.	1.4	41
1688	Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. <i>BMC Public Health</i> , 2020, 20, 271.	1.2	9
1689	Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures. <i>Journal of Infectious Diseases</i> , 2020, 222, 391-395.	1.9	13
1690	Out-of-pocket costs and HIV pre-exposure prophylaxis persistence in a US multicity demonstration project. <i>Health Services Research</i> , 2020, 55, 524-530.	1.0	10
1691	Women's Decision-Making about PrEP for HIV Prevention in Drug Treatment Contexts. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595821990009.	0.6	20
1692	Pre-exposure Prophylaxis Awareness and Use Among Cisgender Men Who Have Sex With Men and Use Methamphetamine in 3 Western US Cities. <i>Sexually Transmitted Diseases</i> , 2020, 47, 217-223.	0.8	5
1693	Randomized controlled trial protocol for project BRIDGE: A telephone-administered motivational interviewing intervention targeting risky sexual behavior in older people living with HIV. <i>Contemporary Clinical Trials</i> , 2020, 95, 106047.	0.8	2
1694	Who Accepts and Who Uses Community-Based Secondary Distribution HIV Self-Testing (HIVST) Kits? Findings From the Intervention Arm of a Cluster-Randomized Trial of HIVST Distribution Nested in Four HPTN 071 (PopART) Communities in Zambia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 355-364.	0.9	16
1695	<i>Homo adhaerens</i>: Risk and adherence in biomedical HIV prevention research. <i>Social Studies of Science</i> , 2020, 50, 860-880.	1.5	1
1696	Clinical targeting of HIV capsid protein with a long-acting small molecule. <i>Nature</i> , 2020, 584, 614-618.	13.7	192
1697	Is HIV Self-Testing a Strategy to Increase Repeat Testing Among Pregnant and Postpartum Women? A Pilot Mixed Methods Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 365-371.	0.9	13
1698	A review of HIV pre-exposure prophylaxis (PrEP) programmes by delivery models in the Asia-Pacific through the healthcare accessibility framework. <i>Journal of the International AIDS Society</i> , 2020, 23, e25531.	1.2	12

#	ARTICLE	IF	CITATIONS
1699	Implementing PrEP in the pharmacy. <i>Pharmacy Today</i> , 2020, 26, 39-53.	0.0	3
1700	Using electronic health records to identify candidates for human immunodeficiency virus pre-exposure prophylaxis: An application of super learning to risk prediction when the outcome is rare. <i>Statistics in Medicine</i> , 2020, 39, 3059-3073.	0.8	15
1701	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. <i>Nature Communications</i> , 2020, 11, 3195.	5.8	15
1702	Masculine ideology and Black men who have sex with men's interest in HIV pre-exposure prophylaxis (PrEP). <i>Journal of Health Psychology</i> , 2021, 26, 2908-2920.	1.3	7
1703	Associations between schistosomiasis and HIV acquisition risk in four prospective cohorts: a nested case-control analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25534.	1.2	6
1704	Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. <i>Lancet HIV</i> , 2020, 7, e472-e481.	2.1	97
1705	Preconception Care Uptake and Immediate Outcomes among Discordant Couples Accessing Routine HIV Care in Kenya. <i>Obstetrics and Gynecology International</i> , 2020, 2020, 1-6.	0.5	0
1706	Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs. <i>AIDS and Behavior</i> , 2020, 24, 2400-2408.	1.4	3
1707	Disclosure of HIV Status and HIV Sexual Transmission Behaviors among HIV-Positive Black Men Who Have Sex with Men in the BROTHERS (HPTN 061) Study. <i>Journal of Urban Health</i> , 2020, 97, 692-703.	1.8	6
1708	STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. <i>BMC Infectious Diseases</i> , 2020, 20, 110.	1.3	108
1709	Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate + emtricitabine for HIV pre-exposure prophylaxis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25420.	1.2	13
1710	Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. <i>Lancet HIV</i> , 2020, 7, e249-e261.	2.1	94
1711	The role of syringe exchange programs and sexual identity in awareness of pre-exposure prophylaxis (PrEP) for male persons who inject drugs. <i>International Journal of Drug Policy</i> , 2020, 77, 102671.	1.6	27
1712	Modeling HIV Pre-Exposure Prophylaxis. <i>Frontiers in Pharmacology</i> , 2020, 10, 1514.	1.6	6
1713	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020, 16, e1007626.	1.5	20
1714	Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review. <i>AIDS Patient Care and STDs</i> , 2020, 34, 111-123.	1.1	127
1715	Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries. <i>Journal of the International AIDS Society</i> , 2020, 23, e25451.	1.2	20
1716	Lessons on PrEP from the SEARCH study in east Africa. <i>Lancet HIV</i> , 2020, 7, e219-e220.	2.1	7

#	ARTICLE	IF	CITATIONS
1717	Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions. <i>Annals of Epidemiology</i> , 2020, 44, 16-30.	0.9	28
1718	Human immunodeficiency virus prevention strategies in China. <i>Chinese Medical Journal</i> , 2020, 133, 318-325.	0.9	8
1719	Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV. <i>PLoS ONE</i> , 2020, 15, e0227632.	1.1	55
1720	HIV treatment response among female sex workers participating in a treatment as prevention demonstration project in Cotonou, Benin. <i>PLoS ONE</i> , 2020, 15, e0227184.	1.1	4
1721	Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria. <i>BMC Public Health</i> , 2020, 20, 69.	1.2	50
1722	&lt;p&gt;Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 107-118.	0.8	12
1723	Understanding Demand for PrEP and Early Experiences of PrEP Use Among Young Adults in Rural Kenya and Uganda: A Qualitative Study. <i>AIDS and Behavior</i> , 2020, 24, 2149-2162.	1.4	65
1724	Sexual Behavior and Perceived HIV Risk Among HIV-Negative Members of Serodiscordant Couples in East Africa. <i>AIDS and Behavior</i> , 2020, 24, 2082-2090.	1.4	5
1725	A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	49
1726	The Effect of Depression on Adherence to HIV Pre-exposure Prophylaxis Among High-Risk South African Women in HPTN 067/ADAPT. <i>AIDS and Behavior</i> , 2020, 24, 2178-2187.	1.4	13
1727	Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. <i>PLoS Computational Biology</i> , 2020, 16, e1007482.	1.5	5
1728	Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial. <i>AIDS and Behavior</i> , 2020, 24, 3244-3251.	1.4	6
1729	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	9.5	74
1730	Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate. <i>Pharmaceutical Research</i> , 2020, 37, 83.	1.7	30
1731	HIV-Related Mistrust (or HIV Conspiracy Theories) and Willingness to Use PrEP Among Black Women in the United States. <i>AIDS and Behavior</i> , 2020, 24, 2927-2934.	1.4	47
1732	An Exploration of Pre-exposure Prophylaxis (PrEP) Initiation Among Women Who Inject Drugs. <i>Archives of Sexual Behavior</i> , 2020, 49, 2205-2212.	1.2	20
1733	Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 1778-1811.	1.3	187
1734	PrEP for HIV Prevention: Evidence, Global Scale-up, and Emerging Options. <i>Cell Host and Microbe</i> , 2020, 27, 502-506.	5.1	30

#	ARTICLE	IF	CITATIONS
1735	Pre-exposure Prophylaxis Use Among Predominantly African American and Hispanic Women at Risk for HIV Acquisition in New York City. <i>Journal of the Association of Nurses in AIDS Care</i> , 2020, 31, 110-114.	0.4	6
1736	Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	6
1737	HIV Post-Exposure Prophylaxis (PEP) Awareness and Non-Occupational PEP (nPEP) Prescribing History Among U.S. Healthcare Providers. <i>AIDS and Behavior</i> , 2020, 24, 3124-3131.	1.4	11
1738	Implementation of HIV Preexposure Prophylaxis in a Homeless Primary Care Setting at the Veterans Affairs. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272090837.	1.0	10
1739	A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595822091923.	0.6	66
1740	Willingness to use PrEP among female university students in Lesotho. <i>PLoS ONE</i> , 2020, 15, e0230565.	1.1	5
1741	“Now that PrEP is reducing the risk of transmission of HIV, why then do you still insist that we use condoms?”—the condom quandary among PrEP users and health care providers in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 92-100.	0.6	12
1742	PrEP awareness among people living with HIV in Florida: Florida Cohort study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 428-433.	0.6	3
1743	Prevention of HIV transmission with sperm washing within fertile serodiscordant couples undergoing non-stimulated intrauterine insemination. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 478-485.	0.6	4
1744	Awareness of and attitudes toward pre-exposure prophylaxis among African American women living in low-income neighborhoods in a Southeastern city. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 239-243.	0.6	24
1745	Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. <i>Clinical Infectious Diseases</i> , 2021, 72, 486-489.	2.9	12
1746	Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). <i>Canadian Journal of Public Health</i> , 2021, 112, 89-96.	1.1	11
1747	Factors Associated with Preferred Pre-Exposure Prophylaxis Dosing Regimen Among Men Who Have Sex with Men in Real-World Settings: A Mixed-Effect Model Analysis. <i>AIDS and Behavior</i> , 2021, 25, 249-258.	1.4	9
1748	A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections. <i>HIV Medicine</i> , 2021, 22, 75-82.	1.0	13
1749	Where are we with pre-exposure prophylaxis use in Central and Eastern Europe? Data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group. <i>HIV Medicine</i> , 2021, 22, 67-72.	1.0	8
1750	A Pilot Study to Evaluate a Novel Pre-exposure Prophylaxis Peer Outreach and Navigation Intervention for Women at High Risk for HIV Infection. <i>AIDS and Behavior</i> , 2021, 25, 1411-1422.	1.4	29
1751	Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model. <i>Journal of Investigative Medicine</i> , 2021, 69, 28-40.	0.7	4
1752	DOT Diary: Developing a Novel Mobile App Using Artificial Intelligence and an Electronic Sexual Diary to Measure and Support PrEP Adherence Among Young Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2021, 25, 1001-1012.	1.4	29



#	ARTICLE	IF	CITATIONS
1753	Design and Delivery of Real-Time Adherence Data to Men Who Have Sex with Men Using Antiretroviral Pre-exposure Prophylaxis via an Ingestible Electronic Sensor. <i>AIDS and Behavior</i> , 2021, 25, 1661-1674.	1.4	16
1754	Low awareness of and willingness to use PrEP in the Chinese YMSM: An alert in YMSM HIV prevention. <i>HIV Medicine</i> , 2021, 22, 185-193.	1.0	12
1755	Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 421-428.	0.5	12
1756	Development of pH-sensitive vaginal films based on methacrylate copolymers for topical HIV-1 pre-exposure prophylaxis. <i>Acta Biomaterialia</i> , 2021, 121, 316-327.	4.1	19
1757	Pre-exposure Prophylaxis (PrEP) Awareness and Prescribing Behaviors Among Primary Care Providers: DocStyles Survey, 2016-2020, United States. <i>AIDS and Behavior</i> , 2021, 25, 1267-1275.	1.4	11
1758	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Primary African Isolates. <i>Journal of Virology</i> , 2021, 95, .	1.5	18
1759	Optimal Allocation of Societal HIV Prevention Resources to Reduce HIV Incidence in the United States. <i>American Journal of Public Health</i> , 2021, 111, 150-158.	1.5	10
1760	Predictors of HIV Preexposure Prophylaxis Initiation Among Public Health Clients in Rural and Small Urban Areas in Iowa. <i>Public Health Reports</i> , 2021, 136, 172-182.	1.3	4
1761	Development and Psychometric Evaluation of the PrEP Sexual Expectancies (PSEXES) Scale. <i>AIDS and Behavior</i> , 2021, 25, 1192-1198.	1.4	0
1762	Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 692-698.	1.3	8
1763	Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 712-720.	0.6	27
1764	Modeling the Impact of PrEP Programs for Adolescent Sexual Minority Males Based on Empirical Estimates for the PrEP Continuum of Care. <i>Journal of Adolescent Health</i> , 2021, 68, 488-496.	1.2	8
1765	Impact of Medicaid Expansion on PrEP Utilization in the US: 2012-2018. <i>AIDS and Behavior</i> , 2021, 25, 1103-1111.	1.4	15
1767	Integrating Pre- and Post-exposure Prophylaxes Programs for HIV Prevention Guidelines in Manila, Philippines. <i>Sexuality Research and Social Policy</i> , 2021, 18, 672-681.	1.4	2
1768	Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States. <i>AIDS and Behavior</i> , 2021, 25, 667-678.	1.4	35
1769	Potential Impact and Cost-Effectiveness of Condomless-Sex-Related Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. <i>Journal of Infectious Diseases</i> , 2021, 223, 1345-1355.	1.9	22
1770	Gearing up for PrEP in the Middle East and North Africa: An Initial Look at Willingness to Take PrEP among Young Men Who Have Sex with Men in Beirut, Lebanon. <i>Behavioral Medicine</i> , 2021, 47, 111-119.	1.0	5
1771	Mechanisms of Retroviral Resistance. <i>Updates in Clinical Dermatology</i> , 2021, , 75-90.	0.1	1

#	ARTICLE	IF	CITATIONS
1772	<i>Mycobacterium tuberculosis</i> -Specific T Cell Responses are Impaired During Late Pregnancy With Elevated Biomarkers of Tuberculosis Risk Postpartum. SSRN Electronic Journal, 0, , .	0.4	0
1773	Progression and transmission of HIV (PATH 4.0)-A new agent-based evolving network simulation for modeling HIV transmission clusters. Mathematical Biosciences and Engineering, 2021, 18, 2150-2181.	1.0	7
1774	Trajectories of PrEP Adherence Among Young Women Aged 16 to 25 in Cape Town, South Africa. AIDS and Behavior, 2021, 25, 2046-2053.	1.4	19
1775	Effectiveness of a Novel HIV Self-Testing Service with Online Real-Time Counseling Support (HIVST-Online) in Increasing HIV Testing Rate and Repeated HIV Testing among Men Who Have Sex with Men in Hong Kong: Results of a Pilot Implementation Project. International Journal of Environmental Research and Public Health, 2021, 18, 729.	1.2	32
1776	“I wish to remain HIV negative” Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya. PLoS ONE, 2021, 16, e0244226.	1.1	25
1777	The case for an HIV cure and how to get there. Lancet HIV, 2021, 8, e51-e58.	2.1	46
1778	The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review. Pan African Medical Journal, 2021, 38, 308.	0.3	1
1779	Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women. Seminars in Immunology, 2021, 51, 101482.	2.7	9
1780	Prevalence and correlates of cervical squamous intraepithelial lesions among HIV-infected and uninfected women in Central Kenya. Pan African Medical Journal, 2021, 39, 44.	0.3	1
1781	Estimating HIV pre-exposure prophylaxis need and impact in Malawi, Mozambique and Zambia: A geospatial and risk-based analysis. PLoS Medicine, 2021, 18, e1003482.	3.9	5
1782	United States Ending the Human Immunodeficiency Virus (HIV) Epidemic Plan: Evaluation of the Role of Industry Funding in Published Pre-Exposure Prophylaxis (PrEP) Literature. SSRN Electronic Journal, 0, , .	0.4	0
1783	The Stigma Struggles of Biomedical Progress: Understanding Community Engagement with PrEP by People Who Use Drugs. Social Aspects of HIV, 2021, , 173-185.	0.1	0
1784	“Belt and braces approach; added benefit and extra reassurance” a multi-stakeholder examination of the challenges to effective provision of pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM) in Northern and Central England. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 736-745.	0.6	2
1785	Imagined Futures and Unintended Consequences in the Making of PrEP: An Evidence-Making Intervention Perspective. Social Aspects of HIV, 2021, , 249-264.	0.1	2
1786	Pre-exposure prophylaxis use among HIV serodiscordant couples: a qualitative study in Mozambique. Global Health Action, 2021, 14, 1940764.	0.7	6
1787	HIV-Infektion “Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. The Springer Reference Pflögerapie, Gesundheit, 2021, , 1001-1006.	0.2	0
1788	Patient-Led Decision-Making for HIV Preexposure Prophylaxis. Current HIV/AIDS Reports, 2021, 18, 48-56.	1.1	15
1789	A Scoping Review of HIV Pre-exposure Prophylaxis Stigma and Implications for Stigma-Reduction Interventions for Men and Transwomen Who Have Sex with Men. AIDS and Behavior, 2021, 25, 2054-2070.	1.4	31

#	ARTICLE	IF	CITATIONS
1790	Assessment of PrEP Awareness, PrEP Discussion with a Provider, and PrEP Use by Transmission Risk Group with an Emphasis on the Southern United States. <i>AIDS and Behavior</i> , 2021, 25, 2985-2991.	1.4	12
1791	Equity considerations in outcome measures of the HIV pre-exposure prophylaxis care continuum in high-income countries: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e040701.	0.8	1
1792	The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques. <i>Antiviral Research</i> , 2021, 186, 105001.	1.9	2
1793	Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e77-e86.	2.1	55
1795	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV</i> , 2021, 8, e87-e95.	2.1	70
1796	The Other U=U: Untested and Untreated Genital Tract Inflammation in People Living With and Exposed to Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2021, 224, 1-4.	1.9	12
1797	Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis. <i>International Journal of STD and AIDS</i> , 2021, 32, 806-815.	0.5	3
1798	Yes, I'm interested in taking PrEP! PrEP interest among women respondents to the European community-based survey Flash! PrEP in Europe. <i>PLoS ONE</i> , 2021, 16, e0246037.	1.1	7
1799	In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1189-1206.	3.3	8
1800	The PEARL study: a prospective two-group pilot PrEP promotion intervention for cisgender female sex workers living in Baltimore, MD, U.S.. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1-10.	0.6	4
1801	Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. <i>International Journal of STD and AIDS</i> , 2021, 32, 638-647.	0.5	4
1802	HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. <i>PLoS Medicine</i> , 2021, 18, e1003492.	3.9	35
1803	Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108477.	1.6	11
1804	A Mechanistic In Vivo / Ex Vivo Pharmacokinetic-Pharmacodynamic Model of Tenofovir for HIV Prevention. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 179-187.	1.3	2
1805	Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda. <i>Sexually Transmitted Infections</i> , 2021, , sextrans-2020-054718.	0.8	1
1806	Incidence and Prevalence of Incarceration in a Longitudinal Cohort of Women at Risk for Human Immunodeficiency Virus in the United States, 2007-2017. <i>Journal of Women's Health</i> , 2021, 30, 694-704.	1.5	8
1807	Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 165-186.	1.8	13
1808	Sexually Transmitted Infection Testing and Prevalence Before and After Preexposure Prophylaxis Initiation Among Men Aged ≥18 Years in US Private Settings. <i>Sexually Transmitted Diseases</i> , 2021, 48, 515-520.	0.8	3

#	ARTICLE	IF	CITATIONS
1809	CD34T+ Humanized Mouse Model to Study Mucosal HIV-1 Transmission and Prevention. <i>Vaccines</i> , 2021, 9, 198.	2.1	4
1810	A Review of Recent HIV Prevention Interventions and Future Considerations for Nursing Science. <i>Journal of the Association of Nurses in AIDS Care</i> , 2021, 32, 373-391.	0.4	2
1811	Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1147-1149.	1.0	1
1812	Effect of Medicaid Expansions on HIV Diagnoses and Pre-Exposure Prophylaxis Use. <i>American Journal of Preventive Medicine</i> , 2021, 60, 335-342.	1.6	9
1813	PrEP Awareness, Use, Intention to Use, and Information Source Among Geosocial Networking Application Users in Mexico in 2018â€“2019. <i>AIDS and Behavior</i> , 2021, 25, 2743-2754.	1.4	8
1814	Antiretroviral therapy based HIV prevention targeting young women who sell sex: a mixed method approach to understand the implementation of PrEP in a rural area of KwaZulu-Natal, South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 232-240.	0.6	11
1815	Early Colorectal Responses to HIV-1 and Modulation by Antiretroviral Drugs. <i>Vaccines</i> , 2021, 9, 231.	2.1	7
1816	Factors Associated With Peripartum Virologic Suppression in Eastern Cape Province, South Africa: A Retrospective Cross-Sectional Analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, 1750-1758.	2.9	0
1817	Preexposure prophylaxis is effective on a national level, but is it enough. <i>Aids</i> , 2021, 35, 691-692.	1.0	0
1818	Genital Abnormalities, Hormonal Contraception, and Human Immunodeficiency Virus Transmission Risk in Rwandan Serodifferent Couples. <i>Journal of Infectious Diseases</i> , 2021, 224, 81-91.	1.9	6
1819	Primary HIV-1 infection in users of pre-exposure prophylaxis. <i>Lancet HIV,the</i> , 2021, 8, e166-e174.	2.1	23
1820	Antiretroviral Drug Treatment of Individuals that Used Preexposure Prophylaxis (PrEP) Before Diagnosis. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 141-152.	0.8	0
1821	Factors Predicting Uptake of Sexually Transmitted Infections Testing among Men Who Have Sex with Men Who Are â€œPre-Exposure Prophylaxis Touristsâ€œ”An Observational Prospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3582.	1.2	9
1822	Call to action: how can the US Ending the HIV Epidemic initiative succeed?. <i>Lancet, The</i> , 2021, 397, 1151-1156.	6.3	24
1823	Commentary title: COVID-19 research, Africa, and global health. <i>Journal of Virus Eradication</i> , 2021, 7, 100030.	0.3	1
1824	Community Legal Systems: Targeting PrEP and HIV Education to Decrease Risk of HIV Transmission. <i>AIDS and Behavior</i> , 2021, 25, 2578-2590.	1.4	2
1825	Motivations to use hormonal contraceptive methods and condoms among HIV-positive and negative women randomized to a progestin contraceptive in Malawi: a qualitative study. <i>BMC Women's Health</i> , 2021, 21, 114.	0.8	2
1826	HIV and women in the USA: what we know and where to go from here. <i>Lancet, The</i> , 2021, 397, 1107-1115.	6.3	35

#	ARTICLE	IF	CITATIONS
1827	Mixed-Methods Evaluation of the Incorporation of Home Specimen Self-Collection Kits for Laboratory Testing in a Telehealth Program for HIV Pre-exposure Prophylaxis. <i>AIDS and Behavior</i> , 2021, 25, 2463-2482.	1.4	18
1828	Implementing Implementation Research: Teaching Implementation Research to HIV Researchers. <i>Current HIV/AIDS Reports</i> , 2021, 18, 186-197.	1.1	4
1829	Use of propensity score matching to create counterfactual group to assess potential HIV prevention interventions. <i>Scientific Reports</i> , 2021, 11, 7017.	1.6	5
1830	HIV Pathogenesis in the Human Female Reproductive Tract. <i>Current HIV/AIDS Reports</i> , 2021, 18, 139-156.	1.1	10
1831	Patient perspectives of pharmacists prescribing HIV pre-exposure prophylaxis: A survey of patients receiving antiretroviral therapy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e75-e79.	0.7	11
1832	Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. <i>PLoS Computational Biology</i> , 2021, 17, e1008752.	1.5	41
1833	Preexposure prophylaxis care continuum among transgender women at a patient-centered preexposure prophylaxis program in Atlanta, Georgia. <i>Aids</i> , 2021, 35, 524-526.	1.0	3
1834	Role of Social Networks and Social Norms in Future PrEP Use in a Racially Diverse Sample of At-Risk Women and Members of Their Social Networks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 422-429.	0.9	9
1835	“We are in this together”: dyadic-level influence and decision-making among HIV serodiscordant couples in Tanzania receiving access to PrEP. <i>BMC Public Health</i> , 2021, 21, 720.	1.2	7
1836	Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 1149-1156.	2.9	15
1837	Immunization by exposure to live virus (SIVmne/HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge. <i>PLoS ONE</i> , 2021, 16, e0240495.	1.1	0
1838	“PrEP just isn't my priority”: Adherence challenges among women who inject drugs participating in a pre-exposure prophylaxis (PrEP) demonstration project in Philadelphia, PA USA. <i>Social Science and Medicine</i> , 2021, 275, 113809.	1.8	14
1839	The Past, Present, and Future of PrEP implementation Among People Who Use Drugs. <i>Current HIV/AIDS Reports</i> , 2021, 18, 328-338.	1.1	22
1840	Awareness, acceptability, and intention to initiate HIV pre-exposure prophylaxis among pregnant women. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, 34, 201-213.	0.6	6
1841	A Systematic Review of the Social Network Strategy to Optimize HIV Testing in Key Populations to End the Epidemic in the United States. <i>AIDS and Behavior</i> , 2021, 25, 2680-2698.	1.4	13
1842	Risk Management on Pre-Exposure Prophylaxis Adherence of Men Who Have Sex with Multiple Men: A Multicenter Prospective Cohort Study. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 1749-1761.	1.2	9
1843	Primary Care Providers' Perspectives on Using Automated HIV Risk Prediction Models to Identify Potential Candidates for Pre-exposure Prophylaxis. <i>AIDS and Behavior</i> , 2021, 25, 3651-3657.	1.4	8
1844	Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1245-1251.	0.9	2

#	ARTICLE	IF	CITATIONS
1845	A randomized controlled trial evaluating combination detection of HIV in Malawian sexually transmitted infections clinics. <i>Journal of the International AIDS Society</i> , 2021, 24, e25701.	1.2	7
1846	Perceived Interruptions to HIV Prevention and Treatment Services Associated With COVID-19 for Gay, Bisexual, and Other Men Who Have Sex With Men in 20 Countries. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 87, 644-651.	0.9	69
1847	Recent Advances and New Challenges in Cisgender Women's Gynecologic and Obstetric Health in the Context of HIV. <i>Clinical Obstetrics and Gynecology</i> , 2021, 64, 475-490.	0.6	2
1848	HIV PrEP implementation: A multi-level systems approach. <i>Evaluation and Program Planning</i> , 2022, 90, 101966.	0.9	9
1849	Getting to Zero: A Demonstration Project of Partner HIV Testing in the Prenatal Setting in Chicago, Illinois. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 37-44.	0.5	2
1850	Adaptation and validation of simple tools to screen and monitor for oral PrEP adherence. <i>PLoS ONE</i> , 2021, 16, e0251823.	1.1	0
1851	Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1367-1373.	1.0	11
1852	Health Care Providers as Agents of Change: Integrating PrEP With Other Sexual and Reproductive Health Services for Adolescent Girls and Young Women. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	8
1853	Urban sexual health clinic patients with "undetermined risk" for HIV are less likely to receive PrEP. <i>Sexually Transmitted Diseases</i> , 2021, Publish Ahead of Print, 881-886.	0.8	0
1854	The Role of Alcohol-Related Behavioral Research in the Design of HIV Secondary Prevention Interventions in the Era of Antiretroviral Therapy: Targeted Research Priorities Moving Forward. <i>AIDS and Behavior</i> , 2021, 25, 365-380.	1.4	5
1855	The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence. <i>AIDS and Behavior</i> , 2021, 25, 4169-4179.	1.4	5
1856	Preferences for pre-exposure prophylaxis among U.S. military men who have sex with men: results of an adaptive choice based conjoint analysis study. <i>Military Medical Research</i> , 2021, 8, 32.	1.9	5
1857	Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25744.	1.2	12
1858	Antiretroviral drug exposure in urethral and glans surface sampling of the penis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2368-2374.	1.3	5
1859	HIV risk and pre-exposure prophylaxis interest among women seeking post-abortion care in Kenya: a cross-sectional study. <i>Journal of the International AIDS Society</i> , 2021, 24, e25703.	1.2	4
1860	Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey. <i>BMC Public Health</i> , 2021, 21, 943.	1.2	4
1861	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2129-2136.	1.3	10
1862	Platforms for Personalized Polytherapeutics Discovery in COVID-19. <i>Journal of Molecular Biology</i> , 2021, 433, 166945.	2.0	4



#	ARTICLE	IF	CITATIONS
1863	The Influence of PrEP-Related Stigma and Social Support on PrEP-Use Disclosure among Women Who Inject Drugs and Social Network Members. <i>AIDS and Behavior</i> , 2021, 25, 3922-3932.	1.4	9
1864	Experiencia de un programa de profilaxis preexposición en una unidad de virus de la inmunodeficiencia humana hospitalaria. Descripción del perfil basal del usuario e identificación de oportunidades de mejora. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2023, 41, 24-28.	0.3	7
1865	Long-Acting Cabotegravir for HIV/AIDS Prophylaxis. <i>Biochemistry</i> , 2021, 60, 1731-1740.	1.2	12
1866	The Value of Assessing Self-Reported and Biological Indicators of Outcomes in Evaluating HIV Programs. <i>Current HIV/AIDS Reports</i> , 2021, 18, 365-376.	1.1	1
1867	Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South Africa. <i>Archives of Sexual Behavior</i> , 2021, 50, 1729-1742.	1.2	57
1868	A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 655-669.	0.8	1
1869	Applying a Nursing Perspective to Address the Challenges Experienced by Cisgender Women in the HIV Status Neutral Care Continuum: A Review of the Literature. <i>Journal of the Association of Nurses in AIDS Care</i> , 2021, 32, 283-305.	0.4	6
1871	The impact of condom use on the HIV epidemic. <i>Gates Open Research</i> , 2021, 5, 91.	2.0	3
1872	Predictors of HIV Status Disclosure to Sexual Partners Among People Living with HIV in Brazil. <i>AIDS and Behavior</i> , 2021, 25, 3538-3546.	1.4	2
1873	Perceived Social Influences on Women's Decisions to use Medications not Studied in Pregnancy. A Qualitative Ethical Analysis of Preexposure Prophylaxis Implementation Research in Kenya. <i>Journal of Empirical Research on Human Research Ethics</i> , 2021, 16, 225-237.	0.6	3
1874	CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions. <i>Cell Reports Medicine</i> , 2021, 2, 100322.	3.3	5
1875	Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention. <i>AIDS and Behavior</i> , 2021, 25, 2801-2814.	1.4	5
1876	PrEP University: A Multi-Disciplinary University-Based HIV Prevention Education Program. <i>Journal of Community Health</i> , 2021, 46, 1213-1220.	1.9	5
1877	Linking Women Experiencing Incarceration to Community-Based HIV Pre-Exposure Prophylaxis Care: A Qualitative Study. <i>AIDS Education and Prevention</i> , 2021, 33, 216-233.	0.6	10
1878	Tonse Pamodzi: Developing a combination strategy to support adherence to antiretroviral therapy and HIV pre-exposure prophylaxis during pregnancy and breastfeeding. <i>PLoS ONE</i> , 2021, 16, e0253280.	1.1	8
1879	Combination adherence strategy to support HIV antiretroviral therapy and pre-exposure prophylaxis adherence during pregnancy and breastfeeding: protocol for a pair of pilot randomised trials. <i>BMJ Open</i> , 2021, 11, e046032.	0.8	8
1881	Uptake and outcomes of a novel community-based HIV post-exposure prophylaxis (PEP) programme in rural Kenya and Uganda. <i>Journal of the International AIDS Society</i> , 2021, 24, e25670.	1.2	13
1882	Pre-Exposure Prophylaxis for HIV Infection and the Role of the Women's Health Care Provider in HIV Prevention. <i>Journal of Midwifery and Women's Health</i> , 2021, 66, 322-333.	0.7	2

#	ARTICLE	IF	CITATIONS
1883	Client and Provider Experiences in Uganda Suggest Demand for and Highlight the Importance of Addressing HIV Stigma and Gender Norms Within Safer Conception Care. <i>AIDS and Behavior</i> , 2022, 26, 76-87.	1.4	6
1884	Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2021, 334, 453-462.	4.8	12
1885	Considerations for the Design of Pre-exposure Prophylaxis (PrEP) Interventions for Women: Lessons Learned from the Implementation of a Novel PrEP Intervention. <i>AIDS and Behavior</i> , 2021, 25, 3987-3999.	1.4	21
1886	Minimum dataset for monitoring national human immunodeficiency virus pre-exposure prophylaxis (HIV PrEP) programmes: a five-nation consensus, 2019. <i>Eurosurveillance</i> , 2021, 26, .	3.9	3
1887	Fertility and HIV risk in Africa. <i>Review of Economic Dynamics</i> , 2021, , .	0.7	0
1888	Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2021, 24, e25731.	1.2	17
1889	Changing the PrEP Narrative: A Call to Action to Increase PrEP Uptake among Women. <i>Women</i> , 2021, 1, 120-127.	0.5	7
1890	Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> , 2021, 36, 100893.	3.2	27
1891	Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 409-420.	0.5	20
1892	HIV Risk and Pre-Exposure Prophylaxis Eligibility Among Emergency Department Patients. <i>AIDS Patient Care and STDs</i> , 2021, 35, 211-219.	1.1	12
1893	Reflections on 40 Years of AIDS. <i>Emerging Infectious Diseases</i> , 2021, 27, 1553-1560.	2.0	49
1894	Estimating the HIV Effective Reproduction Number in the United States and Evaluating HIV Elimination Strategies. <i>Journal of Public Health Management and Practice</i> , 2021, Publish Ahead of Print, .	0.7	1
1895	HIV pre-exposure prophylaxis (PrEP) knowledge, familiarity, and attitudes among United States healthcare professional students: A cross-sectional study. <i>Preventive Medicine Reports</i> , 2021, 22, 101334.	0.8	10
1896	High-Resolution Quantitative Mapping of Macaque Cervicovaginal Epithelial Thickness: Implications for Mucosal Vaccine Delivery. <i>Frontiers in Immunology</i> , 2021, 12, 660524.	2.2	1
1897	Initial implementation of PrEP in Zambia: health policy development and service delivery scale-up. <i>BMJ Open</i> , 2021, 11, e047017.	0.8	19
1898	Integration of HIV Prevention With Sexual and Reproductive Health Services: Evidence for Contraceptive Options and HIV Outcomes Study Experience of Integrating Oral Pre-exposure HIV Prophylaxis in Family Planning Services in Lusaka, Zambia. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	4
1899	Pre-exposure Prophylaxis (PrEP) Information on Instagram: Content Analysis. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e23876.	1.2	15
1900	Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation, Retention and Adherence. <i>AIDS and Behavior</i> , 2022, 26, 205-217.	1.4	30

#	ARTICLE	IF	CITATIONS
1901	The Community PrEP Study: a randomized control trial leveraging community-based platforms to improve access and adherence to pre-exposure prophylaxis to prevent HIV among adolescent girls and young women in South Africaâ€”study protocol. <i>Trials</i> , 2021, 22, 489.	0.7	14
1902	Qualitative Assessment of Barriers and Facilitators of PrEP Use Before and After Rollout of a PrEP Program for Priority Populations in South-central Uganda. <i>AIDS and Behavior</i> , 2021, 25, 3547-3562.	1.4	18
1903	Longitudinal pre-exposure prophylaxis (PrEP) acceptability, initiation and adherence among criminal justice-involved adults in the USA: the Southern PrEP Cohort Study (SPECS) protocol. <i>BMJ Open</i> , 2021, 11, e047340.	0.8	6
1904	â€œShades of riskâ€: Understanding current PrEP usersâ€™ sexually transmitted infection perceptions. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-6.	0.6	2
1905	Loss to Follow-Up and Re-Engagement in HIV Pre-Exposure Prophylaxis Care in the United States, 2013â€“2019. <i>AIDS Patient Care and STDs</i> , 2021, 35, 271-277.	1.1	13
1907	The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couplesâ€™ perspectives and use of pre-exposure prophylaxis (PrEP). <i>BMJ Open</i> , 2021, 11, e048993.	0.8	3
1908	Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2675-2680.	1.3	6
1909	Sexually Transmitted Infections Treatment Guidelines, 2021. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-187.	26.7	841
1910	A cross-sectional survey of general practitioner knowledge, attitudes, and clinical experience of HIV PrEP. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 0, , 1.	0.8	0
1911	Willingness to use HIV pre-exposure prophylaxis and associated factors among men who have sex with men in Liuzhou, China. <i>AIDS Research and Therapy</i> , 2021, 18, 46.	0.7	10
1912	Factors associated with PrEP adherence among MSM living in Jackson, Mississippi. <i>Journal of HIV/AIDS and Social Services</i> , 2021, 20, 246-261.	0.7	6
1913	Safety Assessment of Microbicide 2P23 on the Rectal and Vaginal Microbiota and Its Antiviral Activity on HIV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 702172.	2.2	2
1914	Pills, Injections, Rings, or Implants? PrEP Formulation Preferences of PrEP-Experienced African Women for HIV Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, e30-e32.	0.9	9
1915	Reaching Those Most at Risk for HIV Acquisition: Evaluating Racial/Ethnic Disparities in the Preexposure Prophylaxis Care Continuum in Baltimore City, Maryland. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1145-1153.	0.9	14
1916	Are men who have sex with men at higher risk for HIV in Latin America more aware of PrEP?. <i>PLoS ONE</i> , 2021, 16, e0255557.	1.1	7
1917	Trends in the Number and Characteristics of HIV Pre-Exposure Prophylaxis Providers in the United States, 2014â€“2019. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 282-289.	0.9	13
1918	Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe. <i>Frontiers in Medicine</i> , 2021, 8, 722247.	1.2	2
1919	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359

#	ARTICLE	IF	CITATIONS
1920	Multipurpose Prevention Technologies: Opportunities and Challenges to Ensure Advancement of the Most Promising MPTs. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	14
1921	Forty years of AIDS: a retrospective and the way forward. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	8
1922	Preference for and Efficacy of a PrEP Decision Aid for Women with Substance Use Disorders. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1913-1927.	0.8	8
1923	An individually randomized controlled trial of a mother-daughter HIV/STI prevention program for adolescent girls and young women in South Africa: IMARA-SA study protocol. <i>BMC Public Health</i> , 2021, 21, 1708.	1.2	4
1924	Associations between antiretroviral therapy-related experiences and mental health status among people living with HIV in China: a prospective observational cohort study. <i>AIDS Research and Therapy</i> , 2021, 18, 60.	0.7	6
1925	Alcohol Use and the Risk of Communicable Diseases. <i>Nutrients</i> , 2021, 13, 3317.	1.7	23
1926	Non-therapeutic male circumcision in infancy or childhood and risk of human immunodeficiency virus and other sexually transmitted infections: national cohort study in Denmark. <i>European Journal of Epidemiology</i> , 2022, 37, 251-259.	2.5	9
1927	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. <i>Vaccines</i> , 2021, 9, 1001.	2.1	2
1928	Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE) Tj ETQq0 0.0,rgBT /Overlock 10	0.7	23
1929	Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 290-302.	1.3	47
1930	Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs. <i>HIV Medicine</i> , 2021, 22, 965-970.	1.0	11
1931	Studies on the prevalence of HIV/AIDS in Bangladesh including other developing countries. <i>Advances in Traditional Medicine</i> , 2023, 23, 647-658.	1.0	12
1932	Awareness, knowledge and comfort of pharmacy students on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV prevention. <i>Pharmacy Education</i> , 0, , 517-527.	0.2	2
1933	How Can We Support the Use of Oral PrEP Among Young Women who Sell Sex? A PrEP Cascade Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 45-56.	0.9	7
1934	What Will It Take to End HIV in the United States?. <i>Annals of Internal Medicine</i> , 2021, 174, 1542-1553.	2.0	12
1935	The spatiotemporal distribution of pre-exposure prophylaxis accessibility in the United States, 2016-2020. <i>Annals of Epidemiology</i> , 2021, 64, 102-110.	0.9	10
1936	Genital mucosal drug concentrations and anti-HIV activity in tenofovir-based PrEP products. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 87-97.	0.9	6
1937	Understanding issues around use of oral pre exposure prophylaxis among female sex workers in India. <i>BMC Infectious Diseases</i> , 2021, 21, 930.	1.3	10

#	ARTICLE	IF	CITATIONS
1938	Reddit on PrEP: Posts About Pre-exposure Prophylaxis for HIV from Reddit Users, 2014–2019. <i>AIDS and Behavior</i> , 2022, 26, 1084-1094.	1.4	6
1939	Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro. <i>Molecular Pharmacology</i> , 2021, 100, 588-596.	1.0	5
1940	Dealing with Dilemmas: Understanding the Process and Challenges of Disclosing the HIV Status of People Living with HIV/AIDS Through Gender Lens. <i>Journal of Health Management</i> , 2021, 23, 380-400.	0.4	1
1941	Improving quality of PrEP counseling for adolescent girls and young women in Kenya with standardized patient actors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 34-39.	0.9	6
1942	Awareness of and willingness to use HIV pre-exposure prophylaxis among community residents. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1957-1961.	1.5	2
1943	Long-acting drug delivery systems: applications for sexual and reproductive health. , 2022, , 163-202.		0
1944	An Unfinished History: A Story of Ongoing Events and Mutating HIV Problems. <i>Social Aspects of HIV</i> , 2021, , 289-302.	0.1	0
1945	“PrEP Is a Programme”: What Does this Mean for Policy. <i>Social Aspects of HIV</i> , 2021, , 21-34.	0.1	1
1946	A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use. <i>AIDS Patient Care and STDs</i> , 2021, 35, 23-30.	1.1	26
1947	Pre-Exposure Prophylaxis Training among Medical Schools in the United States. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110287.	1.0	5
1948	A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa. <i>BMC Health Services Research</i> , 2021, 21, 17.	0.9	13
1949	“I Just Decided to Stop”: Understanding PrEP Discontinuation Among Individuals Initiating PrEP in HIV Care Centers in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, e150-e158.	0.9	27
1950	Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV-Challenged Nonhuman Primates. <i>Advanced Therapeutics</i> , 2021, 4, 2000163.	1.6	28
1951	Beyond <sc>HIV</sc> prevention: everyday life priorities and demand for Pr<sc>EP</sc> among Ugandan <sc>HIV</sc> serodiscordant couples. <i>Journal of the International AIDS Society</i> , 2019, 22, e25225.	1.2	34
1952	Advances, Promises, and Challenges in HIV Prevention. , 2014, , 3-28.		1
1954	Adherence to HIV Treatment as Prevention and Preexposure Prophylaxis. , 2014, , 69-108.		2
1955	Revolution or Evolution? What Can Approaches Based on the Use of Antiretroviral Drugs Contribute to HIV Prevention in Gay Communities in High-Income Countries?. , 2014, , 181-204.		3
1956	Authentic Community Engagement and Community-Based Participatory Research for Public Health and Medicine. , 2014, , 1-10.		4

#	ARTICLE	IF	CITATIONS
1957	Ethics and Research with Pregnant Women: Lessons from HIV/AIDS. Research Ethics Forum, 2016, , 227-246.	0.1	7
1958	Understanding the HIV/AIDS Epidemic in the United States—The Role of Syndemics in Shaping the Public’s Health. Social Disparities in Health and Health Care, 2016, , 1-17.	0.0	2
1959	The Social, Structural, and Clinical Context of HIV Prevention and Care for Black/African American and Hispanic Women/Latinas in the United States. Social Disparities in Health and Health Care, 2016, , 131-175.	0.0	3
1961	HIV Serodiscordant Couples and the Discourse of Normality: Reconciling the Biomedical and the Social in Porto Alegre, Brazil. Social Aspects of HIV, 2017, , 55-69.	0.1	5
1962	The Democratic Biopolitics of PrEP. Politologische Aufklärung - Konstruktivistische Perspektiven, 2019, , 121-153.	0.4	14
1963	The Influence of Relationship Dynamics and Sexual Agreements on Perceived Partner Support and Benefit of PrEP Use Among Same-Sex Male Couples in the U.S.. AIDS and Behavior, 2020, 24, 2169-2177.	1.4	14
1964	Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study. Prevention Science, 2017, 18, 737-747.	1.5	104
1965	Role of Social and Sexual Network Factors in PrEP Utilization Among YMSM and Transgender Women in Chicago. Prevention Science, 2019, 20, 1089-1097.	1.5	31
1966	Perfil de los nuevos diagnósticos de infección por VIH y factores de riesgo asociados al diagnóstico tardío en una consulta especializada durante el periodo 2014-2018. Medicina Clínica, 2020, 155, 482-487.	0.3	4
1967	Geospatial perspectives on health: The PrEP4Love campaign and the role of local context in health promotion messaging. Social Science and Medicine, 2020, 265, 113497.	1.8	10
1968	Global PrEP roll-out: recommendations for programmatic success. Lancet HIV,the, 2019, 6, e137-e140.	2.1	66
1969	Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. Lancet HIV,the, 2020, 7, e721-e730.	2.1	38
1970	How to beat HIV. Nature, 2015, 523, 146-148.	18.7	5
1971	Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. Chemical Biology, 2017, , 300-357.	0.1	4
1972	Early experience of implementing a national HIV pre-exposure prophylaxis service in Wales, United Kingdom 2017. Sexual Health, 2019, 16, 56.	0.4	7
1973	Social and behavioural research prospects for sexually transmissible infection prevention in the era of advances in biomedical approaches. Sexual Health, 2020, 17, 103.	0.4	4
1974	Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opinion on Drug Safety, 2017, 16, 867-871.	1.0	14
1975	Long-term follow-up of HIV seroconverters in microbicide trials — rationale, study design, and challenges in MTN-015. HIV Clinical Trials, 2016, 17, 204-211.	2.0	7



#	ARTICLE	IF	CITATIONS
1976	Differing Experiences with Pre-Exposure Prophylaxis in Boston Among Lesbian, Gay, Bisexual, and Transgender Specialists and Generalists in Primary Care: Implications for Scale-Up. <i>AIDS Patient Care and STDs</i> , 2017, 31, 297-304.	1.1	39
1977	Numerical optimal control for HIV prevention with dynamic budget allocation. <i>Mathematical Medicine and Biology</i> , 2018, 35, 469-491.	0.8	7
1978	Attitudes Among Men and Women Regarding Pre-exposure Prophylaxis to Prevent HIV Acquisition in an Urban HIV-Prevalent Setting in the United States. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.4	2
1979	Barriers to the uptake of postexposure prophylaxis among Nairobi-based female sex workers. <i>Aids</i> , 2016, 30, 99-103.	1.0	4
1980	Brief Report: Bacterial Vaginosis and Risk of HIV Infection in the Context of CD101 Gene Variation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 584-587.	0.9	2
1989	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <i>JCI Insight</i> , 2017, 2, .	2.3	11
1990	Challenges in optimizing preexposure prophylaxis development, engagement, and access for HIV prevention. <i>Journal of Clinical Investigation</i> , 2019, 129, 5071-5073.	3.9	2
1991	ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions. <i>Journal of Clinical Investigation</i> , 2016, 126, 892-904.	3.9	30
1992	Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016â€“June 2018. <i>Public Health Reports</i> , 2020, 135, 202-210.	1.3	17
1993	- Microbicide Formulation Development: Scale-Up, Affordability, and Intellectual Property Issues. , 2014, , 558-571.		7
1994	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. <i>Gates Open Research</i> , 2017, 1, 3.	2.0	71
1995	Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa. <i>Gates Open Research</i> , 2017, 1, 3.	2.0	75
1996	Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. <i>Gates Open Research</i> , 0, 3, 1504.	2.0	15
1997	Community Inclusion in PrEP Demonstration Projects: Lessons for Scaling Up. <i>Gates Open Research</i> , 2019, 3, 1504.	2.0	17
1998	Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. <i>Gates Open Research</i> , 2020, 4, 29.	2.0	16
1999	Evaluation of a behavior-centered design strategy for creating demand for oral PrEP among young women in Cape Town, South Africa. <i>Gates Open Research</i> , 2020, 4, 29.	2.0	14
2000	The Incidence Patterns Model to Estimate the Distribution of New HIV Infections in Sub-Saharan Africa: Development and Validation of a Mathematical Model. <i>PLoS Medicine</i> , 2016, 13, e1002121.	3.9	16
2001	Implementation science and the Health Resources and Services Administrationâ€™s Ryan White HIV/AIDS Programâ€™s work towards ending the HIV epidemic in the United States. <i>PLoS Medicine</i> , 2020, 17, e1003128.	3.9	16

#	ARTICLE	IF	CITATIONS
2002	Universal Access to HIV Treatment versus Universal â€˜Test and Treatâ€™: Transmission, Drug Resistance & Treatment Costs. PLoS ONE, 2012, 7, e41212.	1.1	49
2003	Ambiguity, Ambivalence, and Apprehensions of Taking HIV-1 Pre-Exposure Prophylaxis among Male Couples in San Francisco: A Mixed Methods Study. PLoS ONE, 2012, 7, e50061.	1.1	79
2004	Understanding the Potential Impact of a Combination HIV Prevention Intervention in a Hyper-Endemic Community. PLoS ONE, 2013, 8, e54575.	1.1	36
2005	MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments. PLoS ONE, 2013, 8, e55013.	1.1	174
2006	Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice. PLoS ONE, 2013, 8, e60024.	1.1	54
2007	Incidence and Predictors of Pregnancy among a Cohort of HIV-Positive Women Initiating Antiretroviral Therapy in Mbarara, Uganda. PLoS ONE, 2013, 8, e63411.	1.1	51
2008	Estradiol Regulation of Nucleotidases in Female Reproductive Tract Epithelial Cells and Fibroblasts. PLoS ONE, 2013, 8, e69854.	1.1	21
2009	Population-Level Benefits from Providing Effective HIV Prevention Means to Pregnant Women in High Prevalence Settings. PLoS ONE, 2013, 8, e73770.	1.1	6
2010	Global Expression of Molecular Transporters in the Human Vaginal Tract: Implications for HIV Chemoprophylaxis. PLoS ONE, 2013, 8, e77340.	1.1	14
2011	Analytic Review of Modeling Studies of ARV Based PrEP Interventions Reveals Strong Influence of Drug-Resistance Assumptions on the Population-Level Effectiveness. PLoS ONE, 2013, 8, e80927.	1.1	12
2012	No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. PLoS ONE, 2013, 8, e81997.	1.1	193
2013	How Much Demand for New HIV Prevention Technologies Can We Really Expect? Results from a Discrete Choice Experiment in South Africa. PLoS ONE, 2013, 8, e83193.	1.1	53
2014	Womenâ€™s Experiences with Oral and Vaginal Pre-Exposure Prophylaxis: The VOICE-C Qualitative Study in Johannesburg, South Africa. PLoS ONE, 2014, 9, e89118.	1.1	228
2015	Bone Mineral Density Changes among HIV-Uninfected Young Adults in a Randomised Trial of Pre-Exposure Prophylaxis with Tenofovir-Emtricitabine or Placebo in Botswana. PLoS ONE, 2014, 9, e90111.	1.1	69
2016	Risk Behaviors and Risk Factors for HIV Infection among Participants in the Bangkok Tenofovir Study, an HIV Pre-Exposure Prophylaxis Trial among People Who Inject Drugs. PLoS ONE, 2014, 9, e92809.	1.1	21
2017	Trends in Condom Use and Risk Behaviours after Sexual Exposure to HIV: A Seven-Year Observational Study. PLoS ONE, 2014, 9, e104350.	1.1	13
2018	The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa. PLoS ONE, 2014, 9, e106410.	1.1	11
2019	Estimating the Cost-Effectiveness of Pre-Exposure Prophylaxis to Reduce HIV-1 and HSV-2 Incidence in HIV-Serodiscordant Couples in South Africa. PLoS ONE, 2015, 10, e0115511.	1.1	17

#	ARTICLE	IF	CITATIONS
2020	Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection. PLoS ONE, 2016, 11, e0143109.	1.1	51
2021	Knowledge, Attitudes, and Acceptability of Pre-Exposure Prophylaxis among Individuals Living with HIV in an Urban HIV Clinic. PLoS ONE, 2016, 11, e0145670.	1.1	22
2022	Correlates of HIV Testing Experience among Migrant Workers from Myanmar Residing in Thailand: A Secondary Data Analysis. PLoS ONE, 2016, 11, e0154669.	1.1	14
2023	What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach. PLoS ONE, 2016, 11, e0154893.	1.1	163
2024	PEP and TasP Awareness among Italian MSM, PLWHA, and High-Risk Heterosexuals and Demographic, Behavioral, and Social Correlates. PLoS ONE, 2016, 11, e0157339.	1.1	32
2025	How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS ONE, 2016, 11, e0158620.	1.1	19
2026	Prioritizing Risk in Preparation for a Demonstration Project: A Mixed Methods Feasibility Study of Oral Pre-Exposure Prophylaxis (PrEP) among Female Sex Workers in South India. PLoS ONE, 2016, 11, e0166889.	1.1	28
2027	Implementation and assessment of a prevention with positives intervention among people living with HIV at five hospitals in Thailand. PLoS ONE, 2017, 12, e0170558.	1.1	2
2028	Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS ONE, 2017, 12, e0172354.	1.1	160
2029	Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation. PLoS ONE, 2017, 12, e0173057.	1.1	24
2030	An intravaginal ring for real-time evaluation of adherence to therapy. PLoS ONE, 2017, 12, e0174729.	1.1	5
2031	The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya. PLoS ONE, 2017, 12, e0175447.	1.1	17
2032	HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS ONE, 2017, 12, e0178594.	1.1	4
2033	Beyond HIV-serodiscordance: Partnership communication dynamics that affect engagement in safer conception care. PLoS ONE, 2017, 12, e0183131.	1.1	20
2034	Improving retention in HIV care among adolescents and adults in low- and middle-income countries: A systematic review of the literature. PLoS ONE, 2017, 12, e0184879.	1.1	108
2035	Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China. PLoS ONE, 2018, 13, e0191671.	1.1	40
2036	“You can’t have a PrEP program without a PrEP Coordinator” Implementation of a PrEP panel management intervention. PLoS ONE, 2020, 15, e0240745.	1.1	14
2037	PrEP discontinuation among Latino/a and Black MSM and transgender women: A need for PrEP support services. PLoS ONE, 2020, 15, e0241340.	1.1	35

#	ARTICLE	IF	CITATIONS
2038	Longitudinal trends in PrEP familiarity, attitudes, use and discontinuation among a national probability sample of gay and bisexual men, 2016â€“2018. PLoS ONE, 2020, 15, e0244448.	1.1	20
2039	Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision. PLoS ONE, 2020, 15, e0244761.	1.1	10
2040	Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathogens, 2015, 11, e1005075.	2.1	60
2041	Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1. PLoS Pathogens, 2017, 13, e1006703.	2.1	16
2042	Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B. Journal of Clinical and Translational Hepatology, 2013, 1, 33-8.	0.7	10
2043	Tackling the social and structural drivers of HIV in Canada. Canada Communicable Disease Report, 2015, 41, 322-326.	0.6	4
2044	Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition â€” United States, 2015. Morbidity and Mortality Weekly Report, 2015, 64, 1291-1295.	9.0	293
2045	Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020. MMWR Recommendations and Reports, 2020, 69, 1-12.	26.7	56
2046	Major Infectious Diseases: Key Messages from Disease Control Priorities, Third Edition. , 2017, , 1-27.		28
2047	Sexually Transmitted Infections: Impact and Cost-Effectiveness of Prevention. , 2017, , 203-232.		26
2048	HIV Care Continuum in Adults and Children: Cost-Effectiveness Considerations. , 2017, , 67-90.		1
2049	Cost-Effectiveness of Interventions to Prevent HIV Acquisition. , 2017, , 137-155.		8
2050	Tailoring the Local HIV/AIDS Response to Local HIV/AIDS Epidemics. , 2017, , 157-178.		6
2051	Updating the management of sexually transmitted infections. Australian Prescriber, 2015, 38, 204-208.	0.5	3
2052	Missed Signals: Not Investigating High HIV Incidence in Pregnant Women in Africa. SSRN Electronic Journal, 0, , .	0.4	2
2053	Global Efforts against HIV Epidemic and HIV Vaccine Development. Tropical Medicine and Health, 2014, 42, S91-S92.	1.0	3
2054	Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate Vaccines in Three Vehicles. Current Drug Delivery, 2020, 17, 387-395.	0.8	12
2055	Why Do We Need New Drug Classes for HIV Treatment and Prevention?. Current Topics in Medicinal Chemistry, 2016, 16, 1343-1349.	1.0	19

#	ARTICLE	IF	CITATIONS
2056	Social Justice and HIV Vaccine Research in the Age of Pre-Exposure Prophylaxis and Treatment as Prevention. <i>Current HIV Research</i> , 2014, 11, 473-480.	0.2	9
2057	University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development. <i>JMIR Research Protocols</i> , 2018, 7, e10365.	0.5	40
2058	Smartphone-Based Contingency Management Intervention to Improve Pre-Exposure Prophylaxis Adherence: Pilot Trial. <i>JMIR MHealth and UHealth</i> , 2018, 6, e10456.	1.8	43
2059	Empowering With PrEP (E-PrEP), a Peer-Led Social Media-Based Intervention to Facilitate HIV Preexposure Prophylaxis Adoption Among Young Black and Latinx Gay and Bisexual Men: Protocol for a Cluster Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11375.	0.5	65
2060	Quality of HIV Websites With Information About Pre-Exposure Prophylaxis or Treatment as Prevention for Men Who Have Sex With Men: Systematic Evaluation. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e11384.	1.2	5
2061	Spatial Access and Willingness to Use Pre-Exposure Prophylaxis Among Black/African American Individuals in the United States: Cross-Sectional Survey. <i>JMIR Public Health and Surveillance</i> , 2019, 5, e12405.	1.2	33
2062	Pre-Exposure Prophylaxis Integration into Family Planning Services at Title X Clinics in the Southeastern United States: A Geographically-Targeted Mixed Methods Study (Phase 1 ATN 155). <i>JMIR Research Protocols</i> , 2019, 8, e12774.	0.5	13
2063	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15029.	0.5	14
2064	A Web-Based Intervention to Reduce Decision Conflict Regarding HIV Pre-Exposure Prophylaxis: Protocol for a Clinical Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15080.	0.5	8
2065	Protocol Development for HMU! (HIV Prevention for Methamphetamine Users), a Study of Peer Navigation and Text Messaging to Promote Pre-Exposure Prophylaxis Adherence and Persistence Among People Who Use Methamphetamine: Qualitative Focus Group and Interview Study. <i>JMIR Formative Research</i> , 2020, 4, e18118.	0.7	5
2066	A Mobile Gaming Intervention for Persons on Pre-Exposure Prophylaxis: Protocol for Intervention Development and Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e18640.	0.5	8
2067	Mobile App (UPrEPU) to Monitor Adherence to Pre-exposure Prophylaxis in Men Who Have Sex With Men: Protocol for a User-Centered Approach to Mobile App Design and Development. <i>JMIR Research Protocols</i> , 2020, 9, e20360.	0.5	9
2068	A Simple Pre-Exposure Prophylaxis (PrEP) Optimization Intervention for Health Care Providers Prescribing PrEP: Pilot Study. <i>JMIR Formative Research</i> , 2018, 2, e2.	0.7	19
2069	Preexposure Prophylaxis Modality Preferences Among Men Who Have Sex With Men and Use Social Media in the United States. <i>Journal of Medical Internet Research</i> , 2016, 18, e111.	2.1	27
2071	Pre-Exposure Prophylaxis YouTube Videos: Content Evaluation. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e19.	1.2	19
2072	Functional Knowledge of Pre-Exposure Prophylaxis for HIV Prevention Among Participants in a Web-Based Survey of Sexually Active Gay, Bisexual, and Other Men Who Have Sex With Men: Cross-Sectional Study. <i>JMIR Public Health and Surveillance</i> , 2018, 4, e13.	1.2	21
2073	Gender-Specific Combination HIV Prevention for Youth in High-Burden Settings: The MP3 Youth Observational Pilot Study Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e22.	0.5	8
2074	Rilpivirine: The Key for Long-term Success. <i>AIDS Reviews</i> , 2017, 19, .	0.5	7

#	ARTICLE	IF	CITATIONS
2076	Pre-exposure Prophylaxis as HIV Prevention in High Risk Adolescents. <i>Journal of Pediatrics and Pediatric Medicine</i> , 2018, 2, 5-10.	0.9	5
2077	A Review of Pre-Exposure Prophylaxis Adherence among Female Sex Workers. <i>Yonsei Medical Journal</i> , 2020, 61, 349.	0.9	17
2078	“What if They Are Pre-conception? What Should We Do?” Knowledge, Practices, and Preferences for Safer Conception Among Women Living With HIV and Healthcare Providers in Gaborone, Botswana. <i>Frontiers in Global Women S Health</i> , 2020, 1, .	1.1	6
2079	The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis. <i>Antiviral Therapy</i> , 2020, 25, 21-32.	0.6	26
2080	An exact approach to calibrating infectious disease models to surveillance data: The case of HIV and HSV-2. <i>Mathematical Biosciences and Engineering</i> , 2017, 15, 153-179.	1.0	3
2081	Empirical Treatment and Prevention of COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 142.	1.0	18
2082	Imaging endocervical mucus anatomy and dynamics in macaque female reproductive track using optical coherence tomography. <i>Quantitative Imaging in Medicine and Surgery</i> , 2015, 5, 40-5.	1.1	3
2083	Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. <i>Southern African Journal of HIV Medicine</i> , 2016, 17, 455.	0.3	77
2084	Antiretroviral pre-exposure prophylaxis: A new opportunity to slow HIV spread in India. <i>Indian Journal of Medical Research</i> , 2016, 143, 125.	0.4	7
2085	Pre- and post-sexual exposure prophylaxis of HIV: An update. <i>Indian Journal of Sexually Transmitted Diseases and AIDS</i> , 2017, 38, 1.	0.6	11
2086	Microvascular Endothelial Dysfunction and Enhanced Thromboxane and Endothelial Contractility in Patients with HIV. <i>Journal of AIDS &amp; Clinical Research</i> , 2013, 04, 267.	0.5	17
2087	Adherence to Antiretroviral Therapy for the Success of Emerging Interventions to Prevent HIV Transmission: A Wake up Call. <i>Journal of AIDS &amp; Clinical Research</i> , 2012, 01, .	0.5	7
2088	The Role of the Pharmacist in Pre-Exposure Prophylaxis. <i>Pharmacology &amp; Pharmacy</i> , 2014, 05, 225-228.	0.2	5
2089	Prevalence and Incidence of HIV Infection among Fishermen along Lake Victoria Beaches in Kisumu County, Kenya. <i>World Journal of AIDS</i> , 2014, 04, 219-231.	0.1	7
2090	Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana. <i>World Journal of AIDS</i> , 2015, 05, 10-20.	0.1	17
2091	Asking about adherence “from flipping the coin to strong evidence. <i>Swiss Medical Weekly</i> , 2014, 144, w14016.	0.8	8
2092	Barriers and Facilitators of Adherence in User-Dependent HIV Prevention Trials, a Systematic Review. <i>International STD Research &amp; Reviews</i> , 2013, 1, 12-29.	0.2	9
2093	Transitions Between Preexposure Prophylaxis Eligibility States and HIV Infection in The Lisbon Cohort of HIV-Negative Men Who Have Sex with Men: a Multistate Model Analysis. <i>American Journal of Epidemiology</i> , 2021, , .	1.6	1



#	ARTICLE	IF	CITATIONS
2094	Adherence to oral HIV pre-exposure prophylaxis among female sex workers in Kampala, Uganda. <i>African Health Sciences</i> , 2021, 21, 1048-1058.	0.3	6
2095	Assemblages of excess and pleasures: The sociosexual uses of online and chemical technologies among men who have sex with men. <i>Nursing Philosophy</i> , 2021, , e12370.	0.9	1
2096	Long-term HIV Pre-exposure Prophylaxis Trajectories Among Racial & Ethnic Minority Patients: Short, Declining, & Sustained Adherence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 166-171.	0.9	4
2097	HIV PrEP is more than ART: Longitudinal study of real-world PrEP services data identifies missing measures meaningful to HIV prevention programming. <i>Journal of the International AIDS Society</i> , 2021, 24, e25827.	1.2	12
2098	HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. <i>Nature Reviews Urology</i> , 2022, 19, 7-15.	1.9	6
2099	Metrics of HIV Pre-exposure Prophylaxis (PrEP) Implementation Before and After a Multidisciplinary Task Force at an Academic Institution. <i>Quality Management in Health Care</i> , 2021, Publish Ahead of Print, .	0.4	1
2100	Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1712-1717.	15.2	43
2101	Provider Comfort with Prescribing HIV Pre-Exposure Prophylaxis to Adolescents. <i>AIDS Patient Care and STDs</i> , 2021, 35, 411-417.	1.1	22
2102	Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. <i>AIDS Patient Care and STDs</i> , 2021, 35, 419-427.	1.1	6
2103	Pre-Exposure Prophylaxis (PrEP) Adherence Questionnaire: Psychometric Validation among Sexually Transmitted Infection Patients in China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10980.	1.2	2
2104	Limited risk compensation among women who inject drugs. <i>Sexually Transmitted Diseases</i> , 2021, Publish Ahead of Print, .	0.8	0
2105	Pre-exposure prophylaxis failure with a multiple drug-resistant HIV-1 clade C virus in Brazil. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	0.9	0
2106	Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones. <i>Journal of Controlled Release</i> , 2021, 340, 188-199.	4.8	19
2107	Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the U.S.. <i>American Journal of Preventive Medicine</i> , 2021, 61, S73-S86.	1.6	31
2108	Academic Detailing to Increase Prescribing of HIV Pre-exposure Prophylaxis. <i>American Journal of Preventive Medicine</i> , 2021, 61, S87-S97.	1.6	4
2109	Toward Greater Pre-exposure Prophylaxis Equity: Increasing Provision and Uptake for Black and Hispanic/Latino Individuals in the U.S.. <i>American Journal of Preventive Medicine</i> , 2021, 61, S60-S72.	1.6	42
2110	Knowledge of HIV and HIV pre-exposure prophylaxis among medical and pharmacy students: A national, multi-site, cross-sectional study. <i>Preventive Medicine Reports</i> , 2021, 24, 101590.	0.8	6
2111	The Awareness Framework: A Novel Approach for Understanding HIV Testing and Disclosure in HIV-discordant Dyads. <i>Journal of Antivirals &amp; Antiretrovirals</i> , 2012, 05, 008011.	0.1	2

#	ARTICLE	IF	CITATIONS
2112	HIV Pre-exposure Prophylaxis: Clinical Implications and Real-World Effectiveness. Journal of AIDS & Clinical Research, 2012, 03, .	0.5	0
2113	Infectious Causes of Malignancy and Their Potential Prevention. Infections Journal, 2013, 1, 1-6.	0.0	1
2115	Un d'Épistage Élargi et une prise en charge thérapeutique précoce. Bulletin De L'Academie Nationale De Medecine, 2013, 197, 1157-1175.	0.0	0
2116	Implementing Biomedical HIV Prevention Advances in Thailand. , 2014, , 235-250.		0
2117	Risk Compensation in Response to HIV Prevention. , 2014, , 109-137.		0
2122	HIV Infection among Transgender Women: Challenges and Opportunities. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	0
2124	Bringing new HIV infections to zero “ opportunities and challenges offered by antiretroviral-based prevention in Asia, the Pacific and beyond: An overview of this special issue. Sexual Health, 2014, 11, 97.	0.4	0
2125	Taming the Monster: Need for Africa-initiated, Africa-led HIV Vaccine Research and Development Advocacy in Africa. Journal of Vaccines & Vaccination, 2014, 05, .	0.3	0
2126	Anger Management During Adulthood. , 2014, , 1585-1596.		0
2127	Using DHS to Identify Sites for HIV Prevention Trials. Etude De La Population Africaine, 2014, 28, 904.	0.2	0
2128	HIV Transmission Models: Lessons Learned for Microbicide Formulation Design. , 2014, , 55-89.		0
2129	Baseline Clinical Profile of a “Normal Population” of HIV Exposed Sero-Negative (HESN) Partners May Impact HIV Biomedical Prevention Studies Negatively. World Journal of AIDS, 2015, 05, 299-307.	0.1	0
2130	Epidemiology and Prevention of Acquired Immunodeficiency Syndrome and Human Immunodeficiency Virus Infection. , 2015, , 1483-1502.e8.		5
2131	Transgender Identity and Sexually Transmitted Diseases Including HIV. , 2015, , 337-344.		0
2132	Preexposure Prophylaxis (PrEP). , 2015, , 1-10.		0
2133	9. African-American Women and HIV: Clinical Considerations. , 2015, , .		0
2134	Rapid Antiretroviral Therapy Initiation for Women in an HIV-1 Prevention Clinical Trial Experiencing Primary HIV-1 Infection during Pregnancy or Breastfeeding. PLoS ONE, 2015, 10, e0140773.	1.1	3
2135	The Impact of Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) on Male and Female Fertility. , 2016, , 1-30.		0

#	ARTICLE	IF	CITATIONS
2136	Evaluating Published CER Evidence. , 2016, , 37-51.		0
2137	Laboratory Safety During Assisted Reproduction in Patients with a Bloodborne Virus. , 2016, , 157-178.		0
2138	HIV AND AIDS IN PREGNANCY. Acta Medica Medianae, 2016, 55, 85-91.	0.0	0
2139	Introduction: Making "Difference" New Perspectives on HIV Serodiscordance. Social Aspects of HIV, 2017, , 1-12.	0.1	0
2141	HIV"Medical Perspective. , 2017, , 413-435.		0
2142	Prevention Clinical Trials: Highlights of Evidence and Research. , 2017, , 1-11.		0
2143	Trente annÃ©es d'Ã©volution dans la prise en charge des personnes vivant avec le virus de l'immunodÃ©ficience humaine dÃ©sirant devenir parents: un changement de paradigme. Bulletin De L'Academie Nationale De Medecine, 2017, 201, 281-296.	0.0	0
2145	Comprehensive Prevention with HIV Positive Gay Men. , 2017, , 121-149.		0
2147	HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials. , 2017, , 479-498.		0
2151	Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis. Journal of Nanotechnology and Materials Science, 2017, 4, 53-61.	0.1	2
2152	Not PrEPared to wait any longer: advocating for the use of PrEP in a HIV prevention strategy. Journal of Global Health Reports, 0, 1, .	1.0	0
2153	Optimal Resource Allocation for HIV Prevention and Control. , 2018, , 121-137.		0
2154	Preexposure Prophylaxis (PrEP). , 2018, , 1659-1667.		2
2155	Extensive Homeostatic T Cell Penotypic Variation Within the Collaborative Cross. SSRN Electronic Journal, 0, , .	0.4	1
2156	Prevention Clinical Trials: Highlights of Evidence and Research. , 2018, , 1713-1723.		0
2157	HIV-1 Preexposure Prophylaxis. , 2018, , 886-892.		0
2163	Disease Presentation, Recognition and Prevention. , 2019, , 3-63.		0
2164	Knowledge, Attitude and Practice of Healthcare Workers Towards Availability of Antiretroviral Pre-Exposure Prohylaxis in Nigeria. Journal of Clinical Research in HIV AIDS and Prevention, 2018, 3, 46-59.	0.1	3

#	ARTICLE	IF	CITATIONS
2165	HIV-Infektion – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung. The Springer Reference Pfliegerapie, Gesundheit, 2019, , 1-6.	0.2	0
2166	Development of a targeted educational intervention to increase pre-exposure prophylaxis uptake among cisgender men and transgender individuals who have sex with men and use methamphetamine in Seattle (WA, USA). Sexual Health, 2019, 16, 139-147.	0.4	14
2167	Perceptions of people who inject drugs towards HIV pre-exposure prophylaxis in Australia. Sexual Health, 2019, 16, 383.	0.4	0
2168	African Women and HIV and AIDS. , 2019, , 1-16.		0
2169	Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository. Gates Open Research, 2019, 3, 1511.	2.0	1
2171	Efficacy, Adherence and Side Effects of PrEP for HIV-1 Prevention. International Journal of Biology, 2019, 11, 80.	0.1	4
2173	Community Members' Pre-exposure Prophylaxis Awareness, Attitudes, and Trusted Sources for PrEP Information and Provision, Context Matters Survey, 2015–2016. AIDS Education and Prevention, 2020, 32, 102-S6.	0.6	3
2175	Network Analysis of Organizations Providing HIV Services in Chicago. Journal of Public Health Management and Practice, 2020, Publish Ahead of Print, .	0.7	1
2176	Knowledge and Clinical Uptake of HIV Pre-exposure Prophylaxis by Internal Medicine Residents at a Teaching Hospital in the Southern United States. American Journal of Therapeutics, 2020, Publish Ahead of Print, e806-e807.	0.5	0
2177	Understanding of Perceived Infectiousness and Its Influence on Sexual Behavior Among Individuals With Acute HIV Infection in Lilongwe, Malawi (HPTN 062). AIDS Education and Prevention, 2020, 32, 260-270.	0.6	2
2178	Women Are Less Likely to Be Tested for HIV or Offered Preexposure Prophylaxis at the Time of Sexually Transmitted Infection Diagnosis. Sexually Transmitted Diseases, 2021, 48, 32-36.	0.8	14
2180	Structural, Dosing, and Risk Change Factors Affecting Discontinuation of Pre-exposure Prophylaxis (PrEP) in a Large Urban Clinic. AIDS Education and Prevention, 2020, 32, 271-S13.	0.6	1
2181	HIV and Immigrants from Sub-Saharan Africa and the Caribbean Living in the United States. , 2021, , 111-133.		1
2182	Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research. Current HIV/AIDS Reports, 2021, 18, 490-499.	1.1	13
2183	Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial. AIDS and Behavior, 2022, 26, 1597-1606.	1.4	6
2184	Sexually Transmitted Infections and Sexual Healthcare of Homeless and Street-Involved Youth. , 2020, , 243-270.		1
2185	Modelling the effect of market forces on the impact of introducing human immunodeficiency virus pre-exposure prophylaxis among female sex workers. Health Economics (United Kingdom), 2021, 30, 659-679.	0.8	1
2186	“I did not know about all these” Perceptions regarding safer conception methods by women living with HIV in Gaborone, Botswana. PLoS ONE, 2020, 15, e0242992.	1.1	1

#	ARTICLE	IF	CITATIONS
2188	Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020. Southern African Journal of HIV Medicine, 2020, 21, 1152.	0.3	21
2189	African Women and HIV and AIDS. , 2021, , 2323-2338.		0
2190	Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: A feasibility study. PLoS ONE, 2020, 15, e0224874.	1.1	4
2191	Real-life occurrence of bacterial sexually transmitted infections among PrEP users: improving the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae with multisite screening. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2021, 63, e76.	0.5	1
2193	HIV and Other Sexually Transmitted Infections. , 2020, , 127-139.		0
2194	HIV Prevalence, Risk Factors for Infection, and Uptake of Prevention, Testing, and Treatment among Female Sex Workers in Namibia. Journal of Epidemiology and Global Health, 2020, 10, 351.	1.1	8
2195	Prevention of HIV Infection. , 2020, , 1-29.		0
2197	The dynamics of a simple, risk-structured HIV model. Mathematical Biosciences and Engineering, 2020, 17, 4184-4209.	1.0	1
2201	An Experimental Study of the Effects of Patient Race, Sexual Orientation, and Injection Drug Use on Providers' PrEP-Related Clinical Judgments. AIDS and Behavior, 2022, 26, 1393-1421.	1.4	13
2202	A SWOT Analysis of the Guidelines on Prevention of HIV/AIDS in Japan in the Context of COVID-19. Infectious Disease Reports, 2021, 13, 949-956.	1.5	1
2204	Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study. BMC Public Health, 2021, 21, 2041.	1.2	6
2206	Men's hard for us men to go to the clinic. We naturally have a fear of hospitals. Men's risk perceptions, experiences and program preferences for PrEP: A mixed methods study in Eswatini. PLoS ONE, 2020, 15, e0237427.	1.1	11
2208	Using developmental evaluation to implement an oral pre-exposure prophylaxis (PrEP) project in Kenya. Gates Open Research, 0, 4, 158.	2.0	0
2210	Incorporating Preexposure Prophylaxis Into Routine Reproductive Health Care. Obstetrics and Gynecology, 2020, 136, 1080-1082.	1.2	3
2211	Don't think everybody should take it if they're doing drugs, doing heroin, or having sex for money: a qualitative study exploring perceptions of pre-exposure prophylaxis among female participants in an opioid intervention court program. Substance Abuse Treatment, Prevention, and Policy, 2020, 15, 89.	1.0	4
2212	Preexposure prophylaxis strategies for African-American women affected by mass incarceration. Aids, 2021, 35, 453-462.	1.0	4
2213	From trials to the public health: pre-exposure prophylaxis for HIV prevention. Colombia Medica, 2013, 44, 64-5.	0.7	0
2216	Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users. Morbidity and Mortality Weekly Report, 2013, 62, 463-5.	9.0	67

#	ARTICLE	IF	CITATIONS
2217	The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers. <i>African Journal of Reproductive Health</i> , 2014, 18, 74-83.	1.1	26
2218	Evidence-based HIV/STD prevention intervention for black men who have sex with men. <i>MMWR Supplements</i> , 2014, 63, 21-7.	15.3	10
2219	The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. <i>Journal of Virus Eradication</i> , 2015, 1, 245-249.	0.3	7
2220	Is the HIV vaccine our best shot? - Why the answer to HIV prevention will be found in South Africa. , 2015, 2015, .		0
2221	Beyond the Pap Smear: Gender-responsive HIV Care for Women. <i>Yale Journal of Biology and Medicine</i> , 2016, 89, 193-203.	0.2	5
2222	Oral PrEP for HIV prevention.â€¢It works. <i>Journal of Virus Eradication</i> , 2015, 1, 168-72.	0.3	0
2223	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016, 2, 67-77.	0.3	2
2224	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-55.	0.3	33
2225	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. <i>Journal of Virus Eradication</i> , 2017, 3, 168-184.	0.3	24
2226	The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa. <i>Clinical Research in HIV/AIDS</i> , 2016, 3, .	0.0	1
2227	HIV Prevention: Opportunities and Challenges. <i>Topics in Antiviral Medicine</i> , 2017, 24, 123-126.	0.1	7
2228	Insights in Public Health: In What Ways are Hawaii's HIV Prevention Services Engaging Gay Male Couples and Using Technology?. <i>Hawai'i Journal of Medicine &amp; Public Health: A Journal of Asia Pacific Medicine &amp; Public Health</i> , 2018, 77, 38-45.	0.4	0
2229	Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recommendations and Reports</i> , 2015, 64, 1-137.	26.7	1,132
2230	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. <i>Journal of Virus Eradication</i> , 2018, 4, 143-159.	0.3	2
2231	Maximizing the Benefits of HIV Preexposure Prophylaxis. <i>Topics in Antiviral Medicine</i> , 2018, 25, 138-142.	0.1	22
2232	Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018. <i>Journal of Virus Eradication</i> , 2018, 4, 143-159.	0.3	15
2233	Pre-exposure Prophylaxis as HIV Prevention in High Risk Adolescents. , 2018, 2, 5-10.		3
2234	HIV preexposure prophylaxis in the real world. <i>Topics in Antiviral Medicine</i> , 2014, 22, 670-5.	0.1	0



#	ARTICLE	IF	CITATIONS
2235	CROI 2013: New tools to understand transmission dynamics and prevent HIV infections. Topics in Antiviral Medicine, 2013, 21, 47-61.	0.1	1
2236	HIV prevention: integrating biomedical and behavioral interventions. Topics in Antiviral Medicine, 2014, 22, 702-6.	0.1	4
2238	Sexually Transmitted Infections in the Context of HIV Disease: Clinical Implications. Topics in Antiviral Medicine, 2016, 24, 111-114.	0.1	0
2239	Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation. Topics in Antiviral Medicine, 2015, 23, 85-90.	0.1	13
2240	Implementing a Pre-Exposure Prophylaxis Intervention for Safer Conception among HIV Serodiscordant Couples: Recommendations for Health Care Providers. Journal of Health Disparities Research and Practice, 2018, 11, 19-33.	1.1	3
2241	How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. Journal of Virus Eradication, 2018, 4, 215-224.	0.3	34
2242	Pre-exposure Prophylaxis in Primary Care--A New Era in HIV Prevention. Wisconsin Medical Journal, 2016, 115, 6-8.	0.3	2
2243	The impact of PrEP: results from a multicenter Health Technology Assessment into the Italian setting. Journal of Preventive Medicine and Hygiene, 2020, 61, E451-E463.	0.9	0
2244	The use of objective adherence measures targeting four placebo microbicide delivery forms in the Quatro Clinical Crossover Study. Clinical and Translational Discovery, 2021, 1, e13.	0.2	0
2245	A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Current Opinion in HIV and AIDS, 2022, 17, 22-31.	1.5	30
2246	HIV in Specific Populations. , 2022, , 349-390.		0
2247	HIV Testing and Prevention. , 2022, , 23-43.		0
2248	Sexually Transmitted Infections of the Colon and Rectum. , 2022, , 323-342.		0
2249	HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis. PLoS ONE, 2021, 16, e0259168.	1.1	10
2250	Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial. The Lancet Global Health, 2021, 9, e1730-e1739.	2.9	17
2251	A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in CÔte d'Ivoire: the ANRS 12381 PRINCESSE project. BMC Public Health, 2021, 21, 2214.	1.2	4
2252	Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project. AIDS Patient Care and STDs, 2021, 35, 481-487.	1.1	5
2253	Is tenofovir disoproxil fumarate associated with weight loss?. Aids, 2021, 35, S189-S195.	1.0	25

#	ARTICLE	IF	CITATIONS
2254	Sample size calculation for active-arm trial with counterfactual incidence based on recency assay. <i>Statistical Communications in Infectious Diseases</i> , 2021, 13, .	0.2	3
2255	Race and Sexual Identity Differences in PrEP Continuum Outcomes Among Latino Men in a Large Chicago Area Healthcare Network. <i>AIDS and Behavior</i> , 2022, 26, 1943-1955.	1.4	6
2256	A Primary Care Intervention to Increase HIV Pre-Exposure Prophylaxis (PrEP) Uptake in Patients with Syphilis. <i>Journal of the International Association of Providers of AIDS Care</i> , 2022, 21, 232595822110733.	0.6	5
2257	Association between the geographic accessibility of PrEP and PrEP use among MSM in nonurban areas. <i>Journal of Rural Health</i> , 2022, , .	1.6	9
2258	A REVIEW OF ANALYTICAL TECHNIQUES FOR DETERMINATION OF ANTI-HIV DRUGS. <i>International Journal of Applied Pharmaceutics</i> , 0, , 41-50.	0.3	2
2259	Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. <i>Nature</i> , 2022, 601, 612-616.	13.7	14
2261	Combining information to estimate adherence in studies of pre-exposure prophylaxis for HIV prevention: Application to HPTN 067. <i>Statistics in Medicine</i> , 2022, , .	0.8	0
2262	Women's preferences and acceptance for different drug delivery routes and products. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114133.	6.6	9
2263	HIV Pre-Exposure Prophylaxis (PrEP) in a Brazilian Clinical Setting: Adherence, Adverse Events, Sexual Behavior, and Sexually Transmitted Infections. <i>Archives of Sexual Behavior</i> , 2022, 51, 2603-2611.	1.2	3
2264	Acceptability of HIV pre-exposure prophylaxis in China: A systematic review and meta-analysis. <i>International Journal of STD and AIDS</i> , 2022, 33, 218-231.	0.5	5
2265	The influence of social relationships on PrEP attitudes among women with incarceration experience in the Southeastern USA. <i>Culture, Health and Sexuality</i> , 2023, 25, 110-125.	1.0	1
2266	Pre-Exposure Prophylaxis (PrEP) Initiation and Retention Among Young Kenyan Women. <i>AIDS and Behavior</i> , 2022, 26, 2376-2386.	1.4	6
2267	Design, adaptation, and diffusion of an innovative tool to promote shared contraceptive decision-making: Balanced Counseling Strategy Plus. <i>Gates Open Research</i> , 0, 6, 2.	2.0	1
2268	Feasibility and Acceptability of Home-Collected Samples for Human Immunodeficiency Virus Preexposure Prophylaxis and Severe Acute Respiratory Syndrome Coronavirus 2 Laboratory Tests in San Francisco Primary Care Clinics. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab657.	0.4	5
2269	Gendered behaviors, not identity: Attitudes and beliefs related to HIV risk and pre-exposure prophylaxis among transgender women in the Southeastern United States. <i>PLoS ONE</i> , 2022, 17, e0262205.	1.1	3
2270	Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 47-58.	2.4	4
2271	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. <i>Journal of Infectious Diseases</i> , 2022, 226, 510-520.	1.9	13
2272	Postpartum Mother-To-Child Transmission of HIV in a Breastfeeding Infant. <i>Pediatrics</i> , 2022, 149, .	1.0	0

#	ARTICLE	IF	CITATIONS
2273	Examining stigmatizing beliefs about PrEP use among Black sexual minority men: A test of explanatory mechanisms.. <i>Psychology of Men and Masculinity</i> , 2022, 23, 26-34.	1.0	1
2274	What makes an optimal delivery for PrEP against HIV: A qualitative study in MSM. <i>International Journal of STD and AIDS</i> , 2022, 33, 322-329.	0.5	4
2275	CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. <i>BMJ Open</i> , 2022, 12, e052880.	0.8	18
2276	Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap. <i>Lancet HIV</i> , 2022, 9, e214-e222.	2.1	19
2277	Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel. <i>PLoS ONE</i> , 2022, 17, e0261775.	1.1	19
2278	A pragmatic approach to identifying implementation barriers and facilitators for a novel pre-exposure prophylaxis (PrEP) delivery model at public facilities in urban Uganda. <i>Implementation Science Communications</i> , 2022, 3, 7.	0.8	8
2279	HIV prevention: better choice for better coverage. <i>Journal of the International AIDS Society</i> , 2022, 25, e25872.	1.2	18
2280	HIV disclosure and depressive symptoms among pregnant women living with HIV: a cross-sectional study in the Democratic Republic of Congo. <i>Journal of the International AIDS Society</i> , 2022, 25, e25865.	1.2	2
2281	Incremental costs of integrated PrEP provision and effective use counselling in community-based platforms for adolescent girls and young women in South Africa: an observational study. <i>Journal of the International AIDS Society</i> , 2022, 25, e25875.	1.2	8
2282	High-content analysis and Kinetic Image Cytometry identify toxicity and epigenetic effects of HIV antiretrovirals on human iPSC-neurons and primary neural precursor cells. <i>Journal of Pharmacological and Toxicological Methods</i> , 2022, 114, 107157.	0.3	8
2283	The impact of condom use on the HIV epidemic. <i>Gates Open Research</i> , 0, 5, 91.	2.0	5
2284	Cultivating PEARL (Promoting Empowerment and Risk Reduction): Formative Research for a PrEP Intervention Among Female Sex Workers in Baltimore, Maryland. <i>AIDS and Behavior</i> , 2022, 26, 2664-2675.	1.4	3
2285	Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches. <i>Materials Today Bio</i> , 2022, 13, 100217.	2.6	11
2286	In PrEP: Long-acting antivirals for HIV prevention. <i>Cell Host and Microbe</i> , 2022, 30, 148-150.	5.1	0
2287	Understanding PrEP Acceptability Among Priority Populations: Results from a Qualitative Study of Potential Users in Central Uganda. <i>AIDS and Behavior</i> , 2022, 26, 2676-2685.	1.4	9
2288	Mutations in muscle-type creatine kinase impact HIV prevention. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 165-167.	4.0	0
2289	Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project. <i>Journal of the International AIDS Society</i> , 2021, 24, e25846.	1.2	16
2290	Challenges and Opportunities for Preexposure Prophylaxis. <i>Topics in Antiviral Medicine</i> , 2021, 29, 399-406.	0.1	2

#	ARTICLE	IF	CITATIONS
2291	Ethics and pre-exposure prophylaxis (PrEP) in adolescents: an integrative review. <i>Jornal Brasileiro De DoenÇas Sexualmente TransmissÃveis</i> , 0, 33, .	0.1	0
2292	The Relative Cost-Effectiveness of Long-Acting Injectable Cabotegravir Versus Oral Pre-Exposure Prophylaxis: A Modelled Economic Evaluation and Threshold Analysis in South Africa Based on the HPTN 083 and 084 Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
2293	UK guideline for the use of HIV postâ€exposure prophylaxisÂ2021. <i>HIV Medicine</i> , 2022, 23, 494-545.	1.0	10
2294	Association of HIV Preexposure Prophylaxis Use With HIV Incidence Among Men Who Have Sex With Men in China. <i>JAMA Network Open</i> , 2022, 5, e2148782.	2.8	11
2295	Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	0.6	1
2296	Understanding Influences on Intention to Use Pre-exposure Prophylaxis (PrEP) Among African American Young Adults. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 899-910.	1.8	4
2297	High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 291-299.	0.9	3
2298	Prevalence and incidence of hepatitis C infection amongst men who have sex with men in a <scp>populationâ€based</scp> preâ€exposure prophylaxis program in British Columbia, Canada. <i>Liver International</i> , 2022, 42, 1528-1535.	1.9	3
2299	Crossâ€sectional trends in HIV prevalence among pregnant women in Botswana: an opportunity for PrEP?. <i>Journal of the International AIDS Society</i> , 2022, 25, e25892.	1.2	5
2300	In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2312-2321.	1.6	4
2301	Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis. <i>Wellcome Open Research</i> , 0, 7, 108.	0.9	0
2302	Technology-Based Interventions to Promote the HIV Preexposure Prophylaxis (PrEP) Care Continuum: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2022, 11, e33045.	0.5	1
2303	Using routine programmatic data to measure HIV incidence among pregnant women in Botswana. <i>Population Health Metrics</i> , 2022, 20, 10.	1.3	3
2304	Factors associated with willingness to use oral pre-exposure prophylaxis (PrEP) in a fisher-folk community in peri-urban Kampala, Uganda. <i>BMC Public Health</i> , 2022, 22, 468.	1.2	6
2306	Preferences for Long-Acting and Alternative Modalities for PrEP among Military Men Who Have Sex with Men: Segmentation Results of an Adaptive Choice-Based Conjoint Analysis Study. <i>Journal of Urban Health</i> , 2022, 99, 277-292.	1.8	2
2307	Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3674-3682.	1.1	10
2308	HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa. <i>AIDS and Behavior</i> , 2022, 26, 3099-3109.	1.4	7
2309	Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 390-395.	0.9	1

#	ARTICLE	IF	CITATIONS
2310	Real-world safety of pre-exposure prophylaxis for HIV. <i>Lancet HIV</i> , 2022, 9, e225-e226.	2.1	0
2311	Long-acting injections for HIV prevention among women in sub-Saharan Africa. <i>Lancet</i> , 2022, , .	6.3	1
2312	Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. <i>PLoS Computational Biology</i> , 2022, 18, e1010003.	1.5	8
2314	Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. <i>Lancet HIV</i> , 2022, 9, e242-e253.	2.1	13
2315	Optimizing HIV Prevention Efforts to Achieve EHE Incidence Targets. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 374-380.	0.9	5
2316	Understanding Retention in Pre-Exposure Prophylaxis Care in the South: Insights from an Academic HIV Prevention Clinic. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 306-312.	0.5	3
2318	Attitudes towards, knowledge about, and confidence to prescribe antiretroviral pre-exposure prophylaxis among healthcare providers in Thailand. <i>Medicine (United States)</i> , 2021, 100, e28120.	0.4	8
2319	<i>Mycobacterium tuberculosis</i> -Specific T-Cell Responses Are Impaired During Late Pregnancy With Elevated Biomarkers of Tuberculosis Risk Postpartum. <i>Journal of Infectious Diseases</i> , 2022, 225, 1663-1674.	1.9	6
2320	Integrating PrEP delivery in public health family planning clinics: a protocol for a pragmatic stepped wedge cluster randomized trial in Kenya. <i>Implementation Science Communications</i> , 2021, 2, 135.	0.8	5
2321	Relationship, partner factors and stigma are associated with safer conception information, motivation, and behavioral skills among women living with HIV in Botswana. <i>BMC Public Health</i> , 2021, 21, 2231.	1.2	2
2322	Implementing pre-exposure prophylaxis for HIV prevention in women: the role of the obstetrician-gynecologist. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 764-772.	0.7	2
2323	Feasibility, Acceptability, and Preliminary Efficacy of a Gamified Mobile Health Contingency Management Intervention for PrEP Adherence Among Black MSM. <i>AIDS and Behavior</i> , 2022, 26, 3311-3324.	1.4	3
2324	PrEP service delivery preferences of black Cis-gender women living in the Southern United States. <i>AIDS and Behavior</i> , 2022, 26, 3469-3479.	1.4	8
2325	Preexposure Prophylaxis Implementation in a Reproductive Health Setting: Perspectives From Planned Parenthood Providers and Leaders. <i>Health Promotion Practice</i> , 2023, 24, 764-775.	0.9	1
2327	Not PrEPared to wait any longer: advocating for the use of PrEP in a HIV prevention strategy. <i>Journal of Global Health Reports</i> , 0, , .	1.0	0
2333	Impact of pre-exposure and post-exposure prophylaxes prevention programme on HIV burden and services in a low-resource setting: a simulation modelling approach. <i>Pan African Medical Journal</i> , 2021, 40, 163.	0.3	3
2335	Engagement with HIV and COVID-19 prevention: a national cross-sectional analysis of users on a geosocial networking app (Preprint). <i>Journal of Medical Internet Research</i> , 0, , .	2.1	0
2336	The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir. <i>Antiviral Therapy</i> , 2022, 27, 135965352110675.	0.6	4

#	ARTICLE	IF	CITATIONS
2337	HIV pre-exposure prophylaxis: assessment of acceptability among members of HIV serodiscordant/serostatus unknown couples. <i>International Journal of STD and AIDS</i> , 2022, , 095646242210977.	0.5	0
2338	Characterizing HIV-Preventive, Plasma Tenofovir Concentrationsâ€™A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. <i>Clinical Infectious Diseases</i> , 2022, 75, 1873-1882.	2.9	10
2339	Perceptions on HIV Pre-Exposure Prophylaxis Among Urgent Care Clinicians in the Southern United States. <i>Current HIV Research</i> , 2022, 20, 204-212.	0.2	1
2340	Effectiveness of three delivery models for promoting access to pre-exposure prophylaxis in HIV-1 serodiscordant couples in Nigeria. <i>PLoS ONE</i> , 2022, 17, e0268011.	1.1	0
2341	A comparison of attitudes and knowledge of pre-exposure prophylaxis (PrEP) between hospital and Key Population Led Health Service providers: Lessons for Thailandâ€™s Universal Health Coverage implementation. <i>PLoS ONE</i> , 2022, 17, e0268407.	1.1	9
2342	Economic Abuse and Care-seeking Practices for HIV and Financial Support Services in Women Employed by Sex Work: A Cross-Sectional Baseline Assessment of a Clinical Trial Cohort in Uganda. <i>Journal of Interpersonal Violence</i> , 2023, 38, 1920-1949.	1.3	0
2343	Design, adaptation, and diffusion of an innovative tool to support contraceptive decision-making: Balanced Counseling Strategy Plus. <i>Gates Open Research</i> , 0, 6, 2.	2.0	1
2344	HIV Pre-Exposure Prophylaxis: What Do Pediatricians Need to Know?. <i>Pediatric Annals</i> , 2022, 51, e191-e195.	0.3	1
2346	Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. <i>BMJ Open</i> , 2022, 12, e048478.	0.8	44
2347	Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis. <i>Scientific Reports</i> , 2022, 12, 8224.	1.6	5
2348	Precarious manhood and intentions to initiate preexposure prophylaxis among Black sexual minority men.. <i>Health Psychology</i> , 2022, 41, 474-483.	1.3	2
2351	Factors Associated with Intention to Initiate Pre-exposure Prophylaxis in Cisgender Women at High Behavioral Risk for HIV in Washington, D.C.. <i>Archives of Sexual Behavior</i> , 2022, 51, 2613-2624.	1.2	5
2352	What Predicts a Clinical Discussion About PrEP? Results From Analysis of a U.S. National Cohort of HIV-Vulnerable Sexual and Gender Minorities. <i>AIDS Education and Prevention</i> , 2022, 34, 195-208.	0.6	1
2353	Treatment of hepatitis delta and <scp>HIV</scp> infection. <i>Liver International</i> , 2023, 43, 108-115.	1.9	4
2354	Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). <i>AIDS and Behavior</i> , 0, , .	1.4	1
2355	Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17â€™24â€™Years Old in the USA. <i>Sexuality Research and Social Policy</i> , 2022, 19, 1944-1953.	1.4	2
2356	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. <i>Future Microbiology</i> , 2022, 17, 887-897.	1.0	6
2357	PrEP-aring the General Gynecologist to Offer HIV Pre-exposure Prophylaxis. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 733-738.	0.6	2



#	ARTICLE	IF	CITATIONS
2358	Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis: study protocol for an open-label randomized trial. <i>Trials</i> , 2022, 23, .	0.7	13
2359	Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life—Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain. <i>AIDS and Behavior</i> , 2022, 26, 4055-4062.	1.4	6
2360	Implementing PrEP Services in Diverse Health Care Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S114-S128.	0.9	2
2361	Identification of Determinants and Implementation Strategies to Increase PrEP Uptake Among Black Same Gender—“Loving Men in Mecklenburg County, North Carolina: The PrEP-MECK Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S149-S160.	0.9	6
2362	Acceptability and Appropriateness of Digital PrEP Interventions for Black and Latina Cisgender Women: Perspectives From Service Providers in Los Angeles County. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S134-S140.	0.9	1
2364	Effect of a Reminder System on Pre-exposure Prophylaxis Adherence in Men Who Have Sex With Men: Prospective Cohort Study Based on WeChat Intervention. <i>Journal of Medical Internet Research</i> , 2022, 24, e37936.	2.1	4
2365	Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	2.1	48
2366	The evolution of DREAMS: using data for continuous program improvement. <i>Aids</i> , 2022, 36, S5-S14.	1.0	7
2368	Population-level correlation between incidence of curable sexually transmitted infections and HIV-1 among African women participating in HIV-1 pre-exposure prophylaxis trials. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	0
2369	From policy to practice: uptake of pre-exposure prophylaxis among adolescent girls and young women in United States President's Emergency Plan for AIDS Relief-supported countries, 2017—2020. <i>Aids</i> , 2022, 36, S15-S26.	1.0	7
2370	Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. <i>Lancet HIV,the</i> , 2022, 9, e585-e594.	2.1	5
2371	The predictive value of macaque models of preexposure prophylaxis for HIV prevention. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 179-185.	1.5	4
2373	Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting naïve and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors. <i>Journal of Medical Virology</i> , 0, , .	2.5	2
2374	Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 306-316.	0.9	5
2375	Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	7
2376	Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial. <i>AIDS and Behavior</i> , 2022, 26, 3950-3962.	1.4	7
2377	Exploring the Role of Provider—Patient Communication in Women’s Sexual Health and Pre-Exposure Prophylaxis Care in the Primary Care Settings in New York State of the United States. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8084.	1.2	0
2378	PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	29

#	ARTICLE	IF	CITATIONS
2379	A novel "HIV salience and Perception" scale is associated with PrEP dispensing and adherence among adolescent girls and young women in Kampala, Uganda. <i>AIDS and Behavior</i> , 2023, 27, 279-289.	1.4	1
2380	Awareness, Willingness and Use of HIV Pre-Exposure Prophylaxis Among Female Sex Workers Living in Dar-es-Salaam, Tanzania. <i>AIDS and Behavior</i> , 2023, 27, 335-343.	1.4	3
2381	Trajectories of Oral PrEP Adherence Among Young Kenyan Women: Implications for Promoting Effective PrEP Use. <i>AIDS and Behavior</i> , 2023, 27, 171-181.	1.4	3
2382	Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial. <i>Lancet HIV</i> , 2022, 9, e464-e473.	2.1	23
2383	PrEP program experience in a hospital HIV unit. Description of baseline user profile and identification of opportunities for improvement. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2022, , .	0.2	1
2384	Acceptability and feasibility of leveraging community-based HIV counselling and testing platforms for same-day oral PrEP initiation among adolescent girls and young women in Eastern Cape, South Africa. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	12
2385	Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2386	HIV Prevention: The Promise of Pre-Exposure Prophylaxis in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2017, 46, 265-266.	0.2	2
2387	HIV Transmission Prevention. , 2021, , 30-50.		0
2388	Implementing a National PrEP Program: How Can We Make It Happen?. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 51-54.	0.4	2
2389	A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	1
2390	Impact of daily, oral pre-exposure prophylaxis on the risk of bacterial sexually transmitted infections among cisgender women: a systematic review and narrative synthesis. <i>Wellcome Open Research</i> , 0, 7, 108.	0.9	0
2391	Risk Factors Associated with Loss to Follow-up Among Transgender Women Receiving HIV Pre-exposure Prophylaxis in Chiang Mai province, Thailand. <i>AIDS and Behavior</i> , 2023, 27, 473-483.	1.4	3
2392	How gender norms and "good girl" notions prevent adolescent girls and young women from engaging with PrEP: qualitative insights from Zimbabwe. <i>BMC Women's Health</i> , 2022, 22, .	0.8	9
2393	Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2706-2712.	1.3	4
2394	The Social, Behavioral, and Ethical Modalities of COVID-19 on HIV Care in South Africa: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 9766.	1.2	0
2395	More than just oral PrEP: exploring interest in rectal douche, dissolvable implant, removable implant and injection HIV prevention approaches among racially diverse men who have sex with men in the Northeast Corridor. <i>BMJ Open</i> , 2022, 12, e063474.	0.8	2
2396	Characteristics of HIV seroconversions in a large prospective implementation cohort study of oral HIV pre-exposure prophylaxis in men who have sex with men (EPIC-NSW). <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1

#	ARTICLE	IF	CITATIONS
2397	Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2964-2971.	1.3	3
2398	HIV Prevention Tools Across the Pregnancy Continuum: What Works, What Does Not, and What Can We Do Differently?. <i>Current HIV/AIDS Reports</i> , 2022, 19, 293-300.	1.1	1
2399	A Qualitative Exploration of Various Stigmas Impacting HIV Pre-Exposure Prophylaxis (PrEP) Uptake Among African American Young Adults. <i>Family and Community Health</i> , 2022, 45, 218-227.	0.5	4
2400	PrEP uptake and HIV viral suppression when PrEP is integrated into Ugandan ART clinics for HIV-negative members of HIV-serodifferent couples: A stepped wedge cluster randomized trial. <i>EClinicalMedicine</i> , 2022, 52, 101611.	3.2	9
2401	Drug-level feedback counselling: modest support to PrEP adherence. <i>Lancet HIV</i> , 2022, 9, e668-e669.	2.1	0
2402	Pre-Exposure Prophylaxis for HIV Infection as a Public Health Tool. <i>Journal of Law, Medicine and Ethics</i> , 2022, 50, 24-28.	0.4	5
2403	Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis. <i>Pharmaceutics</i> , 2022, 14, 1801.	2.0	1
2404	Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-14.	0.7	0
2406	Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?. <i>Current HIV/AIDS Reports</i> , 2022, 19, 384-393.	1.1	11
2407	Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
2408	Perceived Risk of HIV Infection and Acceptability of PrEP among Men Who Have Sex with Men in Brazil. <i>Archives of Sexual Behavior</i> , 2023, 52, 773-782.	1.2	5
2409	HIV Pre-exposure Prophylaxis at Two Urban Obstetrics/Gynecology Clinics in Buffalo: Awareness and Attitudes Among Non-Hispanic Black vs. Latinx Patients. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 2294-2301.	1.8	3
2410	Development of a Human Immunodeficiency Virus Risk Prediction Model Using Electronic Health Record Data From an Academic Health System in the Southern United States. <i>Clinical Infectious Diseases</i> , 2023, 76, 299-306.	2.9	7
2411	“Ask the way from those who have walked it before” Grandmothers™ roles in health-related decision making and HIV pre-exposure prophylaxis use among pregnant and breastfeeding women in sub-Saharan Africa. <i>PLoS ONE</i> , 2022, 17, e0271684.	1.1	0
2412	Understanding PrEP decision making among pregnant women in Lilongwe, Malawi: A mixed-methods study. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	5
2413	Pre-exposure prophylaxis for HIV: effective and underused. <i>Cmaj</i> , 2022, 194, E1164-E1170.	0.9	0
2414	Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 909-923.	0.5	1
2415	Provider-client rapport in pre-exposure prophylaxis delivery: a qualitative analysis of provider and client experiences of an implementation science project in Kenya. <i>Sexual and Reproductive Health Matters</i> , 2022, 30, .	0.7	1

#	ARTICLE	IF	CITATIONS
2416	Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. <i>Clinical Trials</i> , 0, , 174077452211183.	0.7	0
2417	Vaginal microbial shifts are unaffected by oral pre-exposure prophylaxis in South African women. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
2419	Recommendations for Improving Oral Pre-exposure Prophylaxis Implementation and Social Marketing in Ugandan Fisherfolk Communities: A Qualitative Exploration. , 0, , 0272684X2211136.		2
2420	HIV awareness, pre-exposure prophylaxis perceptions and experiences among people who exchange sex: qualitative and community based participatory study. <i>BMC Public Health</i> , 2022, 22, .	1.2	1
2421	Perceived influence of alcohol consumption, substance use, and mental health on PrEP adherence and condom use among PrEP-prescribed gay, bisexual, and other men-who-have-sex-with-men: a qualitative investigation. <i>BMC Public Health</i> , 2022, 22, .	1.2	1
2422	Improving HIV preexposure prophylaxis implementation within healthcare settings. <i>Aids</i> , 2022, 36, 1883-1885.	1.0	0
2423	Identifying HIV sequences that escape antibody neutralization using random forests and collaborative targeted learning. <i>Journal of Causal Inference</i> , 2022, 10, 280-295.	0.5	0
2424	Management and treatment of human immunodeficiency virus. , 2022, , 1585-1610.		0
2425	Integrating enhanced HIV pre-exposure prophylaxis into a sexually transmitted infection clinic in Lilongwe (ePrEP STI): A prospective cohort study (Preprint). <i>JMIR Research Protocols</i> , 0, , .	0.5	0
2426	Episodic Use of Pre-Exposure Prophylaxis Among Young Cisgender Women in Siaya County, Kenya. <i>AIDS Patient Care and STDs</i> , 2022, 36, 379-388.	1.1	5
2427	The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.. <i>AIDS and Behavior</i> , 2023, 27, 1478-1485.	1.4	3
2428	A retrospective analysis of bone loss in tenofovir-emtricitabine therapy for HIV PrEP. <i>International Journal of STD and AIDS</i> , 2022, 33, 1183-1192.	0.5	2
2429	MTN-033: a Phase 1 Study Comparing Applicator versus "œas Lubricant"•Delivery of Rectal Dapivirine Gel. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	0
2430	Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and Pharmacokinetics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	1
2431	Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1365-1380.	2.4	13
2432	Out-of-pocket Expenses and Time Spent on Clinic Visits Among HIV Pre-exposure Prophylaxis Users and Other Clinic Attendees in Eswatini. <i>AIDS and Behavior</i> , 0, , .	1.4	4
2433	Between- and Within-Individual Sociodemographic and Psychological Determinants of PrEP Adherence Among Men Who have Sex with Men Prescribed a Daily PrEP Regimen in Wales. <i>AIDS and Behavior</i> , 0, , .	1.4	1
2434	Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA. <i>Harm Reduction Journal</i> , 2022, 19, .	1.3	1

#	ARTICLE	IF	CITATIONS
2436	Clinic-Integrated Mobile Health Intervention (JomPrEP App) to Improve Uptake of HIV Testing and Pre-exposure Prophylaxis Among Men Who Have Sex With Men in Malaysia: Protocol for an Intervention Development and Multiphase Trial. <i>JMIR Research Protocols</i> , 2022, 11, e43318.	0.5	6
2437	The impact of prevention-effective PrEP use on HIV incidence: a mathematical modelling study. <i>Journal of the International AIDS Society</i> , 2022, 25, .	1.2	7
2438	Human Immunodeficiency Virus Preexposure Prophylaxis: The Next Wave in Emergency Department-Based Human Immunodeficiency Virus Prevention. <i>Annals of Emergency Medicine</i> , 2022, , .	0.3	0
2440	MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya. <i>BMJ Open</i> , 2022, 12, e064037.	0.8	0
2441	Self-reported and pill count measures of adherence to oral HIV PrEP among female sex workers living in South-Western Uganda. <i>PLoS ONE</i> , 2022, 17, e0277226.	1.1	1
2442	Understanding Psychosocial Determinants of PrEP Uptake Among Cisgender Women Experiencing Heightened HIV Risk: Implications for Multi-Level Communication Intervention. <i>Health Communication</i> , 0, , 1-12.	1.8	3
2443	A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 92, 310-316.	0.9	8
2444	Interrogating the promise of long-acting HIV pre-exposure prophylaxis. <i>Trends in Molecular Medicine</i> , 2022, , .	3.5	2
2445	Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 1-11.	1.5	3
2446	Short-term oral pre-exposure prophylaxis against HIV-1 modulates the transcriptome of foreskin tissue in young men in Africa. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
2448	Cell and Tissue Specific Metabolism of Nucleoside and Nucleotide Drugs: Case Studies and Implications for Precision Medicine. <i>Drug Metabolism and Disposition</i> , 2023, 51, 360-368.	1.7	3
2449	Pharmacokinetics, the immunological impact and the effect on HIV ex-vivo infectivity of maraviroc, raltegravir and lopinavir in MSM using Post-exposure Prophylaxis.. <i>AIDS Research and Human Retroviruses</i> , 0, , .	0.5	0
2451	Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques. <i>EBioMedicine</i> , 2022, 86, 104361.	2.7	5
2452	Interventions to increase the uptake and continuation of pre-exposure prophylaxis (PrEP) by adolescent girls and young women at high risk of HIV in low-income and middle-income countries: a scoping review. <i>BMJ Global Health</i> , 2022, 7, e009474.	2.0	5
2453	Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?. <i>HIV Medicine</i> , 2023, 24, 653-663.	1.0	5
2454	Characterizing the Impact of the COVID-19 Pandemic on HIV PrEP care: A Review and Synthesis of the Literature. <i>AIDS and Behavior</i> , 2023, 27, 2089-2102.	1.4	6
2455	Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 497-503.	1.3	3
2456	Correlations between oral Pre-Exposure Prophylaxis (PrEP) initiations and policies that enable the use of PrEP to address HIV globally. <i>PLOS Global Public Health</i> , 2022, 2, e0001202.	0.5	0

#	ARTICLE	IF	CITATIONS
2458	Non- <i>Lactobacillus</i> -Dominant and Polymicrobial Vaginal Microbiomes Are More Common in Younger South African Women and Predictive of Increased Risk of Human Immunodeficiency Virus Acquisition. <i>Clinical Infectious Diseases</i> , 2023, 76, 1372-1381.	2.9	4
2459	Black Sexual Minority Men's Stigma-Based Experiences Surrounding Pre-exposure Prophylaxis in the Southern United States. <i>LGBT Health</i> , 2023, 10, 245-251.	1.8	4
2461	PrEP stigma among current and non-current PrEP users in Thailand: A comparison between hospital and key population-led health service settings. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
2462	Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2464	Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using <i>HIV</i> Recent Infection Assays: A Consensus Statement from the Forum <i>HIV</i> Prevention Trial Design Project. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 114, 29-40.	2.3	4
2465	Prevalence of renal and bone risk factors among individuals prescribed oral pre-exposure prophylaxis for HIV. <i>IJID Regions</i> , 2023, 6, 68-75.	0.5	1
2466	A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 896-903.	2.3	1
2467	Predictors of delayed Anti-Retroviral Therapy initiation among adults referred for HIV treatment in Uganda: a cross-sectional study. <i>BMC Health Services Research</i> , 2023, 23, .	0.9	3
2468	Awareness and use of HIV pre-exposure prophylaxis and factors associated with awareness among MSM in Beijing, China. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
2469	Assessing the Preliminary Efficacy of a Nonrandomized, Clinic-Based HIV Risk Reduction Pilot Intervention for PrEP-Initiated, Alcohol- and Other Drug-Using Women of Color in Miami, FL. <i>Journal of Racial and Ethnic Health Disparities</i> , 0, , .	1.8	0
2470	Long-acting PrEP: new opportunities with some drawbacks. <i>Lancet HIV</i> , the, 2023, 10, e213-e215.	2.1	0
2471	HIV Pre-exposure Prophylaxis Persistence and Adherence Among Men Who Have Sex With Men in Four US Cities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, 34-41.	0.9	4
2472	Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women. <i>Clinical Infectious Diseases</i> , 2023, 76, 1850-1853.	2.9	9
2473	Biomedical Strategies for Human Immunodeficiency Virus (HIV) Prevention? A New Paradigm. <i>Annals of the Academy of Medicine, Singapore</i> , 2012, 41, 595-601.	0.2	7
2474	Human Immunodeficiency Virus (HIV) Prevention Education in Singapore: Challenges for the Future. <i>Annals of the Academy of Medicine, Singapore</i> , 2012, 41, 602-609.	0.2	10
2475	Prophylaxie prÃ©exposition au VIH : efficace et sous-utilisÃ©e. <i>Cmaj</i> , 2022, 194, E1544-E1550.	0.9	0
2476	Insights into HIV-1 Transmission Dynamics Using Routinely Collected Data in the Mid-Atlantic United States. <i>Viruses</i> , 2023, 15, 68.	1.5	0
2477	Integrating pre-exposure prophylaxis of HIV infection into family planning services: a scoping review. <i>BMJ Sexual and Reproductive Health</i> , 2023, 49, 210-218.	0.9	3



#	ARTICLE	IF	CITATIONS
2478	Travestis, transgender women and young MSM are at high risk for PrEP early loss to follow-up in Rio de Janeiro, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2023, 27, 102733.	0.3	3
2479	“I don't know why I am taking this pill” Young women navigation of disclosure and support for PrEP uptake and adherence in Eastern Cape Province, South Africa. <i>PLOS Global Public Health</i> , 2023, 3, e0000636.	0.5	2
2480	HIV pre-exposure prophylaxis (PrEP) knowledge among general practitioners in 2020: A French survey. <i>Infectious Diseases Now</i> , 2023, 53, 104649.	0.7	1
2481	Attitudes towards participating in research involving digital pill systems to measure oral HIV pre-exposure chemoprophylaxis: a cross-sectional study among men who have sex with men with substance use in the USA. <i>BMJ Open</i> , 2023, 13, e067549.	0.8	1
2482	Predominance of High-Level Tetracycline-Resistant <i>Neisseria gonorrhoeae</i> in Kenya: Implications for Global Implementation of Doxycycline Postexposure Prophylaxis for Prevention of Sexually Transmitted Infections. <i>Sexually Transmitted Diseases</i> , 2023, 50, 317-319.	0.8	5
2483	Uptake, Adherence and Retention of Daily Oral Pre-Exposure Prophylaxis among Female Sex Workers in the Greater Gaborone City, Botswana. <i>International STD Research &amp; Reviews</i> , 0, , 12-24.	0.2	0
2484	Predictors of Human Immunodeficiency Virus Pre-Exposure Prophylaxis (PrEP) Uptake in a Sexual Health Clinic With Rapid PrEP Initiation. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	1
2485	Personalizing prevention: Advances in pharmacotherapy for <sc>HIV</sc> prevention. <i>Pharmacotherapy</i> , 2023, 43, 305-320.	1.2	1
2486	Neurodegeneration Associated with HIV-1 in the Era of cART. , 2022, , 1999-2028.		0
2487	Low rate of pre-exposure prophylaxis and post-exposure prophylaxis uptake and high prevalence of transmitted drug resistance among newly diagnosed primary HIV infections in Shenzhen, China: a real-world retrospective study. <i>Chinese Medical Journal</i> , 2022, 135, 2730-2737.	0.9	1
2488	Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa. <i>Aids</i> , 2023, 37, 977-986.	1.0	4
2489	Providing HIV pre-exposure prophylaxis to men who have sex with men and transgender women in hospitals and community-led clinics in Thailand: acceptance, patterns of use, trends in risk behaviors, and HIV incidence. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2023, 35, 524-537.	0.6	0
2491	Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2023, 10, e154-e163.	2.1	8
2492	Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection. <i>Nature Communications</i> , 2023, 14, .	5.8	6
2493	Insufficient PrEP: an assessment of primary care prescribing habits and use of pre-exposure prophylaxis in patients at risk of HIV acquisition at a single medical centre. <i>Sexually Transmitted Infections</i> , 0, , sextrans-2022-055551.	0.8	1
2494	Multi-dimensional mismatch and barriers for promoting PrEP among men who have sex with men in China: a cross sectional survey from the Demand-side. <i>AIDS Research and Therapy</i> , 2023, 20, .	0.7	1
2495	Variations in Pre-exposure Prophylaxis (PrEP) Awareness and Healthcare Provider Interactions in a Nationally Representative Sample of American Men Aged 15-49 Years: A Cross-Sectional Study. <i>AIDS and Behavior</i> , 2023, 27, 2932-2943.	1.4	1
2496	Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis. <i>Journal of the International AIDS Society</i> , 2023, 26, .	1.2	3

#	ARTICLE	IF	CITATIONS
2497	Preventing HIV and achieving pregnancy among HIV sero-different couples: Pilot study of a safer conception intervention in Zimbabwe. PLOS Global Public Health, 2023, 3, e0000796.	0.5	0
2498	Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study. PLoS ONE, 2023, 18, e0280339.	1.1	0
2500	What motivated men to start PrEP? A cross-section of men starting PrEP in Buffalo city municipality, South Africa. BMC Public Health, 2023, 23, .	1.2	5
2501	DYNAMICS OF PRE-EXPOSURE (PrEP) ELIGIBILITY DUE TO WAXING AND WANING OF HIV RISK IN RAKAI, UGANDA. Journal of Acquired Immune Deficiency Syndromes (1999), 2023, Publish Ahead of Print, .	0.9	0
2502	Post-exposure and pre-exposure prophylaxis as HIV preventive measures. Zdravstvena Zastita, 2022, 51, 32-45.	0.0	0
2503	Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward. Pharmacoeconomics, 2023, 41, 787-802.	1.7	1
2504	Uptake and continuation of HIV pre-exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya. Journal of the International AIDS Society, 2023, 26, .	1.2	2
2505	Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysis via CiteSpace. Frontiers in Microbiology, 0, 14, .	1.5	0
2506	Exploring the causes of preexposure prophylaxis of HIV failure—future developments for overcoming the same—a mini review. Journal of Human Virology & Retrovirology, 2019, 7, 1-5.	0.1	1
2507	Comparison of the effectiveness of different HIV-1 prevention methods, and their mechanisms.. , 0, 36, 675-681.		0
2508	Addressing the Need for a Preexposure Prophylaxis Monitoring and Evaluation Implementation Guide: Experience From Zambia. Global Health, Science and Practice, 0, , .	0.6	1
2509	Understanding Retention in the HIV Pre-Exposure Prophylaxis Cascade Among Cisgender Women. AIDS Patient Care and STDs, 2023, 37, 205-211.	1.1	6
2510	Modelling the impact of combining HIV prevention interventions on HIV dynamics in fishing communities in Uganda. BMC Infectious Diseases, 2023, 23, .	1.3	0
2511	Building bridges to care: the experience of peer navigation in enabling linkage to PrEP for adolescent men who have sex with men and transgender women. Cadernos De Saude Publica, 2023, 39, .	0.4	3
2512	PrEPare for Work: A Pilot Randomized Controlled Trial of an Intervention to Optimize HIV PrEP Outcomes Among Male Sex Workers. AIDS and Behavior, 2023, 27, 3294-3305.	1.4	2
2513	Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old. Scientific Reports, 2023, 13, .	1.6	4
2514	Prediction of Sex and the Potential Use of On-Demand PrEP Among Young Men Who Have Sex With Men in the U.S.. Journal of Acquired Immune Deficiency Syndromes (1999), 2023, Publish Ahead of Print, .	0.9	0
2515	Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV. Global Health, Science and Practice, 2023, 11, e2200401.	0.6	2

#	ARTICLE	IF	CITATIONS
2516	Prevalence and Correlates of HIV-Associated Health Behaviors in a Population-Based Sample of Puerto Rican Adults, 2019. <i>Ethnicity and Disease</i> , 2023, 33, 17-25.	1.0	0
2517	Acceptability and Feasibility of a Mobile Phone Application to Support HIV Pre-exposure Prophylaxis Among Women with Opioid Use Disorder. <i>AIDS and Behavior</i> , 0, , .	1.4	0
2518	A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	3
2519	The Fidelity of a Pharmacy-Based Oral HIV Pre-Exposure Prophylaxis Delivery Model in Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 93, 379-386.	0.9	2
2520	Barriers and facilitators to <scp>HIV Pre-Exposure</scp> Prophylaxis (<scp>PrEP</scp>) in Specialist Sexual Health Services in the United Kingdom: A systematic review using the <scp>PrEP</scp> Care Continuum. <i>HIV Medicine</i> , 2023, 24, 893-913.	1.0	7
2522	Exploring Current Practice, Knowledge, and Challenges of Sexually Transmitted Infection/HIV Management and Pre-Exposure Prophylaxis Among Japanese Health Care Professionals: A Cross-Sectional Web Survey. <i>AIDS Patient Care and STDs</i> , 0, , .	1.1	0
2542	Prevention, treatment and cure of HIV infection. <i>Nature Reviews Microbiology</i> , 2023, 21, 657-670.	13.6	21
2548	A Scoping Review of Oral Pre-exposure Prophylaxis for Cisgender and Transgender Adolescent Girls and Young Women: What Works and Where Do We Go from Here?. <i>AIDS and Behavior</i> , 2023, 27, 3223-3238.	1.4	1
2583	Sex Differences in HIV Infection. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 61-73.	0.7	0
2595	Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence. <i>Nature Medicine</i> , 2023, 29, 2748-2752.	15.2	3